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1. Introduction 
1.1. Colorectal cancer 
1.1.1. Pathogenesis of colorectal cancer 
Colorectal cancer is one of the most frequent cancers in the western hemisphere 
besides lung and breast cancer (Ries et al., 2002). Colorectal carcinomas arise both 
sporadically at a median age of 67 years and hereditarily at a median age of 42 years 
(Kinzler and Vogelstein, 1996); about 5 - 15 % of all colorectal cancers are inherited. 
The most frequent inherited forms are familial adenomatous polyposis (FAP, 
characterized by germline mutations in the adenomatous polyposis coli (APC) gene) 
and hereditary nonpolyposis colorectal cancer (HNPCC, characterized by germline 
mutations in mismatch repair (MMR) genes) (Kinzler and Vogelstein, 1996; Weitz et 
al., 2005). 
FAP and the majority of sporadic colorectal cancers develop via the adenoma-
carcinoma sequence proposed by Fearon and Vogelstein (Fearon and Vogelstein, 
1990): The pathologic transformation of normal colonic epithelium to benign tumors 
(called adenoma or adenomatous polyps) and finally invasive tumors (called cancers 
or carcinomas) requires several years and multiple genetic alterations. Mostly one 
oncogene (K-ras) and three tumor suppressor genes (APC, SMAD4 and p53) are 
sequentially genetically altered. Whereas the oncogene K-ras only requires a genetic 
event in one allele, the tumor suppressor genes require genetic events in both alleles 
(Kinzler and Vogelstein, 1996) according to Knudson’s two-hit hypothesis (Knudson, 
1971; Knudson, 1993). The event that triggers the adenoma-carcinoma sequence 
and thereby leads to the development of malignant cancers is the activation of the 
Wnt signaling pathway in consequence of mutations in the adenomatous polyposis 
coli (APC) tumor suppressor gene (reviewed in Smalley and Dale, 2001; Fodde, 
2002). According to a current model, wild-type APC binds nuclear β-catenin and 
exports it to the cytoplasm (Henderson, 2000; Rosin-Arbesfeld et al., 2000), where it 
is phosphorylated by a complex of various proteins including APC. Phosphorylated β-
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catenin becomes ubiquitinated and therefore targeted for degradation by the 
proteasome (Bienz and Clevers, 2000; Polakis, 1997). Mutations in APC prevent 
degradation of β-catenin and lead to its accumulation in the nucleus (Kinzler and 
Vogelstein, 1996). Nuclear β-catenin functions in association with the HMG box 
protein T cell factor 4 (TCF4) as a transcriptional coactivator and thereby enables the 
expression of genes controlled by promoters with TCF4 binding sites (Huber et al., 
1996; Porfiri et al., 1997), for example, c-MYC (He et al., 1998) and Cyclin D2 
(Shtutman et al., 1999; Tetsu and McCormick, 1999). These in turn activate cell 
proliferation. Furthermore, it has been reported that mutations in APC contribute to 
chromosomal instability in cancer cells (Fodde et al., 2001; Kaplan et al., 2001). 
The subsequent genetic alteration occurring in the adenoma-carcinoma sequence 
affects the oncogene K-ras. The K-ras gene encodes a membrane-localized G-
protein involved in signal transduction critical for normal proliferation. Mutations lead 
to constitutively activated Ras protein, which is stimulating cell proliferation (Leslie et 
al., 2002). Proceeding in the adenoma-carcinoma sequence, alterations in the tumor 
suppressor genes SMAD4 (also known as DPC4) and p53 take place. The SMAD4 
protein is a mediator in the inhibitory transforming growth factor β (TGF-β) signaling 
pathway that suppresses cell growth (Miyaki and Kuroki, 2003). Through inactivation 
of SMAD4 cells become resistant against TGF-β-mediated growth suppression (Liu, 
2001). The tumor suppressor gene p53 was termed as “guardian of the genome” 
(Lane, 1992), as p53 mediates growth arrest or apoptosis as response to various 
cellular stresses, like DNA-damage or oncogenic activation (Selivanova, 2004). 
Inactivation of p53 allows therefore the survival of aberrant cells. p53 is esteemed, 
for example, to be responsible for the transition from adenoma to carcinoma (Leslie 
et al., 2002). 
In contrast to FAP, HNPCC and about 15 % percent of sporadic colorectal cancers 
develop as a consequence of mutations in one or more of the three mismatch repair 
genes hMSH2, hMLH1 and hPMS2, which usually maintaining genetic stability. This 
in turn leads to an accumulation of mutations amongst others in oncogenes and 
tumor suppressor genes accelerating tumor progression (Kinzler and Vogelstein, 
1996). A marker for mismatch repair deficiency is the incidence of microsatellite 
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instabilities (MSI), as (frequently occurring) mistakes in the replication of these 
sequences are not sufficiently corrected (Lynch and de la Chapelle, 2003).  
A major obstacle for further profound investigations of colorectal cancers and 
especially for the developing of successful therapy strategies is the lack of suitable 
model systems. Primary culture of colorectal carcinoma is difficult, very laborious, 
and difficult to standardize. In addition, the success rate in establishing cell lines is 
far below 10 %. Hence, there is an urgent demand for cell culture models that closely 
reflect the characteristics of in vitro tumor cells, which would, in general, facilitate the 
investigation of cancers and especially development of successful novel therapy 
strategies. 
1.1.2. Human low passage colon cancer cell lines 
The demand for colon cancer cell lines that closely reflect the in vivo tumor cells 
triggered efforts in the lab of E. Wagner which recently resulted in the generation of 
unique human low passage colon cancer cell lines originating directly from the clinic 
(Vecsey-Semjen et al., 2002). In contrast to other commercially available colon 
cancer cell lines these cell lines still closely resemble the phenotypes of their 
corresponding original tumor cells. Only 5 - 10 passages after harvesting the primary 
tumor cells from the patients were required for the generation of such low passage 
cell lines. Thereby accumulation of alterations due to long-term cultivation was 
avoided. On the other hand, this cell lines were stable enough to be continuously 
cultured, if required. 
Eight novel cell lines were established and intensively characterized (Vecsey-Semjen 
et al., 2002). The established cell lines exhibit widely heterogeneous morphologies 
and can be divided into three categories of different phenotypic morphologies typical 
for the original tumor cells: epithelial-like, piled-up and rounded-up (Fig. 1). Cell lines 
that belong to the epithelial-like category (COGA-1, -5, -10) exhibit mainly an 
epithelial morphology. Piled-up cell lines (COGA-5L, -8, -12) grow preferentially in 
multilayers: COGA-5L cells, for example, formed ball-like clumps on top of an 
attached cell layer. Interestingly, COGA-5L cells originate from the same patient as 
COGA-5 cells, but COGA-5 cells were isolated from the primary tumor, whereas 
COGA-5L cells were derived from the respective lymph node metastasis. COGA-12 
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cells grew as multilayer aggregates surrounded by cells growing as single cell layers. 
Rounded-up cell lines (COGA-2, -3) were loosely attached to the surface of the cell 
culture dish without forming cell-cell contacts.  
epithelial – like piled – up rounded – up
320x200x 320x
COGA-5 COGA-12 COGA-3A B C
 
Fig. 1. Different morphologies of the low passage colon cancer cell lines. Epithelial-like (A), 
piled-up (B) and rounded-up (C) morphologies. Respective magnifications of transmission light 
microscopy are indicated. 
Extensive investigations of the cell lines demonstrated an unexpected diversity of the 
individual tumor cells regarding, for example, mutations mediating oncogenic and 
tumor-suppressive effects. Since the established cell lines closely reflected all 
analyzed features of the corresponding original tumor cells, they are promising in 
vitro model systems for further investigations of colorectal cancers. 
1.1.3. Multicellular tumor spheroids 
The individual low passage colon cancer cells described above closely reflect the 
properties of individual in vivo tumor cells and are therefore very valuable for the 
general investigation of colon cancer and the development of novel therapeutic 
strategies. However, when these cells are grown as traditional monolayer cell 
cultures, the situation is still different from the three-dimensional growth situation of in 
vivo tumors. Therefore, additional requirements exist for an extended model system 
that recapitulates the three-dimensional in vivo situation of cancers better than 
monolayer cell cultures. Multicellular tumor spheroid cultures represent such a three-
dimensional model system. They are intermediates between monolayer cultures and 
in vivo tumors as they resemble the latter more closely with regard to cell shape and 
cell environment. A major feature of multicellular spheroids is that they consist of a 
proliferating cell population at the periphery followed by an intermediate zone with 
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quiescent, yet viable cells passing into a necrotic or apoptotic core in the center of 
the spheroid (Mueller-Klieser, 2000), thereby providing a model system closely to in 
vivo tumors. Recent investigations demonstrated that insufficient nutrient and oxygen 
supply and resultant hypoxia are not or only partly responsible for cell death in 
multicellular spheroids. Processes leading to cell death in multicellular spheroids 
besides hypoxia-induced signaling are yet not well understood (Mueller-Klieser, 
1997). The higher relevance of multicellular spheroids compared to traditional 
monolayer cultures was demonstrated for example by Kobayashi and co-workers 
(Kobayashi et al., 1993). They isolated cells from murine EMT6 tumors exhibiting 
chemoresistance after treatment of the mice with chemotherapeutic drugs. 
Monolayer cultures of these cells failed to exhibit chemoresistance, while multicellular 
spheroids fully recapitulated the chemoresistant phenotype of the respective in vivo 
tumors.  
Multicellular spheroids can be generated by preventing the adhesion of cells to the 
surface of the cell culture dish forcing the cells to develop cell-cell contacts and finally 
form multicellular spheroids. Adhesion can be prevented by three different methods. 
The spinner flask method hinders the cells from adhesion to the flask by stirring and 
the gyratory rotation system by shaking. Inhibition of adhesion by covering of the 
culture plates with a non-adhesive surface (agar, agarose) is accomplished in the so 
called liquid overlay technique (Santini and Rainaldi, 1999). This technique results in 
the formation of multicellular spheroids all with the same defined size and number of 
cells. Whether a certain cell line will form multicellular spheroids (characterized by the 
formation of cell-cell interactions) or only multicellular aggregates, is not predictable.  
For the reasons listed above it was concluded at the start of this thesis that the low 
passage colon cancer cells (closely reflecting the original in vivo tumor cells) grown 
as multicellular spheroids (reflecting the three-dimensional growth of in vivo tumors) 
might be very promising model systems for investigation of colon cancers and 
developing of novel therapy strategies. 
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1.2. Chemotherapy of colorectal cancer 
1.2.1. Chemoresistance against chemotherapeutic drugs 
The standard treatment of colorectal cancer is surgery complemented by 
chemotherapeutic drugs (Macdonald and Astrow, 2001). However, despite advances 
in therapeutic strategies, the five-year survival period in colorectal cancer patients 
still remains unsatisfying. One reason is that cancers or their metastases often 
develop resistance against chemotherapeutic drugs. Chemoresistance can be 
primary (intrinsic) or secondary (acquired). Primary resistant cancers are not 
sensitive to a chemotherapeutic drug from the beginning of the treatment, while 
secondary resistance appears as a consequence of treatment with a 
chemotherapeutic drug that induced a response at the beginning of the treatment 
(Hutter and Sinha, 2001). While it is possible to investigate secondary resistance in 
vitro by generation of chemoresistant sublines through long-term treatment with the 
respective chemotherapeutic drug, primary chemoresistance cannot easily be 
mimicked with traditional monolayer cultures in vitro. The reason for primary 
chemoresistance is the so called multicellular community effect. This means that 
primary resistance, in contrast to secondary resistance, is dictated by the collective 
properties of tumor cell populations rather than by features of the individual tumor 
cells. Primary resistance is hence mediated by interactions of the tumor cells with 
each other and with their surrounding microenvironment and is therefore also called 
multicellular resistance (MCR). Multicellular resistance can be caused as a 
consequence of cell-cell contacts (contact inhibition resistance) or of the 
heterogeneous three-dimensional structure of tumors (Desoize and Jardillier, 2000). 
One possibility to evaluate primary resistance in vitro are multicellular spheroids (as 
described above).  
In contrast to primary resistance, secondary resistance is called unicellular 
resistance. Secondary chemoresistance can be subdivided into typical multidrug 
resistance (MDR) and atypical resistance. Typical MDR is accomplished by effective 
efflux of the chemotherapeutic drug by overexpression of P-glycoprotein (Pgp). Pgp 
(coded by the mdr-1 gene) is a 170 kDa transmembrane protein belonging to the 
unspecific ABC transporter family (Kerb et al., 2001; van Tellingen, 2001). Secondary 
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chemoresistant cells that do not overexpress Pgp are allocated to atypical resistance. 
Atypical resistance can be mediated by alternative ABC transporters, intracellular 
detoxification of chemotherapeutic drugs (by glutathione-S-transferases), increased 
DNA repair, modifications of drug targets or modulation of apoptotic pathways (Hutter 
and Sinha, 2001). 
The various forms of resistance described above must not be seen as independent 
events; moreover they must be taken together to understand the versatile 
phenomenon of chemoresistant cancers. 
1.2.2. Mechanisms of action of 5-fluorouracil 
The standard chemotherapeutic drug used for the treatment of colorectal cancer is 5-
fluorouracil (5-FU) (Schmoll et al., 1999). 5-FU is an analogue of uracil with a fluorine 
atom at the C-5 position in place of hydrogen (Fig. 2). 
 
 
Fig. 2. 5-fluorouracil  
It was demonstrated that rat hepatomas utilized the pyrimidine uracil more rapidly 
than normal tissue (Rutman et al., 1954). 5-FU is taken up into the cells in the same 
manner as uracil (Wohlhueter et al., 1980) and is intracellularly converted to three 
main active metabolites: fluorodeoxyuridine monophosphate (FdUMP), 
fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). The 
cytotoxicity of 5-FU can be ascribed to two distinct mechanisms: The inhibition of the 
nucleotide synthetic enzyme thymidylate synthase (TS) and the misincorporation of 
fluoronucleotides into RNA and DNA (reviewed in Longley et al., 2003). 
Thymidylate synthase catalyses the reductive methylation of deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) necessary for 
the generation of deoxythymidine triphosphate (dTTP). dTTP is essential for DNA 
replication. The 5-FU metabolite FdUMP forms a stable complex with TS and thereby 
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inhibits dTMP synthesis, which finally leads to a lack of dTTP. The downstream 
events are not fully understood. Most likely, the imbalance in the deoxynucleotide 
pool leads to disruption of DNA synthesis and repair, and consequently to lethal DNA 
damage. 
In addition, the accumulation of dUMP and FdUMP (as a result of TS inhibition) will 
lead to an accumulation of dUTP and FdUTP, which are both misincorporated into 
DNA. These misincorporations eventually lead to DNA strand breaks and cell death. 
Moreover, the 5-FU metabolite FUTP is misincorporated into RNA, leading to 
disruption of normal RNA processing. This in turn affects cellular metabolism and 
viability (reviewed in Longley et al., 2003). 
Apoptosis is induced via the death receptor pathway in 5-FU treated cells (Kaufmann 
and Earnshaw, 2000; Eichhorst et al., 2001; Schwartzberg et al., 2002). This 
pathway is activated by increased levels of Fas and Fas ligand, which are mainly up-
regulated by p53 in response to DNA damage (Petak et al., 2000; Petak and 
Houghton, 2001). In addition, initiation of apoptosis via the mitochondrial pathway 
may also play a role in 5-FU-induced apoptosis (Backus et al., 2003). It was 
demonstrated that 5-FU-induced activation of p53 led to upregulation of Bax, a major 
regulator of the mitochondrial apoptosis pathway (Koshiji et al., 1997; Osaki et al., 
1997). 
The novel low passage colon cancer cell lines could represent a powerful model 
system for the investigation of chemoresistance of colorectal cancers. In particular, 5-
FU resistant sublines could provide important insights in the mechanisms involved in 
the development of such resistance against the chemotherapeutic drug. 
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1.3. Gene therapy of colorectal cancer 
Besides solving the problems of chemotherapeutic strategies, alternatives of 
conventional treatment have to be developed. In particular, gene therapy could 
provide a powerful alternative to conventional treatment and lead to novel 
approaches in cancer therapy. Gene therapy, as first proposed 1972 by Friedman 
and Roblin (Friedmann and Roblin, 1972), aims at the delivery of nucleic acids (DNA 
or RNA) into target cells in order to cure patients suffering from different diseases. 
The transferred nucleic acids can be used to turn on or restore a gene function. For 
example, a therapeutic gene can be expressed (‘gain of function’). A relatively new 
field in gene therapy applies nucleic acids to suppress specific gene functions (‘loss 
of function’) by turning off genes with antisense oligonucleotides or double-stranded 
small interfering RNA (siRNA). Although gene therapy has not yet been established 
as standard treatment, it was already applied in various clinical studies, e.g. in the 
field of cancer therapy (most clinical trials), monogenic diseases (Hemophilia A and 
B, cystic fibrosis, severe combined immunodeficiency syndrome), infectious 
diseases, vascular diseases, or DNA vaccination (The Journal of Gene Medicine web 
site, www.wiley.co.uk/genmed/clinical). Gene therapy may hold the potential to 
revolutionize modern molecular medicine, provided that appropriate nucleic acid 
delivery systems (‘vector systems’) are available. 
1.3.1. Gene delivery strategies 
Current gene therapy vectors can be divided into two major groups, namely viral 
vectors derived from natural viruses and nonviral, synthetically manufactured vectors. 
Viruses in general and therefore also viral vectors are highly efficient regarding 
cellular uptake and intracellular delivery of therapeutic genes to the nucleus. 
Therefore, few viral particles are sufficient for the transduction of cells. On the other 
hand, they often cause inflammatory and immune host response and some viral 
vectors even bear the risk of insertional oncogenesis. Nonviral vectors exhibit only 
low immunogenicity, since synthetic vectors present far less or no immunogenic 
proteins or peptides in comparison to viral vectors. An obvious weakness of nonviral 
vectors, however, is their low efficiency in intracellular nucleic acid delivery which 
currently is partly compensated by administration of large amounts of the vectors. 
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Therefore, extensive efforts are necessary to improve the efficiency of nonviral 
vectors. Nonviral vectors are usually based on chemically defined cationic lipids or 
cationic polymers and can be generated protein-free or using non-immunogenic 
human proteins and peptides only. Cationic lipids condensed with DNA are called 
lipoplexes; cationic polymers that are condensed with DNA are called polyplexes. 
Lipoplexes and polyplexes became widely used technique for gene delivery both in 
vitro and in vivo (Felgner et al., 1987; Godbey et al., 1999; Kircheis et al., 2001; Liu 
et al., 2003). Despite significant improvements in lipoplex or polyplex formulations, 
still many obstacles must be overcome (Bally et al., 1999; Godbey et al., 1999; 
Templeton, 2002). For efficient transfection, the delivery vector must ensure a 
sufficient uptake into the cell, endosomal release and uptake into the nucleus. For 
gene delivery in vivo, small particles are necessary without specific interactions with 
biological fluids and non-target cells. The combination of cationic lipids and cationic 
polymers to form lipopolyplexes can be a very promising approach to enhance gene 
transfer efficiency of nonviral vectors. It was reported that the synergistic effects of 
both contribute to their enhanced efficiency (Lampela et al., 2002; Lampela et al., 
2003; Lampela et al., 2004; Lee et al., 2003). Furthermore, the delivery vector should 
guarantee a highly specific cell targeting and expression for in vivo applications. 
1.3.2. Tumor specific cell targeting strategies 
Tumor specific gene transfer can be achieved by modifying gene transfer vectors in a 
way that they only target tumor cells but not other cells. This is, for example, possible 
by integration of ligands into the vectors, which are preferentially taken up by tumor 
cells. Such ligands are, for example, transferrin or EGF. Another strategy is 
transcriptional targeting by tumor specific gene expression mediated through tumor 
specific promoters (Miller and Whelan, 1997). Several approaches have been made 
to develop such promoters. Albeit most of them enabled tumor specific expression, 
they only led to inadequate expression levels (Nettelbeck et al., 1998). Lipinski and 
co-workers (Lipinski et al., 2004) recently developed a promising new promoter, 
CTP4, which is specific for tumors with constitutively activated Wnt signaling 
pathway. The activation of this pathway leads to nuclear accumulation of β-catenin. 
In association with the HMG box protein T cell factor 4 (TCF4), nuclear β-catenin 
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enables the expression of genes controlled by promoters with TCF4 binding sites 
(Huber et al., 1996; Porfiri et al., 1997). The artificial CTP4 promoter contains ten 
such TCF4 binding sites (Fig. 3), which make the CTP4 promoter very specific for 
tumor cells with deregulated levels of β-catenin such as most colorectal carcinomas. 
In addition, it was demonstrated that the CTP4 promoter enabled expression levels 
comparable to expression levels obtained by the strong but non-tissue-specific 
human cytomegalovirus immediate early enhancer/promoter (CMV) in the colorectal 
cancer cell line SW480 (Lipinski et al., 2004). Therefore, it would be very interesting 
to investigate the efficiency of the CTP4 promoter also in the various low passage 
colon cancer cell lines exhibiting widely heterogeneous properties.  
cctttgatc
 
Fig. 3. Composition of the CTP4 promoter. Numbers indicate the base pairs between the TCF4 
binding sites (filled boxes) and the distance from the end of the most proximal site to the start of the 
TATA box (adapted from Lipinski et al., 2004). 
1.3.3. Therapeutic genes 
Tumor specific vector systems enable the delivery of therapeutic genes into cancer 
cells. A promising approach is the delivery of genes that encode immune stimulatory 
factors. These in turn activate the immune system against the tumor cells. Therefore, 
also tumor cells that have not been transfected and do not express the therapeutic 
gene can be eliminated. Interleukin-2 (IL-2) was already reported as an effective 
immune stimulatory factor in immunotherapy studies (Rosenberg et al., 1985; Huland 
and Huland, 1989). This cytokine provides the stimulatory signal necessary for the 
activation of the tumor defense effectors, T and NK lymphocytes (Bubenik, 2004) or 
macrophages (Zatloukal et al., 1995). However, the systemic application of high IL-2 
protein amounts often exhibits side effects, like capillary leakage syndrome or 
hepato- and nephrotoxicity (Bubenik, 2004). Therefore, the selective application of IL-
2 to the tumors via gene therapy is a promising alternative to avoid these side 
effects. Another cancer gene therapy approach is the expression of cytotoxic genes 
in tumor cells that, for example, lead to death of the transfected individual tumor 
cells. However, if the particular cytotoxic gene does not exhibit a so called bystander 
effect, only the transfected cells will be eliminated. Bystander effect means that the 
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therapeutic gene product also acts on cells surrounding the transfected cell. 
Therapeutic gene transfer without such bystander effects is insufficient, since the 
extent of gene transfer is often low. This problem can be circumvented by 
simultaneously expression of an immune stimulatory gene in addition to the cytotoxic 
gene. The efficiency of such a combination gene therapy with suicide and cytokine 
genes could already be demonstrated by combining IL-2 with herpes simplex virus 
thymidine kinase. This enzyme phosphorylates the prodrug ganciclovir (9-[(2-
hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine) (Moolten, 1986) and such 
activated ganciclovir is highly toxic to dividing cells (Kwong et al., 1997; Pizzato et al., 
1998). Recently another bicistronic construct was generated, named 2A-IRES-IL2 
(Kisser, 2003). 2A-IRES-IL2 combines sequences encoding the rhinovirus protease 
2A and IL-2. Rhinoviruses use protease 2A for shutdown of host cell biosynthesis 
after infection. The major substrate of the protease 2A is the translation initiation 
factor eIF4G (Lloyd et al., 1988; Seipelt et al., 1999). By cleaving of eIF4G cellular, 
cap-dependent translation becomes impossible. At the same time the biosynthesis of 
viral proteins is guaranteed by IRES (internal ribosomal entry site) mediated, cap-
independent translation. Thus, heterologous expression of the protease 2A via the 
2A-IRES-IL2 construct will prevent cap-dependent translation of cellular mRNAs and 
therefore reduce viability and proliferation of the transfected cells. Simultaneously, an 
IRES sequence located upstream of the IL-2 encoding sequence enables cap-
independent translation of the IL-2 mRNA. Therefore, efficient expression of the 
immune stimulatory gene is guaranteed although expression of other cellular genes 
is reduced by the protease 2A. It has already been demonstrated that transfection of 
the 2A-IRES-IL2 construct leads to sufficient expression of IL-2 in addition to 
protease 2A expression. For easy monitoring of protease 2A expression the gene 
has been fused with the gene encoding enhanced green fluorescent protein (EGFP) 
in the 2A-IRES-IL2 construct. It was also demonstrated that the expressed protease 
2A is active, as cleaved eIF4G could be detected by western blotting (Kisser, 2003). 
However, the evaluation of reduced viability or proliferation levels in the 2A-IRES-IL2 
transfected cells failed so far. Therefore, it would be interesting to test this novel 
therapeutic gene construct in the low passage human colon cancer cell lines. 
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1.4. Specific aims of the PhD thesis  
For development of drugs against colorectal cancer i) the provision of suitable cell 
model systems, ii) the elucidation of mechanisms limiting the efficiencies of existing 
therapeutic strategies with the objective to find adequate solutions to overcome these 
limitations, and iii) the development of novel therapeutic strategies are important 
issues. These issues have been the basis for the aims of the thesis. 
1.4.1. Initiation and characterization of relevant model systems for colorectal 
cancers 
As a first aim, suitable cellular model systems had to be established and 
characterized for the evaluation of colorectal cancer specific therapeutic strategies. 
The recently generated low passage colon cancer cells, reflecting the characteristics 
of the corresponding original tumor cells (Vecsey-Semjen et al., 2002), were used as 
a starting point. Besides traditional monolayer cultures, multicellular spheroid cultures 
were established with these cells to obtain even more relevant model systems. It has 
been reported that multicellular spheroids exhibit different characteristics compared 
to the corresponding monolayer cultures, such as, for example, higher resistance 
against chemotherapeutic drugs. Therefore, in this thesis differences between 
monolayer cultures and multicellular spheroids were characterized on the level of 
total protein expression. To this end, a proteomics approach using 2D 
electrophoresis followed by protein detection via mass spectrometry was applied. 
1.4.2. Elucidation of mechanisms involved in resistance of colorectal cancers 
against chemotherapy 
The chemotherapeutic drug 5-FU is the standard in the treatment of colorectal 
cancers. A major problem, however, is that treated cells often develop resistance 
against 5-FU. Hence, the second aim of this thesis was the detection of proteins 
associated with chemoresistance against 5-FU. Knowledge of the proteins that are 
involved in mediating 5-FU chemoresistance can lead to the development of 
successful therapeutic strategies to overcome chemoresistance. At first, 
chemoresistant sublines of the low passage colon cancer cells had to be generated. 
Afterwards differences in the protein expression profiles between 5-FU sensitive and 
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resistant sublines should be investigated by 2D electrophoresis. Such differences in 
protein expression may contribute to chemoresistance against 5-FU. Moreover, the 
differences in the expression profiles found between multicellular spheroids and 
monolayer cultures could be associated with intrinsic chemoresistance. 
1.4.3. Development of alternative therapy strategies for colorectal cancers 
Since the available established colorectal cancer therapies are dealing with several 
limitations, alternative therapeutic strategies have to be developed. A promising 
alternative is represented by colorectal cancer specific gene therapy. The third aim of 
this thesis was therefore the development of a novel tumor specific gene therapy 
concept that combines novel strategies for (i) gene transfer, (ii) cancer cell targeting 
and (iii) therapeutic treatment of cancer cells. Therefore, different lipopolyplex 
formulations of reporter gene DNA constructs were generated and their efficiencies in 
gene transfer were investigated using the novel colon carcinoma models. Tumor 
specificity, that was necessary for an in vivo application of these novel gene transfer 
vectors, was obtained by using the artificial promoter CTP4. The efficiency and 
specificity of such tumor specific transcriptionally targeted gene transfer vectors 
containing the CTP4 promoter was compared to corresponding unspecific vectors 
containing the CMV promoter. Finally, the expression of the immune stimulatory gene 
IL-2 alone or in combination with the cytotoxic gene protease 2A and the influence of 
the latter on the proliferation or viability of the transfected cells was investigated. 
Transfer of the therapeutic genes was accomplished with the tumor specific gene 
transfer vectors (transcriptionally targeted lipopolyplexes) developed within the scope 
of this thesis. This novel gene therapy concept was evaluated on traditional 
monolayer cultures of the low passage colon cancer cell lines and also on 
multicellular spheroids of these cells. 
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2. Material and methods 
2.1. Chemicals and reagents 
Multivalent non-biodegradable cationic lipid DOSPER and monovalent cationic lipid 
DOTAP were obtained from Roche (Mannheim, Germany). Multivalent biodegradable 
cationic lipid DOCSPER was 1,3-dioleoyloxy-2-(N5-carbamoyl-spermine)-propane 
(Groth et al., 1998). Linear PEI (PEI22lin) with an average molecular weight of 22 
kDa was achieved from Euromedex (Exgen 500, Euromedex, Souffelweyersheim, 
France). Branched PEIs (PEI2k and PEI25br) with an average molecular weight of 2 
kDa and 25 kDa were obtained from Sigma-Aldrich (Vienna, Austria). PEIs were used 
at a 1 mg/ml stock solution, neutralized with HCl. PLL18 (18 lysine residues) was 
synthesized by Dr. Arnold (Gene Centrum, Munich, Germany) and was used at a 
concentrations of 5 mg/ml. 
Plasmid pCMV-Luc (Photinus pyralis luciferase under control of the CMV 
promoter/enhancer) described in Plank et al. (1992) was produced endotoxin-free by 
Elim Biopharmaceuticals (San Francisco, CA, USA) or Aldevron (Fargo, ND, USA). 
Plasmid pEGFP-N1 (encoding enhanced green fluorescent protein (EGFP) under the 
control of the CMV promoter/enhancer) and pEGFP-Luc (encoding a fusion of EGFP 
and luciferase under the control of the CMV promoter/enhancer) were purchased 
from Clontech Laboratories, Inc. (Palo Alto, CA, USA). Further, pCTP4-Luc (encoding 
luciferase under the control of the CTP4 promoter) (Lipinski et al., 2004), p2A-IRES-
IL2 (encoding rhinoviral protease 2A and simultaneously human interleukin-2 under 
the control of the CMV promoter/enhancer) (Kisser, 2003) and pGShIL-2tet 
(encoding the human interleukin-2 protein under the control of the CMV 
promoter/enhancer) (Buschle et al., 1995; Schreiber et al., 1999) were used and 
amplified endotoxin-free using an EndoFree Plasmid Maxi Kit (Qiagen, Hilden, 
Germany) according to manufacturer’s instructions in our lab. 
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2.2. Molecular biological methods 
2.2.1. Restriction digestion of plasmid DNA 
Plasmid DNA was incubated 1 - 3 h with 3 - 5 units of the desired restriction enzymes 
(Promega, Mannheim, Germany) per µg DNA in the appropriate restriction enzyme 
buffer according to manufacturer’s instructions. Success of digestion was tested by 
agarose gel electrophoresis. 
2.2.2. Dephosphorylation of plasmid DNA fragments 
Digested plasmid DNA fragments were dephosphorylated directly in the restriction 
enzyme buffer by adding 2 - 3 units shrimp alkaline phosphatase (Promega, 
Mannheim, Germany) per µg DNA and incubation for 45 minutes at 37°C. 
Dephosphorylation was stopped by incubation at 65°C for 15 minutes. 
2.2.3. Converting of 5´- overhangs of DNA fragments to blunt ends 
5´- overhangs of digested (and if desired dephosphorylated) plasmid DNA fragments 
were filled to blunt ends directly in the restriction enzyme buffer by adding 1 unit 
Klenow fragment (Promega, Mannheim, Germany) per µg DNA, 40 µM of each dNTP 
and 50 µg/ml acetylated BSA. Reaction was carried out for 10 minutes at RT and the 
reaction was stopped by incubation at 75°C for 10 minutes. 
2.2.4. Isolation of DNA fragments from agarose gels 
DNA fragments were excised from agarose gels with a clean, sharp scalpel. The 
following extraction and cleaning was performed with the QIAquick Gel Extraction Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
2.2.5. Ligation 
A molar ratio of 1:3 of vector DNA (100 ng) and fragment DNA was used for sticky 
end ligations, for blunt end ligations a molar ratio of 1:5 was used. Ligations were 
carried out using 1 – 3 units T4 DNA ligase (Roche, Mannheim) in ATP containing 
ligation buffer in a final volume of 15 µl – 30 µl. Sticky end ligations were incubated at 
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16°C overnight. Blunt end ligations were incubated at 16°C for 3 h and subsequently 
at RT overnight. 
2.2.6. Transformation of E.coli 
Competent E.coli cells (DH5α or JM109) were thawed on ice. 50 – 200 ng DNA were 
mixed with 100 µl bacteria suspension and incubated on ice for 30 minutes. The 
competent E.coli cells were then heat-pulsed at 42°C for 90 seconds and 
subsequently incubated on ice for 2 minutes. 0.9 ml of LB-medium were added prior 
incubation at 37°C for 1 h with shaking. 10 – 300 µl were spread on antibiotic 
(ampicillin or kanamycin) agar plates and incubated at 37°C overnight. 
2.2.7. Preparation of plasmid DNA 
All plasmid DNA preparations were carried out with QIAprep Spin Miniprep Kit or 
EndoFree Plasmid Maxi Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. 
2.2.8. Cloning strategies 
pEGFP-LG-CTP4 (encoding EGFP under the control of the CTP4 promoter) was 
constructed by substitution of the CMV promoter of pEGFP-N1 by the CTP4 promoter 
from pCTP4-Luc (Lipinski et al., 2004). First, a fragment containing the CMV 
promoter was removed from pEGFP-N1 by cleaving the plasmid with Ase I and 
Eco47 III. The cohesive ends originating from the digestion by Ase I were converted 
to blunt ends by Klenow polymerase prior to religation of the vector, leading to the 
plasmid pEGFP-N1-0. Finally a Sac I - Bgl II digested fragment of the pCTP4-Luc 
plasmid, containing the CTP4 promoter, was inserted into the Sac I – BamH I 
restrictions sites of the MCS of the pEGFP-N1-0 plasmid. 
pCTP4-hIL-2 (encoding IL-2 under the control of the CTP4 promoter) was 
constructed by replacement of the luciferase gene of pCTP4-Luc against the hIL-2 
gene from pGShIL-2tet (Buschle et al., 1995; Schreiber et al., 1999). The luciferase 
gene was removed by digestion with Bgl II and BamH I and the Bgl II - Not I digested 
hIL-2 gene from pGShIL-2tet was inserted into the dephosphorylated vector. Both the 
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vector and the insert were converted to blunt ends prior to insertion using Klenow 
polymerase. 
pCTP4-2A-IRES-IL2 (encoding the 2A-IRES-IL2 sequence under control of the CTP4 
promoter) was constructed by inserting a fragment containing the 2A-IRES-IL2 
sequence and a fragment harboring the CTP4 promoter into the pEGFP-N1-0 vector 
(created during the construction of pEGFP-LG-CTP4). The EGFP gene was removed 
from pEGFP-N1-0 by digestion with Sac I and Not I. The fragment containing the 
CTP4 promoter was excised from pCTP4-Luc by digestion with Sac I and Pst I and 
the 2A-IRES-IL2 sequence was excised from p2A-IRES-IL2 (Kisser, 2003) by 
digestion with Pst I and Not I. The fragments containing the CTP4 promoter and the 
2A-IRES-IL2 sequence were inserted into the restriction sites Sac I and Not I of the 
pEGFP-N1-0 vector in a single ligation reaction. As the thereby generated pCTP4-
2A-IRES-IL2 plasmid was smaller than the p2A-IRES-IL2 plasmid (containing the 
CMV promoter), additionally, a plasmid was created that has nearly the same size as 
pCTP4-2A-IRES-IL2 and is harboring the 2A-IRES-IL2 sequence under control of the 
CMV promoter. Therefore, the EGFP gene was removed from the plasmid pEGFP-
N1 (containing the CMV promoter) by digestion with Pst I and Not I and the Pst I - 
Not I digested fragment from p2A-IRES-IL2 harboring the 2A-IRES-IL2 sequence 
was inserted into it, resulting in the plasmid pCMV-2A-IRES-IL2, similar to the 
plasmid pCTP4-2A-IRES-IL2 besides its promoter region. 
2.3. Cell biological methods 
2.3.1. Cell culture 
Cell culture media, antibiotics and fetal calf serum (FCS) were purchased from 
Invitrogen (Karlsruhe, Germany). All cultured cells were grown at 37° C in 5 % CO2 
humidified atmosphere. HeLa (ATCC CCL-2, cervix epithelial adenocarcinoma, non-
colorectal cells) and SW480 (ATCC CCL-228, human colorectal adenocarcinoma 
cells) cells were grown in DMEM medium, supplemented with 10 % serum. Human 
low passage colon carcinoma cells COGA-1, COGA-2, COGA-3, COGA-5, COGA-
5L, COGA-10 and COGA-12 (Vecsey-Semjen et al., 2002) were cultured in RPMI 
1640 medium containing 10 % serum. These cells are originating directly from 
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colorectal cancers in the clinic. All cells were cultured in T25 or T75 flasks purchased 
from Corning Incorporated (Corning, NY, USA) or various well plates purchased from 
TPP (Trasadingen, Switzerland). Harvesting of the cells was performed as followed: 
The cells were shortly washed with 0.05 % trypsin/0.02 % EDTA in PBS solution 
(Invitrogen, Karlsruhe, Germany) and subsequently incubated with fresh 
trypsin/EDTA solution at 37°C. After the detachment of the cells trypsin was inhibited 
by addition of serum containing growth medium. EDTA was removed by 
centrifugation at 180 g to 500 g and subsequently uptake of the cell pellet in fresh 
growth medium. 
2.3.2. Multicellular spheroid culture 
Multicellular spheroids were generated as previously described (Lieubeau-Teillet et 
al., 1998), using the liquid overlay technique. This technique prevents the cells from 
growing on the surface of the culture plates and the cells are thereby forced to 
interact with each other and finally form multicellular spheroids. Briefly, 24-well 
culture plates (Nalge Nunc International, Naperville, IL, USA) were coated with 300 µl 
of 1 % SeaPlague agarose (Biozym, Hess, Germany) in serum-free growth medium. 
Cells from a single-cell suspension were added at 105 per well in a total volume of 1 
ml growth medium with 2 % or 10 % serum. Multicellular spheroids were allowed to 
form over 48 h or 96 h. Multicellular spheroids are resistant against mechanical 
disruption. If they do not exhibit resistance against mechanical disruption they are not 
considered as multicellular spheroids but rather as multicellular aggregates. 
2.3.3. Formation of transfection complexes 
Different cationic lipids (DOCSPER, DOSPER, DOTAP) and/or polycations (PLL18, 
PEI22lin, PEI25br, PEI2k) were mixed with DNA to form various lipoplex, polyplex or 
lipopolyplex formulations. The mixing was performed either in low ionic strength 
solution (water) or in physiological solution (HBS; 150 mM NaCl, 20 mM HEPES, pH 
7.4) as described below. 
Lipopolyplexes were prepared as follows: first plasmid DNA was diluted in water or 
HBS at DNA concentrations ranging from 2.5 to 20 µg/ml. For cotransfection assays 
equal amounts of two different plasmids were mixed together in the same tube. 
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Immediately, polycations were added at optimized molar ratios of PEI nitrogen/DNA 
phosphate (N/P) of 8/1 or a charge ratio of PLL18/DNA of 5/1 (Pelisek et al., 2005) 
and incubated at room temperature for 5 - 10 min. Cationic lipids were diluted in 
similar manner in a separate tube, added to the DNA/polycation pre-complexes at 
optimized w/w ratios of DOCSPER/DNA of 10/1, DOSPER/DNA of 8/1 and 
DOTAP/DNA of 4/1 (Pelisek et al., 2005) and incubated at room temperature for 30 – 
40 min. 
Lipoplexes were prepared as described before (Pelisek et al., 2002). In brief, the 
cationic lipids and the plasmid DNA were diluted at the same ratios as described 
above in separate tubes in water or HBS, mixed together and incubated for 30 – 40 
min at room temperature. Polyplexes were prepared in the same way (Kursa et al., 
2003) at molar ratios as described above. 
Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) containing complexes were 
prepared according to the manufacturer’s instructions. Briefly, plasmid DNA and 
Lipofectamine 2000 at a DNA (in µg)/Lipofectamine 2000 (in µl) ratio of 2:3 were 
diluted in separate tubes in Opti-MEM (Invitrogen, Karlsruhe, Germany) at a DNA 
concentration of 20 µg/ml, mixed together and incubated for 30 min at room 
temperature. 
2.3.4. Measurement of particle size and zeta-potential 
Particle size was measured by dynamic laser-light scattering using a Malvern 
Zetasizer 3000HS (Malvern Instruments, Worcestershire, UK). For particle sizing 
complexes were prepared as for gene transfer and diluted either in low ionic strength 
solution (water) or in physiological solution (HBS) to give a final DNA concentration of 
5 µg/ml. For estimation of the zeta-potential, transfection complexes were diluted in 
10 mM NaCl and the particle charge was determined. The data represent the mean 
of at least three measurements. 
2.3.5. Gene transfer to monolayer cultures 
For luciferase assays 0.5 - 2 x 104 cells were seeded in 96-well plates; for IL-2 
detection and EGFP analysis 0.5 - 2 x 105 cells were seeded in 24-well or 12-well 
plates; for proliferation assays with protease 2A 0.5 - 1 x 104 cells were seeded in 96-
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well plates and for analysis of protease 2A-mediated apoptosis 1 - 2 x 105 cells were 
seeded in 24-well or 12-well plates 24 hours prior transfection. The growth medium 
was removed and replaced with 50 µl (96-well), 200 µl (24-well) or 400 µl (12 well) of 
serum-free medium or medium containing 10 % FCS. Transfection complexes (96-
well: 20 µl, 0.1 µg plasmid DNA; 24-well: 50 µl, 0.25 µg - 1 µg DNA; 12-well: 100 µl, 
0.25 µg - 1 µg DNA) were then added drop-wise to each well. 4 hours following 
incubation at 37°C/5 % CO2, transfection medium was replaced by 100 µl (96-well), 
600 µl (24-well) or 1 ml (12-well) of fresh growth medium. Gene transfer was 
performed in two to five wells/group and experiments were at least repeated twice. 
2.3.6. Gene transfer to multicellular spheroids 
Multicellular spheroids were grown in 1 ml medium containing 10 % serum or in 
serum-reduced (2 %) medium to enhance transfection efficiency. Transfection was 
performed directly in the growth medium to avoid disturbance of the spheroids. Forty-
eight or 96 h after multicellular spheroid formation 700 µl of growth medium were 
removed of each well and lipopolyplex formulation, diluted in a small volume (50µl), 
was added to the multicellular spheroid cultures. Transfection medium was not 
exchanged after transfection. 
2.3.7. Luciferase assay 
Twenty-four hours following gene transfer, medium was removed and the cells were 
washed with phosphate-buffered saline. The cells were then lysed with 50 µl of lysis 
buffer (25 mM Tris, pH 7.8, 2 mM EDTA, 2 mM DTT, 10 % glycerol, 1 % Triton X-
100) and 30 min later the luciferase activity was measured using a Lumat LB9507 
instrument (Berthold, Bad Wildbad, Germany) as described recently (Ogris et al., 
2001). In brief, luciferase light units were recorded from an aliquot of the cell lysate 
with 10 s integration after automatic injection of freshly prepared luciferin substrate 
solution using the Luciferase Assay system (Promega, Mannheim, Germany). 
Luciferase activity was measured in triplicates and the relative light unit (RLU) were 
determined per 1 x 104 cells. 107 light units correspond to two ng of recombinant 
luciferase (Promega, Mannheim, Germany). 
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2.3.8. Human IL-2 ELISA 
Twenty-four hours after transfection growth medium was replaced by fresh medium. 
Forty-eight hours after transfection the supernatants were collected and stored at      
-80°C until IL-2 ELISA was performed. Human IL-2 expression was determined using 
a human IL-2 ELISA kit (Bender MedSystems, Vienna, Austria) according to the 
manufacturer’s instructions. 
2.3.9. Treatment of cells with 5-fluorouracil 
The treatment with different concentrations of 5-fluorouracil (Sigma-Aldrich, 
Taufkirchen, Germany) was performed with 1.5 x 104 cells per well in 96 well plates 
in the case of COGA-5L and COGA-12 cells and 0.4 x 104 cells per well in the case 
of COGA-5 cells. For the determination of the percentage of apoptotic cells 28 x 104 
COGA-12 cells per well in 12 well plates were used. Growth medium was replaced 
with fresh medium every day, to ensure constant concentration of 5-FU. For long-
term (> one week) 5-FU incubations medium was exchanged 3 times per week. 
5-FU was dissolved in DMSO. To exclude effects resulting from DMSO also control 
cells used for comparison were incubated with the same amount of DMSO as the 5-
FU-treated cells received. 
2.3.10. Proliferation and viability assays 
2.3.10.1. Hoechst 33258-based proliferation assay 
Cells were cultured in black 96 well-plates with transparent bottom (Greiner-Bio One, 
Frickenhausen, Germany). At the desired endpoint growth medium was removed and 
the 96 well-plate was frozen at -80°C. After thawing, 100 µl distilled water were 
added per well and the plate was incubated at 37°C for 1 hour. The plate was frozen 
to -80°C and thawed again. This procedure causes rapid cell lysis, resulting in 
release of DNA to form a relatively homogenous solution. 100µl of 2 x TNE Buffer (5 
M NaCl, 20 mM Tris, 2 mM EDTA, pH 7.4) containing 2 µg/ml Hoechst 33258 
(Sigma-Aldrich, Taufkirchen, Germany) were added and fluorescence was measured 
in a SPECTRAFluor Plus plate reader (Tecan, Austria) using excitation and emission 
filters centered at 360 nm and 465 nm, respectively. 
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2.3.10.2. MTT assay  
Cells were cultured in 200 µl growth medium in 96 well-plates. At the desired 
endpoint 20 µl of MTT solution (5mg/ml in PBS) were added and cells were 
incubated 1 h – 4 h at 37° C in 5 % CO2 humidified atmosphere. After forming of blue 
crystals cell culture medium was removed and crystals were solubilized by adding 
100 µl DMSO. Absorbance was measured at a primary wave length of 590 nm and a 
reference wave length of 630 nm in a SPECTRAFluor Plus plate reader (Tecan, 
Austria). 
2.3.11. Flow cytometric analysis  
2.3.11.1. Flow cytometric analysis of EGFP expression 
Forty-eight hours after transfection cells were harvested after incubation with 
trypsin/EDTA solution and kept on ice until analysis. The DNA stain propidium iodide 
(PI) (Sigma-Aldrich, Taufkirchen, Germany) was added to the cell suspension at 1 
µg/ml to discriminate between viable and dead cells. PI only penetrates the nucleus 
after cell membrane integrity is lost. The number of dead cells and EGFP-positive 
cells was quantified using a CyanTM MLE flow cytometer (DakoCytomation, 
Copenhagen, Denmark). PI and EGFP fluorescence were excited at 488 nm. 
Emission of PI fluorescence was detected using a 613±20 nm bandpass filter. Dead 
cells were excluded by gating PI-positive cells by forward scatter versus PI 
fluorescence. Emission of EGFP was detected using a 530±40 nm bandpass filter 
and a 613±20 nm bandpass filter to analyze EGFP positive cells by diagonal gating 
(Ogris et al., 1998). To exclude cell debris and doublets, cells were appropriately 
gated by forward versus side scatter and pulse width, and 2 x 104 gated events per 
sample were collected. Furthermore, the geometric mean channel number as 
measure for the mean fluorescence intensity (MFI) of a EGFP-positive cell population 
was determined. 
2.3.11.2. Flow cytometric analysis of apoptosis 
Apoptotic cells were detected by labeling of apoptotic cells with annexin V and 
following flow cytometry. Annexin V binds to phosphatidylserine in presence of 
calcium. At the onset of apoptosis, phosphatidylserine which is normally found on the 
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internal part of the plasma membrane becomes translocated to the external portion of 
the membrane and thereby available to bind to annexin V (van Engeland et al., 
1998). 
Cells were harvested 48 or 72 hours after transfection or beginning of the treatment 
by using trypsin/EDTA, washed once in PBS and resuspended in annexin V binding 
buffer (Sigma-Aldrich, Taufkirchen, Germany or BioVision, Mountain View, CA, USA) 
at a concentration of approximately 1 x 106 cells/ml. The DNA stain propidium iodide 
(PI) and annexin V-FITC (Sigma-Aldrich, Taufkirchen, Germany) or annexin V-Cy5 
(BioVision, Mountain View, CA, USA) were added at 1 µg/ml each and incubated for 
10 min at RT. Following apoptotic and necrotic cells were determined using a 
CyanTM MLE flow cytometer (DaKoCytomation, Copenhagen, Denmark). Annexin V-
FITC fluorescence was excited at 488 nm and emission was detected using a 
530±40 nm bandpass filter. Annexin V-Cy5 fluorescence was excited at 633 nm and 
emission was detected using a 680±30 nm bandpass filter. PI fluorescence was 
excited at 356 nm or 488 nm and emission was detected using a 700±20 nm or 
575±25 nm bandpass filter, respectively. To exclude cell debris and doublets, cells 
were appropriately gated by forward versus side scatter and pulse width, and 2 x 104 
gated events per sample were collected. Cells which are early in the apoptotic 
process will be stained with annexin V alone. Living cells will not show staining by 
neither annexin V nor PI. Necrotic cells will be stained by both annexin V and PI, as 
PI only penetrates the nucleus after cell membrane integrity is lost. 
2.3.12. Transmission light and epifluorescence microscopy  
Transmission light microscopy of living cells growing as monolayers or multicellular 
spheroids was performed using an Axiovert 200 microscope (Carl Zeiss, Jena, 
Germany) equipped with a Sony DSC-S75 digital camera (Sony Corporation, Tokyo, 
Japan). Light was collected through 5 x 0.12 NA, 10 x 0.25 NA or 32 x 0.40 NA 
objectives (Carl Zeiss, Jena, Germany), and images were captured using phase 
contrast. 
Living or 4 % PFA (para-formaldehyde) fixed cell imaging of EGFP expressing cells 
was performed 48 h after transfection using an Axiovert 200 fluorescence 
microscope (Carl Zeiss, Jena, Germany) equipped with a Zeiss Axiocam camera. 
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Light was collected through a 5 x 0.12 NA or a 10 x 0.25 NA objective (Carl Zeiss, 
Jena, Germany). EGFP fluorescence was excited using a 470±20 nm bandpass filter, 
and emission was collected using a 540±25 nm bandpass filter. Digital image 
recording and image analysis were performed with the Axiovision 3.1 software (Carl 
Zeiss, Jena, Germany). 
2.3.13. Confocal laser scanning microscopy of multicellular spheroids 
Multicellular spheroids were transferred to Lab-Tek 8 chambered coverglasses 
(Nalge Nunc International, Naperville, IL, USA) and fixed in 4 % PFA for 30 – 60 min. 
For counterstaining cells were incubated with DAPI (4',6-Diamidino-2-phenylindole) 
at a concentration of 1 µg/ml in PBS for 15 min. Imaging of EGFP expression of 
transfected multicellular spheroids was performed 48 h after transfection using a 
confocal laser scanning microscope (LSM 510 Meta, Carl Zeiss, Jena, Germany) 
equipped with an UV and an argon laser delivering light at 364 nm and 488 nm, 
respectively. Light was collected through a 10 x 0.3 NA objective (Carl Zeiss, Jena, 
Germany). DAPI fluorescence was excited with the 364 nm line; emission was 
collected using a 385 nm long-pass filter. Excitation of EGFP fluorescence was 
achieved by using the 488 nm line, with the resulting fluorescent wavelengths 
observed using a 505 nm long-pass filter. No signal overspill between the individual 
fluorescence channels was observed. An optical section thickness of 10 µm was 
chosen. Digital image recording and image analysis were performed with the LSM 5 
software, version 3.0 (Carl Zeiss, Jena, Germany). 
2.3.14. Cryosections of multicellular spheroids 
Multicellular spheroids were transferred to a 48-well plate prior fixation in 4 % PFA for 
2 h at 4°C. Subsequently the multicellular spheroids were incubated in 30 % sucrose 
(in water) over night at 4°C. The fixed multicellular spheroids were then embedded in 
tissue freezing medium (Leica Microsystems, Nussloch, Germany) and frozen at        
-20°C. Cryosections were made using a Leica CM3050S cryostat (Leica 
Microsystems, Nussloch, Germany) with a section thickness of 10 µm. Sections were 
transferred to SuperFrost microscope slides (Menzel, Braunschweig, Germany) prior 
to analysis by epifluorescence microscopy. 
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2.4. 2D Electrophoresis and MALDI-TOF mass spectrometry 
2.4.1. Sample preparation 
Cells grown as monolayers were harvested by treatment with trypsin/EDTA, washed 
with 40 ml PBS and 40 ml of 0.5 x PBS (to reduce salt concentration) in a Greiner 
tube, resuspended in 1 ml 0.5 x PBS and transferred to an Eppendorf tube. Washing 
solution was quantitatively removed by centrifugation prior adding of 460µl 2D-lysis-
buffer (9 M Urea, 5 mM EDTA, 4 % CHAPS, 1 % DTE). Cells were lysed for 15 
minutes. All centrifugation steps were carried out at 500 g for 10 min. 
Multicellular spheroids were transferred directly into 40 ml PBS provided in a Greiner 
tube, washed twice with 0.5 x PBS and lysed for 15 minutes directly in the Greiner 
tube after quantitative removal of washing solution. All centrifugation steps were 
carried out at 500 g for 5 min with subsequently removal of the solution by aspiration. 
Cell lysates were homogenized by centrifugation at 17.500 g in a QIAshredder 
Homogenizer (Qiagen, Hilden, Germany) for 2 minutes. After the following 
centrifugation at 17.600 x g for 30 minutes supernatants were transferred into fresh 
Eppendorf tubes. Samples were stored at -80°C. 
2.4.2. Measurement of protein concentration 
The concentration of protein samples was measured with the BIO-RAD protein assay 
(BIO-RAD, Munich, Germany) according to the manufacturer’s instructions. Samples 
were diluted 1:2, as the assay only tolerates 6 M urea. BSA was used for the protein 
standard curve and was therefore diluted in urea 2D-lysis-buffer. 
2.4.3. First dimension: Isoelectric focusing 
In the first dimension proteins were separated according to their isoelectric point. 
Isoelectric focusing (IEF) was carried out by using an Ettan IPGphor Isoelectric 
Focusing System (Amersham Biosciences, Uppsala, Sweden) according to the 
manufacturer’s instructions. Briefly, protein samples (containing 200 µg protein) were 
mixed with 3 µl IPG-Buffer of the appropriate pH and 2 µl of 3 mM bromophenol blue 
in resolving buffer (1.5 M Tris, 0.4 % SDS, pH 8.8) and were filled up to a final 
volume of 460 µl with 2D-lysis-buffer. The total solution was dispensed over the Ettan 
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IPGphor strip holder, a 24 cm pH 4 - 7 IPG DryStrip gel was applied and finally 
covered with 1 – 1.5 ml DryStrip Cover Fluid to prevent evaporation of the sample 
solution. Ettan IPGphor strip holders were placed on the top of the Ettan IPGphor 
platform and IEF was carried out according to the protocol shown in Table 1. 
Focusing took about 30 h at 20°C and 50 µA/strip, until in total 90 kVh were reached. 
Focused IPG DryStrip gels were stored at -80°C. IPG DryStrip gels and all materials 
used for IEF were purchased from Amersham Biosciences (Uppsala, Sweden). 
Step Voltage (V) Step Duration (h:min) 
Rehydration 0 0:10 
1 Step – n – hold 30 8:00 
2 Step – n – hold 50 4:00 
3 Step – n – hold 200 2:00 
4 Step – n – hold 500 2:00 
5 Step – n – hold 2000 2:00 
6 Step – n – hold 4000 2:00 
7 Gradient 8000 1:00 
8 Step – n – hold 8000 8:00 – 12:00 
Table 1. Running conditions for isoelectric focusing. “Step-n-Hold” sets the voltage at the selected 
value for the new step and then holds the voltage constant for the step duration. “Gradient” increases 
the voltage limit linearly with respect to time from the value set for the previous step to the value set for 
current step. 
2.4.4. Second dimension: SDS-page 
In the second dimension proteins were separated according to their molecular 
weight. Second dimension gel electrophoresis was carried out by using an Ettan 
DALTtwelve System (Amersham Biosciences, Uppsala, Sweden). First IPG DryStrip 
gels were equilibrated in equilibration buffer (6 M urea, 3.3 M glycerol, 70 mM SDS, 
3.3 % resolving buffer) containing 65 mM DTE and subsequent in equilibration buffer 
containing 215 mM iodoacetamide for 15 minutes each. The equilibrated IPG 
DryStrip gels were transferred on the top of 11 % SDS-polyacrylamidgels and sealed 
by adding of 1 - 2 ml of 0.5 % agarose (in SDS-running buffer: 1.9 M glycine, 0.25 M 
Tris, 1 % SDS). Second dimension gel electrophoresis was carried out according to 
the protocol shown in Table 2. 
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Step Constant power (W/gel) Time (h:min) Temperature (°C) 
Entry phase 2.5  0:45 20 
Second phase 18  4:00 – 6:00 20 
Table 2. Running conditions for second dimension gel electrophoresis. 
2.4.5. Silver staining 
Silver staining is the most sensitive non-radioactive method (below 1ng) to visualize 
proteins in SDS gels. A modified silver staining protocol, that makes the method 
compatible with mass spectrometry analysis, is shown in Table 3. 
Table 3. Mass spectrometry compatible silver staining protocol. 
2.4.6. 2D image analysis 
Transparency scanning of the silver-stained 2D gels was performed using the 
Amersham Biosciences ImageScanner (Amersham Biosciences, Uppsala, Sweden) 
and the Umax MagicScan 4.5 software (Umax, Duesseldorf, Germany). 2D image 
computer analysis was carried out using the Definiens Proteomweaver 2.2 software 
(Definiens, Munich, Germany) allowing automatic spot detection, spot matching and 
normalization. A protein was considered as differently expressed when the 
expression was at least two-fold up- or down-regulated and the alteration was at 
least detected in three separate gels of at least two independent 2D electrophoresis 
runs. 
Step Solution Time 
1 Fixation 40 % Ethanol  
10 % Acetic acid, glacial 
45 min or o/n 
2 Ethanol Washing 50 % Ethanol 3 x 20 min 
3 Sensitizing 1.3 mM Sodium thiosulfate  2 min 
4 Washing Distilled water 2 x 2 min 
5 Silver reaction 12 mM Silver nitrate  
0.075 % Formaldehyde (37 %)
20 min – 30 min 
6 Washing Distilled water 2 min 
7 Developing 0.57 M Sodium carbonate 
0.05 % Formaldehyde (37 %) 
0.03 mM Sodium thiosulfate 
0.2 min – 5 min 
8 Stop 40 mM EDTA 20 min 
9 Preservation 20 % Ethanol 
4 % Glycerol 
20 min or o/n 
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2.4.7. In-gel digestion 
Protein spots of interest were cut out of the gel with a sharp scalpel, stored at -80°C 
or immediately cut into approximately 1 mm x 1 mm pieces and transferred to 
Eppendorf tubes. The gel pieces were washed with 100 µl water for 30 minutes with 
shaking at 650 rpm. Destaining was carried out with 15 mM potassium ferricyanide 
and 50 mM sodium thiosulfate until dark color disappeared (approx. 5 minutes). 
Destaining was stopped by 3 x washing with 100 µl water for 5 minutes until the 
yellow color was removed. The gel pieces were then successively washed with 100 
µl acetonitrile, 50 mM ammonium bicarbonate and 50 % acetonitrile for 15 minutes 
each with shaking at 650 rpm. All steps were performed at room temperature. 
Digestion was carried out by incubation of the gel pieces in 50 mM ammonium 
bicarbonate containing 160 ng sequencing grade modified Porcine Trypsin 
(Promega, Mannheim, Germany) at 37°C overnight. Supernatants of overnight 
trypsin digestion and of two successive incubations with 100 µl extraction solution (75 
% acetonitrile, 12.5 mM ammonium bicarbonate) at 25°C with full speed shaking for 
30 minutes were transferred to the same fresh Eppendorf tube. The peptide 
containing supernatant was rapidly frozen in liquid nitrogen and lyophilized using a 
speed vac. 
2.4.8. Desalting and spotting of peptides onto the MALDI-TOF MS target 
Lyophilized peptides were solubilized in 0.1 % trifluoroacetic acid (TFA) and desalted 
by using C18 ZipTip pipette tips (Millipore, Bedford, USA). C18 ZipTip pipette tips 
were equilibrated by washing with 50 % acetonitrile and successive 0.1 % TFA each 
10 times. Peptides were bound to the ZipTip by ten aspiration and dispension cycles. 
The Zip Tip was subsequently washed three times with 0.1 % TFA. Desalted 
peptides were then directly eluted onto a clean MALDI-TOF MS (matrix assisted laser 
desorption ionization time of flight mass spectrometry) target with 2 µl of 50 % 
acetonitrile/0.1 % TFA saturated with alpha-cyano-4-hydroxy-cinnamic acid (Bruker 
Daltonics, Leipzig, Germany). 
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2.4.9. MALDI-TOF mass spectrometry and peptide mass fingerprinting 
MALDI-TOF mass spectrometry was carried out using an autoflex II spectrometer 
(Bruker Daltonics, Leipzig, Germany) in the reflector mode. The mass spectrometer 
was calibrated using a peptide calibration standard (Bruker Daltonics, Leipzig, 
Germany). For an enhanced resolution and sensitivity the pulsed ion extraction was 
adjusted. Mass spectra were processed and analyzed using the flexAnalysis 
software (Bruker Daltonics, Leipzig, Germany). Briefly, mass spectra were smoothed 
using the Savitzky Golay algorithm, baseline was subtracted using the Convex Hull 
algorithm and peaks were detected using the SNAP algorithm. Internal recalibration 
of the mass spectra was performed using peaks derived from autoproteolysis of 
trypsin. Peptide mass fingerprinting was performed by using the BioTools software 
(Bruker Daltonics, Leipzig, Germany). Briefly, proteins were identified by database 
search on MASCOT server (http://www.matrixscience.com) using the MSDB 
database. Searches were performed with carboxymethyl as fixed modification and 
oxidation as variable modification. A peptide mass tolerance of 50 ppm and maximal 
one missing cleavage were allowed. 
2D electrophoresis and MALDI-TOF mass spectrometry were established in the lab 
in the context of this PhD thesis. 
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3. Results 
3.1. Multicellular spheroids of low passage colon cancer cell lines 
- A promising model system for colorectal cancer  
The lack of suitable cancer model systems is a major obstacle for the investigation of 
cancer in general and for the development of effective therapy strategies in 
particular. A promising prospect is provided by recently developed low passage colon 
cancer cell lines, closely reflecting the phenotypes of the corresponding original 
tumors. These cell lines provided the starting point of this PhD thesis. It was reported 
previously that tumor cells grown as multicellular spheroids recapitulate the 
properties of in vivo tumors better than the same cells cultured as monolayers (Mayer 
et al., 2001). Therefore, multicellular tumor spheroid cultures of the low passage 
colon cancer cell lines were established which are expected to mirror the three-
dimensional structure of the original tumors even more closely. Differences on the 
level of protein expression between monolayers and multicellular spheroids of the 
low passage colon cancer cells were analyzed in this thesis.  
3.1.1. Establishment of multicellular spheroids of low passage colon cancer 
cell lines 
Five low passage colon cancer cell lines of three different phenotypic morphologies 
(epithelial-like: COGA-5, piled-up: COGA-5L and COGA-12, rounded-up: COGA-2 
and COGA-3) were tested for their ability to form multicellular spheroids. The 
multicellular spheroid formation was performed with the liquid overlay technique. The 
cell line COGA-5 formed fully compact spheroids, the cell lines COGA-5L and COGA-
12 formed partly compact spheroids with local areas of compaction as shown in Fig. 
4. The other cell lines tested did not form multicellular spheroids. 
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Fig. 4. Multicellular spheroids of COGA-5 (A), COGA-5L (B) and COGA-12 (C) cells using the 
liquid overlay technique. 1 x 105 cells were seeded in agarose-covered 24 well plates and cultivated 
in medium containing 10 % serum for 96 h (COGA-5 and COGA-5L) or 72 h (COGA-12). COGA-5 
cells are forming fully compact spheroids, the cell lines COGA-5L and COGA-12 are forming partly 
compact spheroids with local areas of compaction. Respective magnifications of transmission light 
microscopy are indicated. 
3.1.2. Differences in the expression profiles of multicellular spheroids 
compared to corresponding monolayer cultures 
In order to analyze potential differences in protein expression protein extracts of 
monolayer cultures of the cell lines COGA-5, COGA-5L and COGA-12 were 
compared with protein extracts from respective multicellular spheroids by 2D 
electrophoresis. For this purpose, ten multicellular spheroids grown for 96 hours were 
pooled and 200 µg total protein thereof were compared with 200 µg total protein of 
the corresponding monolayer cultures. To have always comparable growing 
conditions monolayer cultures were grown to near confluence prior multicellular 
spheroid formation and sample preparation. As shown in Fig. 5 - 7 2D 
electrophoresis revealed differences in the expression of six proteins in multicellular 
spheroids of COGA-5 cells (five up- and one down-regulated), of four in COGA-5L 
multicellular spheroids (all up-regulated) and of four (all up-regulated) in COGA-12 
multicellular spheroids compared to the respective monolayer cultures. The 
respective abbreviations used for numbering the spots are explained as follows: e.g. 
SPH12-U1 stands for multicellular spheroid of COGA-12 cells, up-regulated spot 
number 1. Two of the differentially regulated proteins in COGA-5L multicellular 
spheroids, i.e. SPH5L-U1 and SPH5L-U2, are probably identical to SPH5-U1 and 
SPH5-U2 that were up-regulated in COGA-5 multicellular spheroids. Moreover, 
SPH5L-U4a and SPH5L-U4b that were up-regulated in COGA-5L multicellular 
spheroids localize at the same position on the 2D gel as SPH12-U3a and SPH12-
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U3b that were up-regulated in COGA-12 multicellular spheroids. The average 
intensities of all detected proteins altered between monolayers and corresponding 
multicellular spheroids are shown in Table 4. 
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Fig. 5. Differences in the expression profiles of multicellular spheroids of COGA-5 cells and 
their corresponding monolayer cultures obtained by 2D electrophoresis. 2D electrophoresis was 
performed with IPG dry strips ph 4 - 7 in the first dimension and 11 % SDS-polyacrylamidgels in the 
second dimension. Representative silver-stained gels are shown. Differences in the expression 
profiles are marked with an arrow. The respective spot intensities are listed in Table 4 and 
corresponding proteins identified by MALDI-TOF mass spectrometry are listed in Table 5. Respective 
abbreviations for numbering of spots: e.g. SPH5-U1: multicellular spheroid of COGA-5 cells, up-
regulated spot number 1. 
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Fig. 6. Differences in the expression profiles of multicellular spheroids of COGA-5L cells and 
their corresponding monolayer cultures obtained by 2D electrophoresis. 2D electrophoresis was 
performed as described in Fig. 5. Representative silver-stained gels are shown. Differences in the 
expression profiles are marked with an arrow. The respective spot intensities are listed in Table 4. 
Respective abbreviations for numbering of spots: e.g. SPH5L-U1: multicellular spheroid of COGA-5L 
cells, up-regulated spot number 1. 
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Fig. 7. Differences in the expression profiles of multicellular spheroids of COGA-12 cells and 
their corresponding monolayer cultures obtained by 2D electrophoresis. 2D electrophoresis was 
performed as described in Fig. 5. Representative silver-stained gels are shown. Differences in the 
expression profiles are marked with an arrow. The respective spot intensities are listed in Table 4 and 
corresponding proteins identified by MALDI-TOF mass spectrometry are listed in Table 5. Respective 
abbreviations for numbering of spots: e.g. SPH12-U1: multicellular spheroid of COGA-12 cells, up-
regulated spot number 1. 
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Spot 
number 
Average intensity 
in monolayer cultures 
Average intensity 
in multicellular spheroids
Ratio 
multicellular spheroids / 
monolayers 
SPH5U-1 0.098 ± 0.041 0.210 ± 0.075 2.15 
SPH5U-2 --- 0.264 ± 0.222 only expressed in multicellular spheroids 
SPH5U-3 0.261 ± 0.223 0.635 ± 0.103 2.44 
SPH5U-4 0.220 ± 0.064 0.762 ± 0.096 3.47 
SPH5U-5 --- 0.256 ± 0.021 only expressed in multicellular spheroids 
SPH5D-1 0.551 ± 0.046 0.198 ± 0.051 0.36 
SPH5LU-1 --- 0.054 ± 0.003 only expressed in multicellular spheroids 
SPH5LU-2* 0.122* ± 0.000 0.191* ± 0.025 1.56* 
SPH5LU-3a 0.80 ± 0.259 0.247 ± 0.013 3.07 
SPH5LU-3b --- 0.060 ± 0.013 only expressed in multicellular spheroids 
SPH12U-1 0.179 ± 0.083 0.461 ± 0.060 2.57 
SPH12U-2 0.301 ± 0.025 0.609 ± 0.086 2.02 
SPH12U-3a 0.057 ± 0.003 0.136 ± 0.026 2.37 
SPH12U-3b --- 0.048 ± 0.002 only expressed in multicellular spheroids 
Table 4. Average intensities of the protein spots altered between 2D gels of monolayers and 
corresponding multicellular spheroids of cell lines COGA-5, COGA-5L and COGA-12. The 
respective normalized average intensities ± SE of at least three separate 2D gels analyzed with the 
Proteomweaver software are listed. (*) does not fulfill the requirement to be at least two-fold up- or 
down-regulated (as described in material and methods). 
The proteins in the differently expressed spots were analyzed by MALDI-TOF mass 
spectrometry and subsequent peptide mass fingerprinting. Therefore, the protein 
spots of interest were cut out of the 2D gel, trypsin-digested and spotted on a MALDI-
TOF target plate. However, MALDI-TOF mass spectrometry did not lead to 
identification of spots from a standard 2D gel with a total protein load of 200 µg 
(corresponding to approximately 0.075 x 106 cells). Therefore, preparative 2D gels (of 
monolayer cultures) were made with total protein of about 10 x 106 cells. In this case, 
staining time of the gels had to be reduced drastically. By using spots of these 
preparative 2D gels for mass spectrometry three of the differently expressed proteins 
in COGA-5 multicellular spheroids could be identified as 15-hydroxyprostaglandin 
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dehydrogenase, LMNA protein and acidic calponin (Table 5). It was also possible to 
identify two differently regulated proteins in COGA-12 multicellular spheroids as the 
same protein, namely acidic ribosomal protein P0 (Table 5). This protein appears at 
two neighboring positions on the 2D gel most likely as a result of different 
posttranslational modifications (PTMs). Corresponding mass spectra and protein 
identifications results are shown in Fig. 8 - 12. None of the changes in the expression 
profile of multicellular spheroids of COGA-5L cells could be ascribed to known 
proteins. 
Spot number 
Protein name 
identified by MALDI-TOF mass spectrometry 
Cell line Regulation in 
 multicellular spheroids
SPH5U-1 not identified COGA-5 up 
SPH5U-2 not identified COGA-5 up 
SPH5U-3 not identified COGA-5 up 
SPH5U-4 15-Hydroxyprostaglandin Dehydrogenase  COGA-5 up 
SPH5U-5 LMNA protein COGA-5 up 
SPH5D-1 Calponin, acidic isoform COGA-5 down 
SPH5LU-1 not identified COGA-5L up 
SPH5LU-2 not identified COGA-5L up 
SPH5LU-3a not identified COGA-5L up 
SPH5LU-3b not identified COGA-5L up 
SPH12U-1 Acidic Ribosomal Protein P0 COGA-12 up 
SPH12U-2 Acidic Ribosomal Protein P0 COGA-12 up 
SPH12U-3a not identified COGA-12 up 
SPH12U-3b not identified COGA-12 up 
Table 5. Proteins differentially expressed between multicellular spheroids of cell lines COGA-5, 
COGA-5L and COGA-12 and corresponding monolayers. 
 
Results 45 
1834.938
842.509
1212.724
975.550
1374.732 2211.069
1512.758
621.955
1733.793
670.253
3337.5012089.036
1072.668 1650.884 2300.081
3119.311
0.00
0.25
0.50
0.75
1.00
1.25
4x10
In
te
ns
. [
a.
u.
]
00 1000 1500 2000 2500 3000
m/z
In
te
ns
ity
 [a
.u
.]
B C
D Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence7 - 19     1212.72  1211.72  1211.70     0.02     0  K.VALVTGAAQGIGR.A 
20 - 28      975.55   974.54   974.58    -0.04     0  R.AFAEALLLK.G 
32 - 46     1701.81  1700.80  1700.86    -0.06     0  K.VALVDWNLEAGVQCK.A 
47 - 57     1275.60  1274.59  1274.61    -0.02     0  K.AALDEQFEPQK.T 
58 - 72     1834.94  1833.93  1833.90     0.03     0  K.TLFIQCDVADQQQLR.D 
77 - 84      957.54   956.54   956.52     0.02     1  R.KVVDHFGR.L 
78 - 84      829.45   828.44   828.42     0.02     0  K.VVDHFGR.L 
85 - 98     1512.76  1511.75  1511.79    -0.04     0  R.LDILVNNAGVNNEK.N 
156 - 163     886.51   885.51   885.48     0.02     0  K.HGIVGFTR.S 
164 - 177    1374.73  1373.72  1373.71     0.02     0  R.SAALAANLMNSGVR.L 
164 - 177    1390.67  1389.66  1389.70    -0.04     0  R.SAALAANLMNSGVR.L Oxidation (M) 
178 - 196    2089.04  2088.03  2088.09    -0.06     0  R.LNAICPGFVNTAILESIEK.E 
250 - 264    1767.78  1766.77  1766.83    -0.05     0  K.GIHFQDYDTTPFQAK.T
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Fig. 8. Identification of spot SPH5U-1. (A) Mass spectrum of SPH5U-1 obtained after in-gel 
digestion and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search 
on MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum 
using peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing 
only 1 missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph. (D) Peptides matched with the sequence of 15-
hydroxyprostaglandin dehydrogenase and their molecular mass are reported.  
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Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence
12 - 25     1359.68  1358.68  1358.68    -0.00     0  R.SGAQASSTPLSPTR.I 
29 - 41     1629.80  1628.79  1628.80    -0.01     1  R.LQEKEDLQELNDR.L 
42 - 48      849.49   848.48   848.48     0.01     0  R.LAVYIDR.V 
51 - 60     1089.56  1088.55  1088.55     0.00     0  R.SLETENAGLR.L
63 - 72     1148.59  1147.58  1147.57     0.01     0  R.ITESEEVVSR.E
79 - 89     1165.54  1164.53  1164.54    -0.01     0  K.AAYEAELGDAR.K 
79 - 90     1293.60  1292.59  1292.64    -0.04     1  K.AAYEAELGDARK.T 
109 - 114     807.43   806.42   806.43    -0.01     1  K.VREEFK.E 
124 - 133    1043.55  1042.55  1042.54     0.01     0  K.EGDLIAAQAR.L
156 - 166    1338.67  1337.66  1337.71    -0.04     1  K.RTLEGELHDLR.G 
157 - 166    1182.60  1181.59  1181.60    -0.02     0  R.TLEGELHDLR.G 
157 - 171    1665.85  1664.84  1664.88    -0.04     1  R.TLEGELHDLRGQVAK.L 
181 - 189    1160.60  1159.59  1159.60    -0.01     1  K.KQLQDEMLR.R 
182 - 189    1032.51  1031.50  1031.51    -0.01     0  K.QLQDEMLR.R 
197 - 208    1509.70  1508.70  1508.75    -0.06     1  R.LQTMKEELDFQK.N 
209 - 216    1023.51  1022.50  1022.50     0.00     0  K.NIYSEELR.E 
367 - 378    1475.75  1474.74  1474.76    -0.02     1  K.LALDMEIHAYRK.L Oxidation (M) 
428 - 439    1320.60  1319.59  1319.63    -0.04     1  R.SSFSQHARTSGR.V
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Fig. 9. Identification of spot SPH5U-2. (A) Mass spectrum of SPH5U-2 obtained after in-gel 
digestion and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search 
on MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum 
using peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing 
only 1 missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph. (D) Peptides matched with the sequence of LMNA 
protein and their molecular mass are reported.  
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Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence
24 - 33     1275.52  1274.51  1274.55    -0.04     0  K.YDHQAEEDLR.N 
34 - 53     2233.06  2232.06  2232.12    -0.07     0  R.NWIEEVTGMSIGPNFQLGLK.D 
65 - 71      728.40   727.39   727.42    -0.03     0  K.LQPGSVK.K 
73 - 91     2202.07  2201.06  2201.11    -0.05     0  K.VNESSLNWPQLENIGNFIK.A 
133 - 143    1187.62  1186.61  1186.63    -0.02     0  K.GFHTTIDIGVK.Y 
151 - 156     751.35   750.34   750.37    -0.03     1  R.RFDEGK.L 
159 - 172    1403.68  1402.67  1402.72    -0.05     0  K.AGQSVIGLQMGTNK.C 
173 - 185    1373.61  1372.60  1372.59     0.02     0  K.CASQAGMTAYGTR.R 
186 - 192     928.47   927.46   927.49    -0.03     1  R.RHLYDPK.M 
193 - 212    2284.06  2283.06  2283.09    -0.03     0  K.MQTDKPFDQTTISLQMGTNK.G 
213 - 225    1216.62  1215.61  1215.60     0.01     0  K.GASQAGMLAPGTR.R 
213 - 225    1232.59  1231.59  1231.60    -0.01     0  K.GASQAGMLAPGTR.R Oxidation (M) 
227 - 232     781.34   780.34   780.37    -0.03     0  R.DIYDQK.L 
233 - 251    2059.97  2058.96  2059.06    -0.10     0  K.LTLQPVDNSTISLQMGTNK.V 
257 - 265     939.48   938.48   938.46     0.01     0  K.GMSVYGLGR.Q 
257 - 265     955.44   954.43   954.46    -0.03     0  K.GMSVYGLGR.Q Oxidation (M) 
266 - 271     749.37   748.36   748.38    -0.02     0  R.QVYDPK.Y 
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Fig. 10. Identification of spot SPH5D-1. (A) Mass spectrum of SPH5D-1 obtained after in-gel 
digestion and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search 
on MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum 
using peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing 
only 1 missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph. (D) Peptides matched with the sequence of acidic 
calponin and their molecular mass are reported.  
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Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence
1 - 6       819.37   818.37   818.37    -0.00     1  -.MPREDR.A Oxidation (M) 
11 - 16      771.37   770.36   770.40    -0.03     0  K.SNYFLK.I 
17 - 26     1217.64  1216.63  1216.67    -0.04     0  K.IIQLLDDYPK.C 
27 - 38     1266.57  1265.56  1265.61    -0.05     0  K.CFIVGADNVGSK.Q 
39 - 44      803.42   802.42   802.41     0.00     0  K.QMQQIR.M 
67 - 77     1221.57  1220.56  1220.61    -0.05     0  R.GHLENNPALEK.L 
78 - 83      748.49   747.48   747.48     0.01     0  K.LLPHIR.G 
78 - 92     1697.92  1696.91  1696.98    -0.06     1  K.LLPHIRGNVGFVFTK.E 
84 - 92      968.52   967.51   967.51     0.00     0  R.GNVGFVFTK.E 
84 - 99     1824.91  1823.91  1823.94    -0.04     1  R.GNVGFVFTKEDLTEIR.D 
93 - 99      875.41   874.40   874.44    -0.04     0  K.EDLTEIR.D 
93 - 106    1676.81  1675.80  1675.85    -0.05     1  K.EDLTEIRDMLLANK.V Oxidation (M) 
113 - 134    2180.02  2179.01  2179.09    -0.08     0  R.AGAIAPCEVTVPAQNTGLGPEK.T 
135 - 146    1313.68  1312.68  1312.70    -0.03     0  K.TSFFQALGITTK.I 
150 - 162    1428.80  1427.79  1427.82    -0.03     0  R.GTIEILSDVQLIK.T 
215 - 220     720.43   719.42   719.40     0.03     0  R.FLEGVR.N 
221 - 246    2787.32  2786.31  2786.44    -0.13     0  R.NVASVCLQIGYPTVASVPHSIINGYK.R 
248 - 264    1895.94  1894.93  1894.99    -0.06     0  R.VLALSVETDYTFPLAEK.V 
267 - 297    2752.34  2751.33  2751.46    -0.13     0  K.AFLADPSAFVAAAPVAAATTAAPAAAAAPAK.V 
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Fig. 11. Identification of spot SPH12U-1. (A) Mass spectrum of SPH12U-1 obtained after in-gel 
digestion and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search 
on MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum 
using peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing 
only 1 missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph (D) Peptides matched with the sequence of acidic 
ribosomal protein P0 and their molecular mass are reported.  
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m/z
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence
11 - 16      771.37   770.37   770.40    -0.03     0  K.SNYFLK.I 
17 - 26     1217.62  1216.61  1216.67    -0.06     0  K.IIQLLDDYPK.C 
27 - 38     1266.57  1265.57  1265.61    -0.04     0  K.CFIVGADNVGSK.Q 
39 - 44      803.46   802.45   802.41     0.04     0  K.QMQQIR.M 
67 - 77     1221.60  1220.60  1220.61    -0.02     0  R.GHLENNPALEK.L 
78 - 83      748.49   747.48   747.48     0.00     0  K.LLPHIR.G 
78 - 92     1697.97  1696.96  1696.98    -0.01     1  K.LLPHIRGNVGFVFTK.E 
84 - 92      968.50   967.49   967.51    -0.02     0  R.GNVGFVFTK.E 
84 - 99     1824.97  1823.96  1823.94     0.02     1  R.GNVGFVFTKEDLTEIR.D 
93 - 99      875.44   874.43   874.44    -0.01     0  K.EDLTEIR.D 
93 - 106    1676.82  1675.82  1675.85    -0.03     1  K.EDLTEIRDMLLANK.V Oxidation (M) 
107 - 112     584.35   583.34   583.34    -0.01     0  K.VPAAAR.A 
113 - 134    2180.08  2179.07  2179.09    -0.02     0  R.AGAIAPCEVTVPAQNTGLGPEK.T 
135 - 146    1313.71  1312.70  1312.70     0.00     0  K.TSFFQALGITTK.I 
150 - 162    1428.85  1427.84  1427.82     0.02     0  R.GTIEILSDVQLIK.T 
215 - 220     720.43   719.42   719.40     0.02     0  R.FLEGVR.N 
221 - 246    2787.38  2786.37  2786.44    -0.07     0  R.NVASVCLQIGYPTVASVPHSIINGYK.R 
247 - 264    2052.10  2051.09  2051.09    -0.01     1  K.RVLALSVETDYTFPLAEK.V 
248 - 264    1896.00  1894.99  1894.99    -0.00     0  R.VLALSVETDYTFPLAEK.V 
267 - 297    2752.40  2751.40  2751.46    -0.06     0  K.AFLADPSAFVAAAPVAAATTAAPAAAAAPAK.V 
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Fig. 12. Identification of spot SPH12U-2. (A) Mass spectrum of SPH12U-2 obtained after in-gel 
digestion and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search 
on MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum 
using peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing 
only 1 missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph. (D) Peptides matched with the sequence of acidic 
ribosomal protein P0 and their molecular mass are reported.  
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3.2. Chemotherapy of colorectal cancer – Detection of proteins 
associated with chemoresistance against 5-FU 
The incidence of chemoresistance is a major hindrance for the classical treatment of 
colorectal cancer. Therefore, the investigation of chemoresistance is an important 
objective. In this thesis the detection of proteins associated with acquired 
chemoresistance against 5-FU was performed by comparison of the expression 
profiles of sensitive low passage colon cancer cells and the corresponding resistant 
sublines by 2D electrophoresis. For this purpose, resistant sublines of the low 
passage colon cancer cells were established.  
3.2.1. Determination of 5-FU concentrations required for reduction of 
proliferation of selected low passage colon cancer cells 
For the investigation of acquired chemoresistance the cell lines forming multicellular 
spheroids were used, i.e. COGA-12, COGA-5 and COGA-5L. First, the 5-FU 
concentrations were determined that significantly reduced proliferation of each cell 
line. The proliferation of the 5-FU-treated cell lines was investigated by the Hoechst 
33258 proliferation assay. However, prior the use of this method its reliability was 
verified. For this purpose, COGA-12 cells were harvested by treatment with 
trypsin/EDTA solution and cell concentration was determined. Different cell numbers 
were then transferred to Eppendorf tubes and centrifuged at 500 rpm. The cell pellets 
were used for the performing of the Hoechst 33258 proliferation assay directly in the 
Eppendorf tubes as described in materials and methods. For measurement the whole 
content of the tubes was transferred to black 96 well-plates. Fig. 13 demonstrates 
that the Hoechst 33258-based proliferation assay is reliable for cell numbers ranging 
from 1 x 103 to 7 x 104. 
 
 
 
 
 
Results 51 
 
R2 = 0,9982
0
5000
10000
15000
20000
25000
30000
35000
0 10000 20000 30000 40000 50000 60000 70000 80000
H
oe
ch
st
 fl
uo
re
sc
en
ce
H
oe
ch
st
 fl
uo
re
sc
en
ce
 
Fig. 13. Validation of the Hoechst 33258-based proliferation assay. COGA-12 cells were 
harvested with trypsin/EDTA and the assay was performed by incubating 1 x 103 - 7 x 104 cells with 
100µl H2O at 37°C for 1 hour, following one freeze/thaw cycle. After adding of 100µl 2x TNE buffer 
containing Hoechst 33258, fluorescence was determined at 465 nm in a SPECTRAFluor Plus plate 
reader (excitation: 360 nm). Values are means ± SE of triplicates. 
To determine the optimal 5-FU concentration range for further experiments both cell 
lines COGA-12 and COGA-5L were treated with different concentrations of 5-FU 
ranging from 2.5 µM to 500 µM. The level of cell proliferation was determined from 1 
to 6 days after beginning of the treatment by using the Hoechst 33258-based 
proliferation assay. The results demonstrated that already after two to three days a 
significant reduction of cell proliferation was observed already at low 5-FU 
concentrations of 2.5 µM – 10 µM (Fig. 14).  
Results 52 
DMSO 2.5 µM 5 µM 10 µM
30 µM 100 µM 500 µM
COGA-12
days
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
1 2 3 4 5 6
H
oe
ch
st
 fl
uo
re
sc
en
ce
B
COGA-5L
days
0
5000
10000
15000
20000
25000
30000
1 2 3 4 5 6
Ho
ec
hs
t f
lu
or
es
ce
nc
e
A
H
oe
ch
st
 fl
uo
re
sc
en
ce
H
oe
ch
st
 fl
uo
re
sc
en
ce
Ho
ec
hs
t f
lu
or
es
ce
nc
e
Ho
ec
hs
t f
lu
or
es
ce
nc
e
 
Fig. 14. Kinetics of 5-FU treatment of COGA-5L (A) and COGA-12 (B) cells. 1.5 x 104 cells/well 
were treated from 1 to 6 days with different concentrations of 5-FU. Growth medium was exchanged 
every day. Cell proliferation was determined with the Hoechst 33258-based proliferation assay. Values 
are means ± SE of triplicates. 
The further experiments to determine the 5-FU concentrations required for reduction 
of proliferation of the cell lines COGA-12, COGA-5 and COGA-5L were therefore 
performed in a concentration range of 2.5 µM to 10 µM 5-FU. Cell proliferation was 
determined after two and three days of treatment again by the Hoechst 33258-based 
proliferation assay (Fig. 15). In all tested cell lines the reduction of cell proliferation 
by 5-FU was more pronounced at day three after beginning of the treatment 
compared to day two. After three days the DNA amount of 5 µM 5-FU-treated COGA-
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5L and COGA-12 cells was 49 % and 44 % compared to the respective untreated 
cells (Fig. 15). Increasing of the 5-FU concentration to 10 µM further reduced the 
proliferation of COGA-12 cells down to 25 % compared to untreated cells. In COGA-5 
cells 5 µM 5-FU and 10 µM 5-FU reduced proliferation to 73 % and 62 % of the 
proliferation of untreated cells, respectively (Fig. 15). 
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Fig. 15. Determination of 5-FU concentrations required for reduction of proliferation of COGA-5 
(A), COGA-5L (B) and COGA-12 (C) cells. 1.5 x 104 COGA-5L or COGA-12 cells/well and 0.4 x 104 
COGA-5 cells/well were treated for 2 and 3 days with different concentrations of 5-FU. Growth medium 
was exchanged every day. Cell proliferation was determined with the Hoechst 33258-based 
proliferation assay. Proliferation levels are shown as the percentage of proliferation levels of the 
respective untreated cells. The values are means ± SE of triplicates of 2 - 3 independent experiments. 
3.2.2. Long-term 5-FU treatment of selected low passage colon cancer cells  
In order to obtain chemoresistant sublines COGA-12, COGA-5 and COGA-5L cells 
were treated continuously with 5-FU. First, all cell lines were treated for one month 
with 10 µM 5-FU. In a separate experiment, COGA-5 cells were additionally 
incubated with 5 µM 5-FU. Growth medium containing 5-FU was replaced three times 
per week to ensure constant 5-FU concentrations. COGA-5 cells did not survive the 
treatment with 5 µM or 10 µM 5-FU for one month. Concentrations of 5-FU lower than 
5 µM, however, did not reduce proliferation of COGA-5 cells. Therefore, no 
chemoresistant sublines of COGA-5 could be established. For COGA-12 and COGA-
5L cells the concentration of 5-FU was doubled after one month and cells were 
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incubated for another two months with continuously 5-FU-containing growth medium 
exchange three times a week. After total 5-FU treatment for three months the 5-FU 
containing medium was removed and the cell lines were propagated in 5-FU free 
medium. 
3.2.3. Effect of 5-FU on proliferation of the long-term 5-FU-pretreated sublines 
In order to test whether the long-term 5-FU-pretreated sublines of COGA-5L and 
COGA-12 (referred to as COGA-12/G6) developed resistance against 5-FU, the 
effect of 5-FU on their proliferation was compared to the parental not 5-FU-pretreated 
cell lines. Proliferation of COGA-12/G6 cells was only reduced to 73 % and 56 % of 
the proliferation of untreated COGA-12/G6 cells after treatment with 5 µM and 10 µM 
5-FU for three days (Fig. 16). Therefore, COGA-12/G6 cells were more resistant 
against 5-FU than the parental COGA-12 cells, where proliferation was reduced to 37 
% and 24 % compared to untreated COGA-12 cells by three-day treatment with 5 µM 
and 10 µM 5-FU in parallel experiments (Fig. 16). The long-term 5-FU pretreated 
COGA-5L subline did not demonstrate an enhanced proliferation level when 
retreated with 5-FU in comparison to parental COGA-5L cell line (data not shown). 
Thus, no COGA-5L chemoresistant subline could be established. 
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Fig. 16. Proliferation levels of three months 5-FU-pretreated COGA-12 cells (referred to as 
COGA-12/G6) and parental COGA-12 cells (not 5-FU-pretreated) after incubation with different 
concentrations of 5-FU for three days. Growth medium was exchanged every day. Cell proliferation 
was determined with the Hoechst 33258-based proliferation assay. Proliferation levels are shown as 
the percentage of the proliferation levels of the respective untreated cells. The values are means ± SE 
of triplicates in two independent experiments. 
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3.2.4. Effect of 5-FU on the induction of apoptosis in the long-term 5-FU 
pretreated subline COGA-12/G6 
Next, it was investigated if in addition to the enhanced proliferation despite of the 
presence of 5-FU also the percentage of 5-FU-induced apoptosis is lower in the 
chemoresistant subline COGA-12/G6 compared to the parental COGA-12 cell line. 
Therefore, both cell lines were treated for three days with 20 µM 5-FU. Afterwards, 
the level of apoptosis and necrosis in 5-FU treated cells was determined after 
staining with annexin V-FITC and propidium iodide (PI), and subsequent flow 
cytometric analysis. Thereby, PI fluorescence was determined at a wavelength of 
575 nm after excitation at 488 nm. However, also autofluorescence of 5-FU-treated 
COGA-12 cells (and not of untreated cells) was detected under these conditions 
(data not shown). Therefore, the flow cytometric analysis was modified. PI was 
excited at a wavelength of 356 nm and the emission was detected using a 700±20 
nm bandpass filter thereby excluding the autofluorescence of 5-FU treated cells (data 
not shown). 
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Fig. 17. Percentage of apoptotic cells in 5-FU treated chemoresistant COGA-12/G6 cells and 
parental COGA-12 cells. 2.8 x 105 cells per well were incubated with 20 µM 5-FU for three days. 
Growth medium was exchanged every day. Necrotic cells were detected after staining with propidium 
iodide and apoptotic cells after staining with annexin V and subsequent flow cytometry. The values are 
representative means ± SE of duplicates in two independent experiments. 
As shown in Fig. 17 the modified flow cytometric analysis revealed that 20 µM 5-FU 
induced 32 % apoptotic and 14 % necrotic cells within the parental COGA-12 cells 
three days after beginning of the treatment, whereas in resistant COGA-12/G6 cells 
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the levels of apoptotic and necrotic cells were only 6 % and 12 %, respectively. It is 
noteworthy that the percentages of apoptotic and necrotic cells in COGA-12/G6 cells 
treated with 20 µM 5-FU did not differ from control levels of untreated COGA-12/G6 
cells (7 % apoptotic and 12 % necrotic cells). 
Thus, COGA-12/G6 cells pretreated with 5-FU for three months were resistant 
against both 5-FU-induced apoptosis and inhibition of proliferation. Moreover, the 
morphology of the resistant COGA-12/G6 cells was slightly different compared to the 
parental COGA-12 cells (Fig. 18), and they did not form multicellular spheroids. 
COGA-12 COGA-12/G6
320x
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Fig. 18. Morphologies of parental COGA-12 (A) and 5-FU resistant COGA-12/G6 cells (B). 
Respective magnifications of transmission light microscopy are indicated. 
3.2.5. Effect of 5-FU on proliferation and apoptosis in long-term propagated 
COGA-12 cells 
Since the resistant COGA-12/G6 cells were cultured long term, it was investigated if 
already the long culture time of this cells has changed their response to 5-FU. To this 
end, parental COGA-12 cells were cultivated for the same time as COGA-12/G6 
cells, but in the absence of 5-FU treatment. These high passage cells (referred to as 
COGA-12/NO) also demonstrated altered morphology when compared with the 
parental low passage COGA-12 cells as shown in Fig. 19, and they also were not 
able to form multicellular spheroids. 
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Fig. 19. Morphologies of low (A) and high (B) passage COGA-12 cells. High passage COGA-12 
cells are referred to as COGA-12/NO. Respective magnifications of transmission light microscopy are 
indicated. 
The effect of 5-FU on proliferation of COGA-12/NO cells was investigated similar as 
described before. The COGA-12/NO cells exhibited comparable sensitivity to 5-FU-
induced reduction of proliferation as the parental short term cultivated COGA-12 cells 
(Fig. 20).  
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Fig. 20. Proliferation levels of low and high passage COGA-12 cells after incubation with 
different concentrations of 5-FU for three days. High passage COGA-12 cells are referred to as 
COGA-12/NO. Growth medium was exchanged every day. Cell proliferation was determined with the 
Hoechst 33258-based proliferation assay. Proliferation levels are shown as the percentage of 
proliferation levels of the respective untreated cells. The values are means ± SE of triplicates. 
Next, the level of 5-FU induced apoptosis of COGA-12/NO cells was investigated 
(Fig. 21). Surprisingly, after 5-FU treatment the percentage of apoptotic COGA-
12/NO cells was as low as in the 5-FU resistant COGA-12/G6 cells (7 %). This result 
suggested that the COGA-12/NO cells also developed resistance against 5-FU-
induced apoptosis, because of changes attributed to their long term cultivation. 
However, they did not develop resistance against 5-FU-induced inhibition of 
proliferation. 
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Fig. 21. Percentage of apoptotic cells in 5-FU treated low and high passage COGA-12 cells. 2.8 
x 105 cells per well were incubated with 20 µM 5-FU for three days. Growth medium was exchanged 
every day. Necrotic cells were detected after staining with propidium iodide and apoptotic cells after 
staining with annexin V and subsequent flow cytometry. The values are representative means ± SE of 
duplicates in two independent experiments. 
3.2.6. Differences in the expression profiles of chemoresistant cells compared 
to corresponding chemosensitive cells 
To discover changes in the expression profile that are responsible for mediating the 
above described chemoresistance, the expression profile of the chemoresistant 
subline COGA-12/G6 was compared with the expression profile of the corresponding 
5-FU sensitive parental cell line COGA-12 by 2D electrophoresis. 2D electrophoresis 
was performed with 200µg total protein of sensitive COGA-12 cells and resistant 
COGA-12/G6 cells. In addition, 2D electrophoresis was also performed with COGA-
12/NO cells, which were resistant against 5-FU-induced apoptosis as consequence 
of long-term cultivation without 5-FU treatment, to distinguish between changes in the 
expression profile due to long-term 5-FU treatment or long-term propagation alone. 
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Fig. 22. Differences in the expression profiles of COGA-12, COGA-12/G6 and COGA-12/NO cells 
obtained by 2D electrophoresis. 2D electrophoresis was performed with IPG dry strips ph 4 - 7 in 
the first dimension and 11 % SDS-polyacrylamidgels in the second dimension. Representative silver 
stained gels are shown. Differences in the expression profiles are marked with an arrow. The 
respective spot intensities are listed in Table 6 and corresponding proteins identified by MALDI-TOF 
mass spectrometry are listed in Table 7. Respective abbreviations for numbering of spots: e.g. G6-D1: 
COGA-12/G6 cells, down-regulated spot number 1. 
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As shown in Fig. 22 the performance of 2D electrophoresis revealed four spots that 
were differentially expressed between parental COGA-12 and chemoresistant 
COGA-12/G6 cells. One of them was up-regulated and the other three were down- 
regulated in the chemoresistant subline. All four changes were found exclusively in 
COGA-12/G6 cells but not in COGA-12/NO cells when compared to COGA-12 cells. 
It is important to note that one spot was detected that was exclusively differentially 
expressed between COGA-12/NO and COGA-12 cells as shown in Fig. 22 (up-
regulated in COGA-12/NO). The average intensities of all regulated proteins between 
COGA-12 cells and chemoresistant COGA-12/G6 or long-term cultivated COGA-
12/NO cells are shown in Table 6. 
The proteins that belong to the differentially expressed spots were identified by 
MALDI-TOF mass spectrometry and subsequent peptide mass fingerprinting. To 
achieve sufficient sensitivity for mass spectrometry, spots of preparative 2D gels with 
the total protein amount of 10 x 106 cells were used as described above. The 
identified proteins are shown in Table 7. Corresponding mass spectra and protein 
identifications results are shown in Fig. 23 - 27. The up-regulated protein in 
chemoresistant COGA-12/G6 cells was identified as cytokeratin 18. Two of the down-
regulated proteins were identified as the same protein, namely heat shock protein 
(HSP) 27. The two proteins represent most likely two different posttranslational 
modifications (PTMs) of HSP27. The other down-regulated protein in COGA-12/G6 
cells was identified as aldehyde dehydrogenase 1B1. The spot differentially 
expressed in long-term cultivated COGA-12/NO cells was identified as maspin (Table 
7). 
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Spot 
number 
Average intensity 
in COGA-12 cells 
Average intensity 
in COGA-12/G6 cells 
or COGA-12/NO cells 
Ratio 
COGA-12/G6 / COGA-12 cells 
or COGA-12/NO / COGA-12 cells 
G6U-1 0.756 ± 0.214 2.057 ± 0.312 2.72 
G6D-1 0.710 ± 0.065 --- not expressed in COGA-12/G6 
G6D-2 0.762 ± 0.111 --- not expressed in COGA-12/G6 
G6D-3 0.410 ± 0.109 0.111 ± 0.016 0.27 
NOU-1 --- 0.506 ± 0.070 only expressed in COGA-12/NO 
Table 6. Average intensities of the protein spots altered between 2D gels of COGA-12 cells and 
5-FU resistant COGA-12/G6 cells or long-term cultivated COGA-12/NO cells. The respective 
normalized average intensities ± SE of at least three separate 2D gels analyzed with the 
Proteomweaver software are listed.  
 
Spot number 
Protein name 
identified by MALDI-TOF mass spectrometry 
Regulation in COGA-12/G6 
or COGA-12/NO cells 
G6U-1 Cytokeratin 18 up 
G6D-1 Aldehyde Dehydrogenase 1B1 down 
G6D-2 Heat shock protein 27 down 
G6D-3 Heat shock protein 27 down 
NOU-1 Maspin up 
Table 7. Proteins differentially expressed between parental COGA-12 cells and 5-FU resistant 
COGA-12/G6 or long-term cultivated COGA-12/NO cells 
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RMS error 27 ppm
m/z
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence
6 - 13      975.44   974.43   974.45    -0.02     0  R.STFSTNYR.S 
90 - 96      837.46   836.45   836.44     0.01     0  R.LASYLDR.V 
111 - 117     924.50   923.50   923.52    -0.02     1  K.IREHLEK.K 
131 - 136     758.47   757.46   757.43     0.03     0  K.IIEDLR.A 
137 - 148    1319.61  1318.60  1318.66    -0.06     0  R.AQIFANTVDNAR.I 
149 - 157    1041.59  1040.58  1040.60    -0.02     0  R.IVLQIDNAR.L 
158 - 164     807.43   806.42   806.39     0.03     0  R.LAADDFR.V 
165 - 174    1239.58  1238.57  1238.63    -0.06     1  R.VKYETELAMR.Q 
187 - 195    1046.54  1045.54  1045.54    -0.00     0  K.VIDDTNITR.L 
196 - 213    2177.23  2176.22  2176.17     0.05     1  R.LQLETEIEALKEELLFMK.K 
247 - 252     734.40   733.39   733.38     0.01     0  K.IMADIR.A Oxidation (M) 
253 - 260     965.44   964.44   964.46    -0.03     0  R.AQYDELAR.K 
317 - 324     889.47   888.47   888.47    -0.00     0  K.ASLENSLR.E 
372 - 380    1065.54  1064.53  1064.55    -0.02     0  K.LEAEIATYR.R 
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Fig. 23. Identification of spot G6U-1. (A) Mass spectrum of G6U-1 obtained after in-gel digestion 
and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search on 
MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum using 
peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing only 1 
missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph. (D) Peptides matched with the sequence of 
cytokeratin 18 and their molecular mass are reported.  
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Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence
52 - 73     2325.19  2324.18  2324.18     0.01     1  K.KTFPTVNPTTGEVIGHVAEGDR.A 
53 - 73     2197.10  2196.09  2196.08     0.01     0  K.TFPTVNPTTGEVIGHVAEGDR.A 
53 - 78     2753.38  2752.37  2752.34     0.03     1  K.TFPTVNPTTGEVIGHVAEGDRADVDR.A 
74 - 81      873.47   872.47   872.47    -0.00     1  R.ADVDRAVK.A 
108 - 114     815.45   814.44   814.45    -0.01     0  R.LADLVER.D 
117 - 144    3170.58  3169.57  3169.61    -0.04     0  R.VYLASLETLDNGKPFQESYALDLDEVIK.V 
148 - 155     957.44   956.43   956.44    -0.00     0  R.YFAGWADK.W 
160 - 172    1609.74  1608.73  1608.72     0.01     0  K.TIPMDGQHFCFTR.H 
160 - 172    1625.70  1624.69  1624.71    -0.02     0  K.TIPMDGQHFCFTR.H Oxidation (M) 
210 - 226    1817.03  1816.03  1816.03    -0.01     0  K.VAEQTPLSALYLASLIK.E 
227 - 257    3096.50  3095.49  3095.54    -0.05     0  K.EAGFPPGVVNIITGYGPTAGAAIAQHMDVDK.V 
227 - 257    3112.52  3111.51  3111.53    -0.02     0  K.EAGFPPGVVNIITGYGPTAGAAIAQHMDVDK.V Ox.(M
258 - 272    1586.79  1585.78  1585.85    -0.06     0  K.VAFTGSTEVGHLIQK.A 
273 - 281     931.47   930.46   930.49    -0.02     1  K.AAGDSNLKR.V 
281 - 289     972.54   971.54   971.58    -0.04     1  K.RVTLELGGK.S 
282 - 289     816.48   815.47   815.48    -0.01     0  R.VTLELGGK.S 
325 - 338    1775.90  1774.90  1774.84     0.05     0  R.TFVEESIYNEFLER.T 
348 - 369    2561.28  2560.27  2560.22     0.05     1  K.VGNPFELDTQQGPQVDKEQFER.V 
384 - 390     804.42   803.41   803.40     0.02     0  K.LLCGGER.F 
395 - 411    1913.98  1912.98  1912.95     0.03     0  R.GFFIKPTVFGGVQDDMR.I 
395 - 411    1929.98  1928.97  1928.95     0.03     0  R.GFFIKPTVFGGVQDDMR.I Oxidation (M) 
412 - 426    1715.91  1714.91  1714.97    -0.06     1  R.IAKEEIFGPVQPLFK.F 
415 - 426    1403.71  1402.70  1402.75    -0.05     0  K.EEIFGPVQPLFK.F 
429 - 436    1001.56  1000.56  1000.56     0.00     1  K.KIEEVVER.A 
442 - 451    1068.62  1067.61  1067.58     0.04     0  R.YGLAAAVFTR.D
493 - 500     860.42   859.42   859.43    -0.01     0  R.ELGEDGLK.A 
501 - 506     710.35   709.34   709.36    -0.02     0  K.AYTEVK.T 
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Fig. 24. Identification of spot G6D-1. (A) Mass spectrum of G6D-1 obtained after in-gel digestion 
and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search on 
MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum using 
peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing only 1 
missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph. (D) Peptides matched with the sequence of 
aldehyde dehydrogenase 1B1 and their molecular mass are reported. 
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RMS error 18 ppm
m/z
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence
5 - 12      987.58   986.58   986.60    -0.03     1  R.RVPFSLLR.G 
6 - 12      831.51   830.50   830.50     0.00     0  R.VPFSLLR.G 
13 - 20      961.43   960.42   960.45    -0.03     0  R.GPSWDPFR.D 
13 - 27     1902.88  1901.87  1901.86     0.01     1  R.GPSWDPFRDWYPHSR.L 
21 - 27      960.43   959.42   959.42    -0.01     0  R.DWYPHSR.L 
28 - 37     1163.60  1162.60  1162.61    -0.02     0  R.LFDQAFGLPR.L 
80 - 89     1075.54  1074.53  1074.57    -0.04     0  R.QLSSGVSEIR.H 
97 - 112    1783.90  1782.89  1782.92    -0.02     0  R.VSLDVNHFAPDELTVK.T 
128 - 136    1104.53  1103.52  1103.50     0.02     0  R.QDEHGYISR.C 
172 - 188    1905.99  1904.98  1904.98    -0.01     0  K.LATQSNEITIPVTFESR.A 
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Fig. 25. Identification of spot G6D-2. (A) Mass spectrum of G6D-2 obtained after in-gel digestion 
and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search on 
MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum using 
peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing only 1 
missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph. (D) Peptides matched with the sequence of heat 
shock protein 27 and their molecular mass are reported.  
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RMS error 25 ppm
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Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence
6 - 12      831.48   830.47   830.50    -0.03     0  R.VPFSLLR.G 
13 - 20      961.47   960.46   960.45     0.02     0  R.GPSWDPFR.D 
21 - 27      960.45   959.45   959.42     0.02     0  R.DWYPHSR.L 
28 - 37     1163.66  1162.65  1162.61     0.04     0  R.LFDQAFGLPR.L
80 - 89     1075.56  1074.55  1074.57    -0.02     0  R.QLSSGVSEIR.H 
90 - 96      941.49   940.48   940.46     0.02     1  R.HTADRWR.V 
97 - 112    1783.90  1782.89  1782.92    -0.02     0  R.VSLDVNHFAPDELTVK.T 
113 - 123    1146.59  1145.58  1145.63    -0.05     1  K.TKDGVVEITGK.H 
115 - 123     917.47   916.47   916.49    -0.02     0  K.DGVVEITGK.H 
128 - 136    1104.53  1103.53  1103.50     0.03     0  R.QDEHGYISR.C 
141 - 171    3226.58  3225.57  3225.65    -0.08     1  R.KYTLPPGVDPTQVSSSLSPEGTLTVEAPMPK.L 
141 - 171    3242.59  3241.58  3241.64    -0.06     1  R.KYTLPPGVDPTQVSSSLSPEGTLTVEAPMPK.L
Oxidation (M) 
142 - 171    3098.47  3097.46  3097.55    -0.09     0  K.YTLPPGVDPTQVSSSLSPEGTLTVEAPMPK.L 
172 - 188    1906.06  1905.05  1904.98     0.06     0  K.LATQSNEITIPVTFESR.A 
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Fig. 26. Identification of spot G6D-3. (A) Mass spectrum of G6D-3 obtained after in-gel digestion 
and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search on 
MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum using 
peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing only 1 
missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph. (D) Peptides matched with the sequence of heat 
shock protein 27 and their molecular mass are reported.  
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Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence
48 - 64     1870.92  1869.91  1869.92    -0.01     0  K.GDTANEIGQVLHFENVK.D 
97 - 109    1426.73  1425.72  1425.74    -0.02     0  K.SLNLSTEFISSTK.R 
138 - 158    2346.16  2345.15  2345.08     0.07     0  K.DLTDGHFENILADNSVNDQTK.I 
159 - 170    1293.73  1292.72  1292.75    -0.03     0  K.ILVVNAAYFVGK.W 
182 - 186     708.29   707.28   707.31    -0.02     0  K.ECPFR.L 
216 - 224    1101.59  1100.59  1100.62    -0.04     0  K.IIELPFQNK.H 
216 - 234    2297.20  2296.19  2296.30    -0.11     1  K.IIELPFQNKHLSMFILLPK.D 
Oxidation (M) 
271 - 275     557.36   556.35   556.36    -0.00     0  K.LSIPK.F 
322 - 340    2016.92  2015.92  2015.95    -0.03     0  K.VCLEITEDGGDSIEVPGAR.I 
341 - 359    2335.26  2334.25  2334.25    -0.00     1  R.ILQHKDELNADHPFIYIIR.H 
346 - 359    1715.86  1714.85  1714.87    -0.01     0  K.DELNADHPFIYIIR.H 
365 - 371     838.44   837.43   837.47    -0.04     0  R.NIIFFGK.F 
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Fig. 27. Identification of spot NOU-1. (A) Mass spectrum of NOU-1 obtained after in-gel digestion 
and MALDI-TOF analysis. (B-D) Protein identification results obtained by database search on 
MASCOT server. Identifications were obtained after internal recalibration of the mass spectrum using 
peaks deriving from autoproteolysis of trypsin, with 50 ppm, as mass tolerance, and allowing only 1 
missing cleavage. (B) Probability based mowse score. Ions score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater than 64 are significant 
(p<0.05). (C) Root mean square (RMS) error graph. (D) Peptides matched with the sequence of 
maspin and their molecular mass are reported.  
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3.3. Gene therapy of colorectal cancer 
Gene therapy presents an encouraging alternative option for the treatment of 
colorectal cancers. The concept, however, is technically limited by insufficient 
efficiency of gene transfer and insufficient tumor specificity. In this thesis the novel 
cellular model systems were applied for the development and optimization of a novel 
gene therapy concept for colorectal cancers. First, nonviral gene transfer was 
optimized by generation of novel lipopolyplex formulations and comparison to 
lipoplex and polyplex formulations. These experiments were performed in 
collaboration with Dr. Jaroslav Pelisek. Second, the artificial promoter CTP4 was 
evaluated for transcriptional targeting of colorectal cancer cells. And third, therapeutic 
gene constructs for the expression of the immune stimulatory IL-2 gene, optionally in 
combination with the cytopathic rhinovirus protease 2A gene, were tested and 
optimized. The investigations were carried out with the low passage colon cancer cell 
lines and as control SW480 (standard colorectal cell line) and HeLa (non-colorectal) 
cells were used. In addition to traditional monolayer cultures, also multicellular 
spheroids of the low passage cell lines were used for some investigations. 
3.3.1. Optimization of nonviral gene transfer to colorectal cancer cells 
It was already reported that the combination of cationic lipids and polycations to form 
lipopolyplexes significantly improved gene transfer in different cell lines (Lampela et 
al., 2002; Lampela et al., 2003; Lampela et al., 2004; Lee et al., 2003). In this thesis 
different polycations (PLL18, PEI22lin, PEI25br, PEI2k) and cationic lipids 
(DOCSPER, DOSPER, DOTAP) were used to form various lipoplex, polyplex and 
lipopolyplex formulations to find the most adequate formulation that is promising for a 
successful in vivo application. For this purpose, it is necessary that the complexes do 
not aggregate and retain small particle size under physiological conditions, but are 
still efficient in mediating gene transfer. 
3.3.1.1. Generation and biophysical properties of nonviral gene transfer formulations 
Nonviral DNA formulations were generated as described in materials and methods. 
In short, lipoplexes and polyplexes were prepared by mixing plasmid DNA with 
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cationic lipids or polycations, respectively. For the preparation of lipopolyplexes 
plasmid DNA was precomplexed with polycations and subsequently mixed with 
cationic lipids. PEIs were used at an optimized N/P ratio (describes the molar ratio of 
PEI nitrogen to DNA phosphate) of 8/1 and PLL18 at an optimized charge ratio of 5/1 
(Pelisek et al., 2005). Cationic lipids were used at following optimized ratios: 
DOCSPER/DNA at w/w ratio 10/1; DOSPER/DNA at w/w ratio 8/1 and DOTAP/DNA 
at w/w ratio 4/1 (Pelisek et al., 2005). The sizes of the different lipoplex, polyplex, and 
lipopolyplex formulations generated at low or physiological ionic strength were 
measured using dynamic laser-light scattering (Fig. 28).  
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Fig. 28. Size of different lipopolyplex, lipoplex, and polyplex formulations generated at low (A) 
or physiological (B) ionic strength. Plasmid DNA (pCMV-Luc) was complexed in 1 ml of water (A) 
or HBS (B) using 5 µg DNA and different cationic lipids (1: DOCSPER, 2: DOSPER, 3: DOTAP), 
different polycations (PLL18, PEI22lin, PEI25br, PEI2k), or polycation/cationic lipid combinations. The 
values are the means ± SE of triplicates in two independent experiments. Experiments were 
performed by Dr. Jaroslav Pelisek. 
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At low ionic strength polyplexes, lipoplexes and lipopolyplexes were stable in particle 
size within a range of 50-130 nm at room temperature (Fig. 28A). At physiological 
ionic strength (HBS, pH 7.4), lipoplexes of DOTAP and polyplexes of PLL18, 
PEI22lin, PEI25br and PEI2k aggregated at high salt, achieving particle size 
distributions of 1 to 2 µm (Fig. 28B). Lipopolyplexes combined of DOTAP and PLL18, 
PEI22lin, PEI25br and PEI2k formed also large aggregates of over 1 µm at high ionic 
strength conditions (Fig. 28B). In contrast, lipoplexes of DOCSPER or DOSPER and 
their respective lipopolyplexes with PEI25br were stable to aggregation in high salt 
(140 - 220 nm) (Fig. 28B). Therefore, these particular lipopolyplex formulations were 
selected for the further experiments. The zeta-potential of all formulations had a 
positive charge of +20 to +40 mV. 
3.3.1.2. Determination of the efficiencies of the most adequate formulations in gene 
transfer 
The PEI25 lipopolyplex formulations which were stable in physiological salt 
(DOSPER/PEI25br/DNA and DOCSPER/PEI25br/DNA) were tested for their 
efficiency in gene transfer on one representative of each morphological category of 
the low passage colon cancer cell lines, namely COGA-5 (epithelial-like), COGA-12 
(piled-up) and COGA-3 (rounded-up), and in addition on two control cell lines, 
SW480 (standard colorectal cell line) and HeLa (non-colorectal). The efficiency of the 
lipopolyplexes was compared to the corresponding lipoplexes and polyplexes. The 
luciferase activities of these formulations on HeLa, SW480, and COGA-3, -5, and 12 
cells are shown in Fig. 29. Both lipopolyplexes significantly enhanced gene transfer 
(up to 400-fold) compared to the corresponding lipoplexes or polyplexes (Fig. 29). 
The gene transfer was demonstrated to depend on the presence or absence of 
serum in the transfer medium. When performing gene transfer in serum-free medium 
the level of luciferase gene expression was up to 220-fold higher using lipopolyplexes 
compared to corresponding lipoplexes and 110-fold higher compared to the 
corresponding polyplexes (Fig. 29). In the presence of serum the enhancement of 
gene transfer of lipopolyplexes compared to corresponding lipoplexes was up to 400-
fold and compared to the corresponding polyplexes up to 170-fold (Fig. 29). Gene 
transfer efficiencies of lipopolyplexes were 2 to 20-fold lower in the presence of 
serum compared to incubation in serum-free medium (Fig. 29). Lipoplexes were 
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more affected by the presence of serum, with an up to 100-fold decrease in transfer 
efficiency. For polyplexes, the gene transfer in the presence of serum was only up to 
10-fold lower compared to polyplexes in serum-free medium. 
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Fig. 29. Gene transfer efficiencies of lipopolyplexes in comparison to the corresponding 
lipoplexes and polyplexes in Coga-3 (A), Coga-5 (B), Coga-12 (C), HeLa (D) and SW480 (E) cells. 
For transfections 0.1 µg pCMV-Luc per 1 x 104 cells were used. Complexes were formed in HBS. 
Gene transfer was performed either in serum-free medium or in medium containing 10 % serum. 1: 
DOCSPER, 2: DOSPER. The values are means ± SE of triplicates in three independent experiments. 
Experiments were performed in collaboration with Dr. Jaroslav Pelisek. 
As the salt stable lipopolyplex formulations of PEI25br and DOCSPER or DOSPER 
significantly enhanced gene transfer, these formulations were used for all further 
experiments. Moreover, only the cationic lipid DOSPER was used, as DOCSPER and 
DOSPER provided comparable results. 
It is known that sedimentation of large complexes may be helpful for in vitro 
transfection. Therefore, the transfection efficiency of DOSPER/PEI25br/DNA 
lipopolyplexes (which are stable against aggregation in physiological salt) was also 
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compared to DOSPER/PEI22lin/DNA lipopolyplexes (which form large aggregates). 
The aggregated DOSPER/PEI22lin/DNA lipopolyplex formulation displayed nearly 
the same gene transfer efficiency in HeLa and SW480 cells, and only slightly (up to 
3-fold) higher efficiency in the COGA cells as compared to the stable 
DOSPER/PEI25br/DNA lipopolyplexes (Fig. 30). 
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Fig. 30. Gene transfer efficiencies of salt stable DOSPER/PEI25br/DNA lipopolyplexes in 
comparison to DOSPER/PEI22lin/DNA lipopolyplexes aggregating in physiological salt in 
COGA-3 (A), COGA-5 (B), COGA-12 (C), SW480 (D) and HeLa (E) cells. 0.1 µg of pCMV-Luc per 1 
x 104 cells were used for transfection. Gene transfer was performed either in serum-free medium or in 
medium containing 10 % serum. Values are means ± SE of triplicates. Experiments were performed in 
collaboration with Dr. Jaroslav Pelisek. 
3.3.1.3. Transfection of multicellular spheroids with lipopolyplexes 
Furthermore, it was investigated whether lipopolyplexes also enable a sufficient 
transfection of multicellular spheroids. Multicellular spheroids are model systems that 
mimic the three-dimensional structure of in vivo tumors in contrast to traditional 
monolayers. The lipopolyplex formulation was the only formulation that was used for 
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gene transfer, because this formulation resulted in the highest transfection 
efficiencies in the previous cell culture experiment. Multicellular spheroids of cell line 
COGA-12 were chosen for these investigations. They were grown in medium 
containing 2 % or 10 % serum. Forty-eight or 96 hours after their formation 
multicellular spheroids were transfected with 0.1 µg, 0.25 µg, 0.5 µg, 1 µg and 2 µg of 
pEGFP-N1 plasmid by using lipopolyplexes for gene transfer. Forty-eight hours after 
transfection (96 or 144 hours after multicellular spheroid formation) the amount of 
EGFP positive cells was estimated by epifluorescence microscopy. Significant EGFP 
expression could be observed (Fig. 31). However, only the upper, accessible part of 
the multicellular spheroids exposed to the growth medium exhibited EGFP 
fluorescence (Fig. 31A), while the lower part facing the agarose coating on the 
bottom of the culture plate did not (Fig. 31B).  
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Fig. 31. EGFP expression after transfection of multicellular spheroids using lipopolyplexes for 
gene transfer. Multicellular spheroids of COGA-12 cells grown in medium containing 2 % serum were 
transfected with 0.25 µg pEGFP-N1 48 h after multicellular spheroid formation. Forty-eight hours after 
transfection epifluorescence microscopy was performed. Shown are overlays of transmission light and 
epifluorescence images (top panels) and the respective epifluorescence images (lower panels) of the 
upper part (A) and lower part (B) of the same multicellular spheroid. 
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In general, the amount of transfected COGA-12 cells was higher in medium 
containing 2 % serum compared to medium containing 10 % serum, while it didn’t 
make a visual difference if multicellular spheroids were transfected 48 h or 96 h after 
multicellular spheroid formation. The highest number of transfected cells was 
obtained with 0.25 µg and 0.5 µg DNA. No visual difference in the amount of EGFP 
positive cells could be detected between these both concentrations. Confocal laser 
scanning microscopy of DAPI (4',6-Diamidino-2-phenylindole) counterstained, EGFP-
transfected multicellular spheroids revealed that predominantly cells located between 
the surface and about 60 µm depth were transfected (Fig. 32A). DAPI also stained 
only the outer cell layers of the multicellular spheroids. As the depth of penetration of 
confocal laser scanning microscopy is limited, additionally cryosections of the 
transfected multicellular spheroids were prepared. These confirmed that only cells at 
the surface of the multicellular spheroids exhibited EGFP fluorescence (Fig. 32B). 
In summary, lipopolyplexes are not only efficient in gene transfer to monolayers, but 
also in gene transfer to tumor-like three-dimensional model systems.  
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Fig. 32. Distribution of EGFP transfected cells within a multicellular spheroid of COGA-12 cells 
using lipopolyplexes for gene transfer. Multicellular spheroids grown in medium containing 2 % 
serum were transfected with 0.25 µg pEGFP-N1 48 h after spheroid formation. Forty-eight hours after 
transfection multicellular spheroids were fixed in 4 % PFA. (A) For confocal laser scanning microscopy 
cells of the multicellular spheroid were counterstained with DAPI. Confocal laser scanning microscopy 
stack images were taken every 20 µm moving from the outside to the inside of the spheroid. Thereby 
DAPI stained cell layers indicate the surface of the multicellular spheroid. Overlays of EGFP and DAPI 
fluorescence images are shown. (B) 10 µm cryosections of the transfected multicellular spheroids 
were analyzed by epifluorescence microscopy: An overlay of transmission light and epifluorescence 
images (left) and the respective epifluorescence image (right) are shown. 
Results 75 
3.3.2. Transcriptional targeting of colorectal cancer cells 
For therapeutic application, it is furthermore necessary that the high efficient gene 
transfer formulation developed in this thesis is also highly specific for colorectal tumor 
cells. The targeting of colorectal cancer cells was accomplished by the very 
promising artificial tumor specific promoter CTP4. The efficiency and specificity of this 
promoter was investigated in comparison to the strong but unspecific CMV promoter 
in the following experiments.  
3.3.2.1. Gene expression levels after transcriptional targeting in various low passage 
colon cancer cell lines 
Firstly, the relative efficiency of the CTP4 promoter and the CMV promoter was 
compared in transfection experiments with seven low passage colon cancer cell lines 
using the luciferase gene expression plasmids pCTP4-Luc or pCMV-Luc and 
Lipofectamine 2000 for gene transfer (Fig. 33). The low passage colon cancer cell 
lines demonstrate widely heterogeneous morphologies and large diversity regarding 
for example oncogenic and tumor-suppressive mutations. COGA-1, COGA-5 and 
COGA-10 are representatives for epithelial-like morphology, COGA-5L and COGA-12 
for piled-up and COGA-2 and COGA-3 for rounded-up morphology. SW480 
(standard colorectal cell line) and HeLa (non-colorectal) cells were used as controls. 
In the colorectal standard cell line SW480 and in the rounded-up cell lines COGA-2 
and COGA-3 the luciferase expression levels driven by the colon cancer specific 
promoter CTP4 were even higher than the CMV-driven expression levels (in SW480 
cells 5.5-fold, in COGA-2 cells 2.8-fold and in COGA-3 cells 3.7-fold increased 
expression) (Fig. 33F-H). In the piled-up cell line COGA-12 the CTP4-driven 
expression level was even 30-fold higher than the CMV-driven, while in cell line 
COGA-5L the colon cancer specific expression was slightly reduced (2-fold), but still 
in a high range (> 3 x 105 RLU/well) (Fig. 33D-E). In the cell lines with epithelial-like 
morphology COGA-1, COGA-5 and COGA-10 the CTP4-driven luciferase expression 
level was similar (COGA-1) or slightly lower compared to the CMV-driven luciferase 
expression level (in COGA-5 cells a 2.5-fold and in COGA-10 cells a 5-fold reduction) 
(Fig. 33A-C). In contrast, in non-colorectal control HeLa cells with normal β-catenin 
levels, a 2300-fold lower expression of luciferase was detected with the CTP4 
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promoter compared to the CMV promoter (Fig. 33I). This clearly confirms the 
published high specificity of the CTP4 promoter for colorectal cancer cells.  
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Fig. 33. Luciferase expression by the CTP4 promoter in comparison to the CMV promoter in 
various low passage colon cancer cell lines of different morphologies. COGA-1 (A), COGA-5 (B) 
and COGA-10 (C) cells are representatives for epithelial-like morphology, COGA-5L (D) and COGA-12 
(E) cells for piled-up and COGA-2 (F) and COGA-3 (G) cells for rounded-up morphology. SW480 
(standard colorectal cell line) (H) and HeLa (non-colorectal) (I) cells were used as control. 0.05 µg of 
pCMV-Luc or pCTP4-Luc were used for transfection of 1 x 104 cells with Lipofectamine 2000. Gene 
transfer was performed in serum-free medium. The values are representative means ± SE of 
triplicates of at least two independent experiments. 
The results above demonstrate the potential of the novel artificial CTP4 promoter to 
serve as a powerful promoter for cell specific gene therapy. This CTP4 promoter is 
highly efficient in all low passage colon cancer cell lines tested despite their broad 
heterogeneity and, in addition, exhibits a very high specificity for colon carcinoma 
cells. 
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3.3.2.2. Transfection of selected low passage colon cancer cell lines with 
transcriptionally targeted lipopolyplexes 
Next, the efficiency of the CTP4 promoter was investigated using the optimized 
lipopolyplex formulation of DOSPER and PEI25br for gene transfer (transcriptional 
targeted lipopolyplexes). In addition, the results were compared with the 
corresponding lipoplex and polyplex formulations. The investigations were performed 
on the low passage colon cancer cell lines COGA-3, COGA-5 and COGA-12, each 
representing one morphological category, and on the two control cell lines SW480 
and HeLa (Fig. 34).  
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Fig. 34. Luciferase expression by the CTP4 promoter in comparison to the CMV promoter using 
lipopolyplex, lipoplex and polyplex formulations for gene transfer in COGA-3 (A), COGA-5 (B), 
COGA-12 (C), SW480 (D) and HeLa (E) cells. 0.1 µg of pCMV-Luc or pCTP4-Luc were used for 
transfection of 1 x 104 cells. Gene transfer was performed either in serum-free medium or in medium 
containing 10 % serum. Luciferase activities in all transfections are shown as a percentage of the 
activity of the CMV promoter using lipopolyplexes in presence of serum. The activity of 100 % (CMV 
promoter in the presence of serum) corresponds to 2 x 105 RLU in COGA-3 (A) cells, to 7.2 x 105 RLU 
in COGA-5 (B) cells, to 6.2 x 105 RLU in COGA-12 (C) cells, to 957 x 105 RLU in SW480 (D) cells and 
to 42 x 105 RLU in HeLa (E) cells. Values are means ± SE of triplicates. 
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In the cell lines SW480, COGA-3 and COGA-12 the CTP4 promoter resulted in 
significantly higher luciferase expression levels than the CMV promoter, independent 
of the formulation used for transfection. In SW480 cells the CTP4 promoter had up to 
11-fold higher luciferase expression levels when compared with the expression levels 
by the CMV promoter (Fig. 34D). In COGA-3 cells the CTP4 promoter induced up to 
10-fold (Fig. 34A) and in COGA-12 cells up to 20-fold increases in luciferase activity 
(Fig. 34C). Only in the COGA-5 cell line the CTP4 promoter-driven expression level 
of luciferase was reduced to approximately 50 % of the CMV-driven luciferase 
expression (Fig. 34B). In contrast to colon cancer cells, in the control non-colorectal 
cancer cell line HeLa the luciferase expression level obtained by the CTP4 promoter 
was up to 950-fold lower than by the CMV promoter (Fig. 34E). 
Furthermore, the gene transfer efficiencies of lipopolyplexes were significantly 
enhanced compared to corresponding lipoplexes or polyplexes in all cell lines tested, 
also when the luciferase expression was under control of the CTP4 promoter instead 
of the CMV promoter (Fig. 34). The expression levels obtained by lipopolyplex 
formulations were up to 1300-fold higher compared to the corresponding lipoplexes 
of DOSPER and up to 430-fold higher compared to the corresponding polyplexes of 
PEI25br (Fig. 34).  
To sum up, the combination of the novel lipopolyplex formulation with the novel 
artificial CTP4 promoter is very promising for gene therapy strategies of colorectal 
cancer as it enables high efficient gene transfer and both high level and high 
colorectal cancer specific gene expression.  
3.3.2.3. Influence of plasmid DNA concentration on gene expression levels with or 
without transcriptional targeting 
To investigate the influence of the amount of transfected DNA on CMV and CTP4 
promoter-controlled luciferase expression levels, SW480 cells were transfected with 
0.1 µg and 0.05 µg DNA, respectively. Again, lipopolyplex, lipoplex and polyplex 
formulations were used for transfections. In general, the luciferase expression levels 
were lower when 0.05 µg DNA were used for transfection compared to 0.1 µg DNA 
(Fig. 35). However, the range between the expression levels controlled by the CTP4 
promoter and the CMV promoter was more pronounced when lower amounts of DNA 
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were used compared to higher DNA amounts. When 0.05 µg DNA were transfected 
the luciferase expression controlled by the CTP4 promoter was 10-fold higher 
compared to the CMV promoter using lipopolyplexes for transfection, and 85-fold and 
14-fold higher using lipoplexes and polyplexes, respectively. In contrast, when using 
0.1 µg DNA the range between both promoters was only 4-fold in the case of 
lipopolyplexes, 11-fold in the case of lipoplexes and 4-fold in the case of polyplexes 
(Fig. 35). The results demonstrate that the CTP4 promoter is even more efficient at 
lower DNA concentrations than the CMV promoter, which exposes this promoter as a 
promising candidate for in vivo applications, where the DNA amount is limited. 
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Fig. 35. Influence of the dose of transfected plasmid DNA on the CTP4 vs. CMV promoter 
controlled luciferase expression levels in SW480 cells. Indicated amounts of pCMV-Luc or pCTP4-
Luc were used for transfection of 1 x 104 cells. Gene transfer was performed using lipopolyplex, 
lipoplex and polyplex formulations in medium containing 10 % serum. Values are means ± SE of 
triplicates. 
3.3.2.4. Percentage of transfected cells with or without transcriptionally targeted gene 
transfer  
Next, it was investigated whether the enhanced luciferase expression using the 
CTP4 promoter in comparison to the CMV promoter was either the result of 
enhanced gene transfer efficiency or the increased protein expression per cell. For 
this purpose, the percentage of transfected cells and thereby the gene transfer 
efficiency was determined by flow cytometric analysis of EGFP expression. Since 
only a plasmid existed that contained the EGFP encoding gene in combination with 
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the CMV promoter, an analog of this plasmid was designed, which was harboring the 
CTP4 promoter instead of the CMV promoter. The pEGFP-LG-CTP4 vector 
(encoding EGFP under the control of the CTP4 promoter) was constructed by 
substitution of the CMV promoter of pEGFP-N1 by the CTP4 promoter of pCTP4-Luc 
as described in 2.2.8. 
The colon cancer cell lines SW480, COGA-3, COGA-5 and COGA-12 were 
transfected with the plasmids containing the EGFP gene either under control of the 
CMV or the CTP4 promoter. Percentages of EGFP positive cells are shown in Fig. 
36. No significant difference was detectable in the number of transfected cells 
obtained by the CTP4 promoter in comparison with the CMV promoter. The only 
discrepancy between the percentages of EGFP positive cells by both promoters was 
observed in COGA-5 cells transfected in absence of serum (Fig. 36B). This 
discrepancy is due to the sensitivity of the measurement. According to the luciferase 
data the expression levels of the CTP4 promoter were lower compared to the CMV 
promoter in COGA-5 cells. Hence, cells that exhibit very low EGFP expression levels 
driven by the CTP4 promoter can be already sorted out by flow cytometry settings, 
while cells with low EGFP expression levels under CMV promoter control are still 
included, as their expression levels are higher compared to the low EGFP expression 
levels driven by the CTP4 promoter. Thus, the differences in the expression levels of 
the EGFP gene driven by different promoters can lead to the detection of different 
amounts of EGFP positive cells 
Again, all transfection experiments were performed with lipopolyplex, lipoplex and 
polyplex formulations. In presence of serum the highest percentage of transfected 
cells was obtained by using lipopolyplexes, resulting in up to 15 % EGFP positive 
cells in the human low passage colon cancer cell lines regardless of which of the two 
promoters was used (Fig. 36A-C). In the control cell line SW480 even up to 40 % of 
the cells were positive for EGFP when lipopolyplexes were used for transfection (Fig. 
36D). Lower percentages of EGFP positive cells were obtained by using either 
lipoplexes (up to 5 % in the human low passage colon cancer cell lines and up to 7 % 
in SW480 cells) or polyplexes (up to 0.4 % in the human low passage colon cancer 
cell lines and up to 1 % in SW480 cells) for transfection in presence of serum in all 
cell lines (Fig. 36). 
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Fig. 36. Percentage of EGFP positive COGA-3 (A), COGA-5 (B), COGA-12 (C) and SW480 (D) 
cells following gene transfer using plasmids containing the EGFP gene under control of the 
CMV or CTP4 promoter. For transfection of 1 x 105 cells 0.5 µg pCMV-EGFP or pCTP4-LG-EGFP 
were used. EGFP expression was analyzed by flow cytometry. The mean percentages of EGFP 
positive cells ± SE of duplicates are shown. 
Interestingly, in contrast to transfections in the presence of serum, the transfection 
efficiency of lipoplex formulations was comparable with the efficiency of the 
corresponding lipopolyplexes in serum-free medium in all cell lines tested (Fig. 36). 
Polyplexes of PEI25br provided again the lowest amount of EGFP positive cells in all 
experiments performed in the absence of serum as shown in Fig. 36. When using 
lipoplexes and lipopolyplexes for transfections in the absence of serum up to 30 % of 
the low passage colon cancer cells were transfected (Fig. 36A-C). In the cell line 
SW480 up to 50 % of the cells were EGFP positive (Fig. 36D). When using 
polyplexes only up to 9 % of the human low passage colon cancer cells and up to 6 
% of SW480 cells were EGFP positive (Fig. 36). Again, in all cases with exception of 
COGA-5 cells the percentage of EGFP positive cells was independent of the 
promoter used. 
The experiments above demonstrated that the enhanced luciferase expression 
obtained by the CTP4 promoter compared to the CMV promoter is a result of higher 
gene expression attributed to the CTP4 promoter and not of enhanced gene transfer 
efficiency of the transcriptional targeted lipopolyplexes. 
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3.3.2.5. Transfection of multicellular spheroids with transcriptionally targeted 
lipopolyplexes 
In addition, it was investigated whether the tumor specific CTP4 promoter also 
worked in three-dimensional cell cultures. Therefore, multicellular spheroids were 
transfected with lipopolyplexes harboring the EGFP gene under control of the CTP4 
promoter and for comparison the CMV promoter. The use of both promoters led to 
significant EGFP expression (Fig. 37).  
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Fig. 37. Comparison of EGFP expression by the CMV (A) and the CTP4 (B) promoter in 
multicellular spheroids using lipopolyplexes for gene transfer. Multicellular spheroids of COGA-
12 cells grown in medium containing 2 % serum were transfected with 0.25 µg pEGFP-N1 or pEGFP-
LG-CTP4 96 h after multicellular spheroid formation. Forty-eight hours after transfection multicellular 
spheroids were fixed in 4 % PFA and analyzed by epifluorescence microscopy. The top panels show 
transmission light images of whole multicellular spheroids. The squares mark the respective areas of 
the multicellular spheroids that are displayed below as magnified overlays of transmission light and 
epifluorescence images (middle panels) and epifluorescence images (lower panels). 
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Visually, no differences in the number of EGFP positive cells and also in the intensity 
of EGFP expression controlled by the CTP4 promoter could be detected compared to 
transfections performed with the CMV promoter. This demonstrates that the CTP4 
promoter is also very efficient after gene transfer by lipopolyplexes to multicellular 
spheroids. 
3.3.3. Therapeutic strategies for treatment of colorectal cancer  
Finally, two strategies for therapeutic treatment of colorectal cancer following gene 
transfer using lipopolyplexes were explored. First, the expression of the immune 
stimulatory interleukin-2 (IL-2) was investigated. Second, in a more extended 
concept, the expression of a cytotoxic gene coding for the rhinoviral protease 2A in 
addition to the expression of IL-2 was studied. The expression of these therapeutic 
genes was controlled by the tumor specific CTP4 promoter in comparison to the CMV 
promoter. Only two selected colorectal cell lines were used for the experiments 
below, namely COGA-12 and SW480, since both cell lines resulted generally in the 
highest expression levels in the previous experiments. In addition, HeLa cells were 
applied as non-colorectal control in some cases. 
3.3.3.1. Colorectal cancer specific expression of immune stimulatory IL-2  
To investigate the colorectal cancer specific expression of IL-2 after transfection of 
COGA-12 and SW480 cells with lipopolyplexes, plasmids containing the human IL-2 
gene under the control of the CTP4 promoter were used for transfections. In addition, 
plasmids harboring the IL-2 gene in combination with the CMV promoter were 
applied for comparison. Initially, a plasmid encoding the IL-2 under the control of the 
CTP4 promoter (pCTP4-hIL-2) was constructed by substitution of the luciferase gene 
of pCTP4-Luc by the hIL-2 gene from pGShIL-2tet as described in 2.2.8. 
Each plasmid was applied in two different concentrations (0.25 µg and 1 µg of 
plasmid DNA per 1 x 105 cells). When using 0.25 µg DNA in the absence of serum 
the CMV promoter led to secretion of 3.9 ng IL-2 per 105 COGA-12 cells, and to 
secretion of 0.3 ng IL-2 per 105 SW480 cells 48 h following transfection (Fig. 38). The 
use of the CTP4 promoter enhanced the IL-2 production up to 345-fold (95 ng IL-2 
per 105 cells) compared to the IL-2 expression levels achieved by the CMV promoter. 
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The level of secreted IL-2 could be further enhanced by increasing the amount of 
plasmid DNA. As shown in Fig. 38A using 1 µg of plasmid DNA up to 27 ng IL-2 per 
105 COGA-12 cells were detected independent of which promoter was used. In 
SW480 cells CMV promoter-controlled IL-2 gene also demonstrated the highest 
expression at 1 µg DNA (18 ng IL-2 per 105 cells) (Fig. 38B). Interestingly, when the 
CTP4 promoter was used in SW480 cells the maximal level of IL-2 was already 
achieved with 0.25 µg of DNA (95 ng IL-2 per 105 cells). In SW480 cells, no further 
enhancement was measured by higher DNA concentrations in the case of the CTP4 
promoter, while in COGA-12 cells the maximal level of IL-2 was observed first using 1 
µg DNA for transfection. 
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Fig. 38. Interleukin-2 (IL-2) production in COGA-12 (A) and SW480 (B) cells controlled by the 
CMV or CTP4 promoter using lipopolyplexes for gene transfer. Transfection was performed using 
0.25 µg and 1 µg of pGShIL-2tet or pCTP4-hIL-2 per 1 x 105 cells. Twenty-four hours after transfection 
the growth medium was replaced by fresh medium, 48 hours following gene transfer the supernatants 
were collected and the level of secreted human IL-2 per 1 x 105 in 24 hours was determined using an 
IL-2 ELISA kit. Values are means ± SE of duplicates.  
The IL-2 expression was also investigated on multicellular spheroids. According to 
the optimal conditions established for EGFP expression in multicellular spheroids, 
COGA-12 multicellular spheroids grown in medium containing 2 % serum for 48 h 
were transfected with lipopolyplexes containing 0.5 µg of pGS-hIL2-tet (CMV 
promoter) or pCTP4-hIL-2 (CTP4 promoter). The expression of IL-2 was measured 
48 h after transfection (96 h after multicellular spheroid formation) without 
replacement of growth medium after transfection. The use of pGS-hIL2-tet led to 
secretion of about 0.5 ng IL-2 per multicellular spheroid in 48 h and the use of 
pCTP4-hIL-2 to even about 1.4 ng IL-2 per multicellular spheroid in 48 h (Fig. 39). 
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Fig. 39. Interleukin-2 (IL-2) production in COGA-12 multicellular spheroids controlled by the 
CMV or CTP4 promoter using lipopolyplexes for gene transfer. Multicellular spheroids were grown 
in medium containing 2 % serum. Transfection was performed 48 h after multicellular spheroid 
formation using 0.5 µg of pGShIL-2tet or pCTP4-hIL-2 per multicellular spheroid. The growth medium 
was not replaced 24 hours after transfection. Forty-eight hours following gene transfer the 
supernatants were collected and the level of secreted human IL-2 per multicellular spheroid in 48 
hours was determined using an IL-2 ELISA kit. Values are means ± SE of duplicates. 
3.3.3.2. Colorectal cancer specific coexpression of cytotoxic protease 2A and immune 
stimulatory IL-2 
As a more extended therapeutic concept compared to the expression of IL-2 alone, a 
novel bicistronic construct (2A-IRES-IL2) was also evaluated for colorectal cancer 
specific expression with the CTP4 promoter in the low passage human colon cancer 
cell lines. This construct encodes both cytotoxic rhinoviral protease 2A and immune 
stimulatory human IL-2. The expression of protease 2A in transfected cells leads to 
the inability of these cells to initiate cap-dependent translation of their own cellular 
mRNA, leading to a reduced viability or proliferation of these cells. However, IL-2 
protein synthesis, which is necessary for stimulation of the immune system, should 
be unaffected on the translational level. Therefore, a DNA sequence encoding a 
higher-ordered RNA structure known as IRES (internal ribosome entry site) is located 
upstream of the IL-2 sequence in the bicistronic construct 2A-IRES-IL2. This IRES 
allows the cap-independent initiation of translation of IL-2. 
All transfections regarding the investigation of the cytotoxic effect of protease 2A and 
the IRES-mediated expression of IL-2 were performed using only lipopolyplexes. 
Furthermore, the specificity of the 2A-IRES-IL2 construct for colorectal cancer cells 
using the CTP4 promoter was analyzed and compared with the unspecific CMV 
promoter. For this purpose, a plasmid encoding the 2A-IRES-IL2 sequence under 
control of the CTP4 promoter (pCTP4-2A-IRES-IL2) was constructed as described in 
2.2.8. Since the generated pCTP4-2A-IRES-IL2 plasmid was smaller than the p2A-
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IRES-IL2 plasmid (containing the CMV promoter), a novel plasmid was created in 
addition that has nearly the same size as pCTP4-2A-IRES-IL2 and is harboring the 
2A-IRES-IL2 sequence under control of the CMV promoter (pCMV-2A-IRES-IL2).  
3.3.3.2.1. Effect of protease 2A on the overall gene expression of transfected cells 
First, the effect of protease 2A on the reduction of overall cellular gene expression 
was tested. For this purpose, the expression levels of a cotransfected reporter gene 
encoding luciferase were determined. COGA-12, SW480 and HeLa cells were 
transfected with equal amounts of pEGFP-Luc and either pCMV-2A-IRES-IL2, 
pCTP4-2A-IRES-IL2 or pEGFP-N1 as a negative control. The level of luciferase 
expression was measured 24 and 72 hours after transfection. Twenty-four hours after 
transfection the expression of the CMV-driven protease 2A in COGA-12 cells led to 
10-fold lower luciferase expression compared to the control transfection with pEGFP-
N1 without expression of protease 2A (Fig. 40A). In the case of CTP4-driven 
protease 2A the luciferase expression was 3.6-fold lower. Seventy-two hours after 
transfection of COGA-12 cells reduction of luciferase expression by protease 2A was 
even stronger (pCMV-2A-IRES-IL2: 55-fold reduction, pCTP4-2A-IRES-IL2: 4.6-fold 
reduction). In SW480 cells the transfection with pCMV-2A-IRES-IL2 or pCTP4-2A-
IRES-IL2 led to 14- and 18-fold lower luciferase expression compared to the control 
transfection 24 h after transfection (Fig. 40B). Seventy-two hours after transfection 
24-fold and 13-fold reduction of luciferase expression were obtained in SW480 cells 
with pCMV-2A-IRES-IL2 and pCTP4-2A-IRES-IL2, respectively. In HeLa cells the 
transfection with pCMV-2A-IRES-IL2 resulted in 15-fold and 50-fold lower luciferase 
expression levels 24 h and 72 h after transfection compared to transfections with 
control plasmid (without protease 2A) (Fig. 40C). As expected, the transfection with 
pCTP4-2A-IRES-IL2 did not reduce the luciferase expression level in HeLa cells 
compared to the control transfection 24 h after transfection. Seventy-two hours after 
transfection with pCTP4-2A-IRES-IL2 the luciferase expression level of HeLa cells 
was about 1.5-fold lower than the expression level in the control transfection. Albeit 
the CTP4 promoter is highly specific for colorectal cancer cells, it still induced 
expression of low levels of protease 2A sufficient to slightly decrease luciferase 
expression. CTP4 promoter attributed expression levels in HeLa cells that were 
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slightly above background levels were already observed in the transfection 
experiments regarding the comparison of the efficiency of the CMV and CTP4 
promoter (Fig. 33I). 
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Fig. 40. Effect of protease 2A activity on the luciferase expression level of COGA-12 (A), SW480 
(B) and HeLa (C) cells 24 and 72 h after transfection. For transfections 0.025 µg of pCMV-2A-
IRES-IL2, pCTP4-2A-IRES-IL2 or pEGFP-N1 in combination with 0.025µg pEGFP-Luc per 5 x 103 
cells were used. Gene transfer was performed using lipopolyplexes in serum-free medium. Luciferase 
activities in all transfections are shown as a percentage of the activity of the respective coexpression 
of pEGFP-N1 and pEGFP-Luc. In COGA-12 (A) cells 100 % activity corresponds to 0.5 x 106 RLU and 
0.4 x 106 RLU 24 and 72 h after transfection, respectively; in SW480 (B) cells to 2.8 x 106 RLU and 4 x 
106 RLU 24 and 72 h after transfection; in HeLa (C) cells to 28 x 106 RLU and 8 x 106 RLU 24 and 72 
h after transfection. Values are means ± SE of n = 4. 
Next, the influence of the protease 2A on the expression of the cotransfected reporter 
gene EGFP was investigated (Fig. 41). Similar to the experiments described above, 
COGA-12, SW480 and HeLa cells were transfected with equal amounts of pEGFP-
N1 and either pCMV-2A-IRES-IL2, pCTP4-2A-IRES-IL2 or pEGFP-Luc as a negative 
control. pEGFP-Luc encodes a fusion-protein of EGFP and luciferase and was 
chosen for the control, as also the 2A-IRES-IL2 sequence expresses EGFP as a 
fusion-protein with protease 2A. Flow cytometric analysis 48 h after transfection 
revealed that in all cell lines the intensity of EGFP expression was lower when 
protease 2A was present compared to control transfections. In COGA-12 cells the 
intensity of EGFP expression was 1.8-fold and 1.5-fold lower attributed to CMV- and 
CTP4-driven expression of protease 2A compared to the control transfection without 
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protease 2A (Fig. 41A). In SW480 cells the intensity of EGFP expression was about 
1.5-fold lower by CMV-driven expression of protease 2A and about 1.7-fold lower by 
CTP4-driven expression (Fig. 41B). In HeLa cells the transfection with pCMV-2A-
IRES-IL2 reduced the intensity of EGFP expression even 4-fold compared to the 
intensity of the control transfection without protease 2A (Fig. 41C). In contrast to the 
4-fold reduction by pCMV-2A-IRES-IL2, the intensity of EGFP expression was only 
1.3-fold lower after transfection with pCTP4-2A-IRES-IL2. This slight reduction of 
overall gene expression in HeLa cells is again attributable to the low expression 
levels of protease 2A that are caused by the CTP4 promoter.  
0
20
40
60
80
100
120
%
 M
FI
 p
EG
FP
-N
1
0
20
40
60
80
100
120
%
 M
FI
 p
EG
FP
-N
1
COGA-12 SW480
0
20
40
60
80
100
120
%
 M
FI
 p
EG
FP
-N
1
HeLa
A B
C
pCMV-2A-IRES-IL2
pCTP4-2A-IRES-IL2
pEGFP-Luc
%
 M
FI
 E
G
FP
%
 M
FI
 E
G
FP
%
 M
FI
 E
G
FP
%
 M
FI
 p
EG
FP
-N
1
%
 M
FI
 p
EG
FP
-N
1
%
 M
FI
 p
EG
FP
-N
1
%
 M
FI
 p
EG
FP
-N
1
%
 M
FI
 p
EG
FP
-N
1
%
 M
FI
 p
EG
FP
-N
1
%
 M
FI
 E
G
FP
%
 M
FI
 E
G
FP
%
 M
FI
 E
G
FP
%
 M
FI
 E
G
FP
%
 M
FI
 E
G
FP
%
 M
FI
 E
G
FP
 
Fig. 41. Effect of protease 2A activity on the EGFP expression level of COGA-12 (A), SW480 (B) 
and HeLa (C) cells. For the transfections of COGA-12 and HeLa cells 0.25 µg of pCMV-2A-IRES-IL2, 
pCTP4-2A-IRES-IL2 or pEGFP-Luc in combination with 0.25µg pEGFP-N1 per 0.5 x 105 cells were 
used. For the transfection of SW480 cells 0.5 µg of pCMV-2A-IRES-IL2, pCTP4-2A-IRES-IL2 or 
pEGFP-Luc in combination with 0.5 µg pEGFP-N1 per 1 x 105 cells were used. Gene transfer was 
performed using lipopolyplex formulation in serum-free medium. EGFP mean fluorescence intensities 
(MFI) were determined by flow cytometry 48 h after transfection and are shown as a percentage of the 
EGFP MFI of the respective coexpression of pEGFP-Luc and pEGFP-N1. Values are means ± SE of 
triplicates. 
3.3.3.2.2. Effect of protease 2A on the metabolic activity of transfected cells 
To analyze the biological effect of protease 2A expression on cell proliferation and 
viability, the COGA-12, SW480 and HeLa cells were transfected with pCMV-2A-
IRES-IL2 or pCTP4-2A-IRES-IL2, and as control with pEGFP-Luc. Three days after 
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transfection the metabolic activity of the transfected cells was measured using the 
MTT assay (Fig. 42). The metabolic activities of pCMV-2A-IRES-IL2 and pCTP4-2A-
IRES-IL2 transfected cells were compared with the metabolic activity of pEGFP-Luc 
control transfected cells in order to exclude that reduction of metabolic activity was a 
result of toxicity of transfection reagents. In COGA-12 cells the metabolic activity of 
pCMV-2A-IRES-IL2- and pCTP4-2A-IRES-IL2-transfected cells was reduced to 76 % 
and 88 % compared to the metabolic activity of cells transfected with the control 
plasmid pEGFP-Luc (Fig. 42A). In SW480 cells the metabolic activity was reduced 
up to 60 % compared to the metabolic activity of control transfected cells, 
independent of the promoter used (Fig. 42B). In HeLa cells pCMV-2A-IRES-IL2 
reduced cell proliferation up to 60 %, whereas transfection of the pCTP4-2A-IRES-
IL2 plasmid did not reduce cell proliferation compared to cells transfected with the 
control plasmid (Fig. 42C). 
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Fig. 42. Effect of protease 2A activity on the metabolic activity of COGA-12 (A) SW480 (B) and 
HeLa (C) cells. For transfections 0.05 µg of pCMV-2A-IRES-IL2, pCTP4-2A-IRES-IL2 or pEGFP-Luc 
per 5 x 103 COGA-12, SW480 or HeLa cells were used. Gene transfer was performed using 
lipopolyplex formulation in serum-free medium. Metabolic activity was determined 3 days after 
transfection by MTT assay. Metabolic activity levels are shown as a percentage of the metabolic 
activity of the respective pEGFP-Luc control transfections. Values are means ± SE of n = 5 in 2 – 3 
independent experiments. 
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3.3.3.2.3. Effect of protease 2A on the apoptosis rate of transfected cells 
Furthermore, the possible effect of protease 2A to induce apoptosis was investigated. 
COGA-12 and SW480 cells were transfected with pCMV-2A-IRES-IL2, pCTP4-2A-
IRES-IL2 and as control with pEGFP-Luc. Forty-eight hours after transfection the 
cells were incubated with annexin V and propidium iodide to distinguish between 
living, apoptotic and necrotic cells. Subsequently, the extent of apoptotic and necrotic 
cells was measured by flow cytometry. Neither cells transfected with pCMV-2A-IRES-
IL2 nor pCTP4-2A-IRES-IL2 exposed a higher rate of apoptosis or necrosis 
compared to control cells transfected without the cytotoxic gene (Fig. 43).  
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Fig. 43. Effect of protease 2A activity on the percentage of apoptotic COGA-12 (A) and SW480 
(B) cells. For transfections 1 µg of pCMV-2A-IRES-IL2, pCTP4-2A-IRES-IL2 or pEGFP-Luc per 1 x 
105 COGA-12 or SW480 cells were used. Gene transfer was performed using lipopolyplex formulation 
in serum-free medium. Apoptosis and necrosis were determined 48 h after transfection by staining 
with annexin V and propidium iodide and following flow cytometry. Values are representative means ± 
SE of duplicates of three independent experiments. 
3.3.3.2.4. IRES-mediated IL-2 expression  
Finally, it was investigated, whether the 2A-IRES-IL2 constructs also enable the 
expression of the therapeutic gene for IL-2 in COGA-12 and SW480 cells despite the 
observed activity of the protease 2A. Cells were transfected with pCMV-2A-IRES-IL2 
and pCTP4-2A-IRES-IL2 plasmids using lipopolyplexes. COGA-12 cells transfected 
with the CMV promoter containing construct secreted 1.7 ng IL-2 per 105 cells within 
24 h 48 h following transfection, and SW480 cells secreted 2 ng IL-2 per 105 cells 
within 24 h 48 h following transfection (Fig. 44). The use of the CTP4 promoter led to 
IL-2 expression levels of 0.3 ng IL-2/105 cells/24 h in COGA-12 cells and 0.7 ng IL-
2/105 cells/24 h in SW480 cells (Fig. 44). 
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Fig. 44. IRES-mediated interleukin-2 (IL-2) production of COGA-12 (A) and SW480 (B) cells. For 
transfections 0.5 µg of pCMV-2A-IRES-IL2 or pCTP4-2A-IRES-IL2 per 0.5 x 105 COGA-12 cells and 1 
µg of pCMV-2A-IRES-IL2 or pCTP4-2A-IRES-IL2 per 1 x 105 SW480 cells were used. Gene transfer 
was performed using lipopolyplex formulation in serum-free medium. Twenty-four hours after 
transfection the growth medium was replaced by fresh medium, 48 hours following gene transfer the 
supernatants were collected and the level of secreted human IL-2 per 1 x 105 in 24 hours was 
determined using an IL-2 ELISA kit. Values are means ± SE of duplicates. 
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4. Discussion 
4.1. Protein expression pattern in multicellular spheroids 
compared to monolayer cultures of low passage colon cancer 
cells 
A major obstacle for the improvement of existing and the development of novel 
therapeutic strategies for the treatment of colorectal cancer is the lack of reliable 
model systems. Many promising therapeutic approaches that were efficient in 
cultured tumor cells demonstrated low or no efficiency in vivo, since the used in vitro 
model systems did not properly reflect the conditions in vivo. A major reason for this 
phenomenon inheres in additional mutations and alterations in the protein expression 
pattern of the tumor cell lines that accumulate during long-term in vitro cultivation. To 
circumvent this problem novel low passage colon cancer cell lines closely reflecting 
the corresponding in vivo tumor cells were used for all investigations in the present 
work. The relevance of these low passage cell lines to provide reliable model 
systems was confirmed in this thesis, since long-term cultivated COGA-12 cells 
exhibited altered properties and protein expression compared to corresponding low 
passage COGA-12 cells (see discussion in 4.2). 
In addition to traditional monolayer cultures the low passage cell lines were cultivated 
as multicellular spheroids to provide a model system that better reflects the three-
dimensional structure of the respective tumors in vivo. Very similar to the tumor in 
vivo the three-dimensional structure of cultured multicellular spheroids provides 
different properties compared to monolayers, in particular the spatial arrangement of 
the cells. In addition, the three-dimensional arrangement of cells in multicellular 
spheroids very likely causes alterations in the gene expression pattern compared to 
monolayer cultures, which again better reflects the situation in tumors in vivo. 
However, this model system does not provide the recapitulation of interactions of 
tumor cells with extracellular matrix (ECM) or other cell types, like for example 
connective tissue, which also may influence the properties and protein expression of 
tumor cells in vivo (Abbott, 2003). ECM consists of proteins like collagen, elastin and 
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laminin, and gives tissues their mechanical properties. Yet, the only commercially 
available possibility to mimic ECM is represented by Matrigel consisting of structural 
proteins isolated from mouse tumors. Therefore, the utilization of Matrigel is not very 
suitable for human tumor cells. In contrast, generating own human custom matrices 
is very time-consuming, expensive and the properties of these custom-made ECMs 
vary from batch to batch (Abbott, 2003). The absence of other cell types besides the 
low passage cancer cells in the multicellular spheroids used in this work provides the 
advantage of exclusively investigating the protein expression of the tumor cells, 
because contamination with proteins derived from other cell types is prevented. 
Therefore, multicellular spheroids represent one of the most potential, easy-to-handle 
alternative in vitro model systems for the investigation of cancers available at present 
in comparison to conventional monolayer cultures. 
To confirm and characterize differences between multicellular spheroids of the low 
passage colon cancer cell lines and corresponding monolayers the expression 
profiles of both model systems were compared by 2D electrophoresis in this thesis. 
This method enables the investigation of nearly all expressed proteins and, in 
addition, their post translational modifications. In contrast, investigations on the level 
of mRNA do not display post translational modifications, and it is not clear if the 
respective mRNAs are translated to proteins. First, multicellular spheroids of the low 
passage colon cancer cell lines COGA-5, COGA-5L and COGA-12 were established 
(Fig. 4). The other tested low passage colon cancer cell lines (COGA-2, COGA-3, 
COGA-10) failed to form multicellular spheroids and only formed multicellular 
aggregates. Multicellular aggregates clearly differ from multicellular spheroids since 
they expose a lower degree of compaction. It was reported previously that a certain 
degree of compaction enabling cell-to-cell interactions is required for the 
development of the altered properties of multicellular spheroids compared to 
monolayer cultures (Mayer et al., 2001). Accordingly, multicellular aggregates do not 
exhibit altered properties. Whether a certain cell line forms multicellular spheroids 
cannot be predicted. The cell lines COGA-5L and COGA-12 formed partly compact 
spheroids, while the cell line COGA-5 developed fully compact spheroids (Fig. 4). 
The comparison of the protein expression profiles of the particular low passage cells 
cultivated as multicellular spheroids or monolayers by 2D electrophoresis revealed 
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several differences (Fig. 5-7). In multicellular spheroids of the cell line COGA-5 the 
expression of five proteins was found to be up-regulated and one protein was down-
regulated compared to monolayers. In both, COGA-5L and COGA-12 multicellular 
spheroids, four proteins were found up-regulated compared to the respective 
monolayers (Table 4). All expression profiles were analyzed 96 h after formation of 
the multicellular spheroids. The differential expression of these proteins was highly 
reproducible, since differential regulation of the respective proteins was confirmed by 
2D electrophoresis of protein extracts of at least three independent experiments. The 
identified proteins were most likely not the only differentially expressed proteins when 
comparing both culture conditions. Discovery of further differences in protein 
expression, however, was limited for the following reasons: First, proteins were only 
considered as differentially expressed when the differences in the spot intensities 
were at least two-fold. Thus, minor variations that originated from the different 
handling of the separate 2D gels could be excluded. Second, alterations in the 
expression of proteins with low abundance cannot be analyzed by 2D 
electrophoresis, if their expression level is beneath the detection limit of this method 
(lower than 1 ng). Furthermore, only proteins with an isoelectric point in the range of 
pH 4 – 7 were analyzed. Proteins with a more basic isoelectric point cannot be easily 
analyzed by 2D electrophoresis. 
MALDI-TOF mass spectrometry and following peptide mass fingerprinting allowed 
identification of three of the differentially expressed proteins in COGA-5 and two in 
COGA-12 multicellular spheroids (Table 5). The proteins regulated in COGA-5L 
multicellular spheroids could not be identified. The identification failed because the 
amount of protein harvested from the gels was insufficient for proper analysis with 
MALDI-TOF mass spectrometry. Furthermore, only proteins that have been 
characterized before by peptide mass fingerprinting can be identified with this 
method. 
The protein down-regulated in COGA-5 multicellular spheroids was identified as the 
acidic isoform of calponin (Table 4 and 5). Calponins are actin-associated proteins 
and besides acidic calponin two other isoforms are known, namely basic and neutral 
calponins (Applegate et al., 1994; Jin et al., 2003). Basic calponin is the best studied 
isoform. It is expressed exclusively in smooth muscle cells where it plays a role in the 
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regulation of contraction (Winder and Walsh, 1990). Less is known about acidic 
calponin. It is expressed in smooth muscle tissues and in a wide variety of other 
tissues, including heart, brain, placenta, lung, liver, skeletal muscle, kidney, 
pancreas, spleen, thymus, prostate, testis, ovary, small intestine, aorta, and also the 
colon (Maguchi et al., 1995). Acidic calponin is not involved in contraction (Fujii et al., 
2002) but may play a role in cytoskeletal organization, since it binds to actin 
(Applegate et al., 1994; Yoshimoto et al., 2000). The different expression pattern of 
calponin in multicellular spheroids implies that the cytoskeleton is differentially 
organized in monolayer cells compared to multicellular spheroids. 
One of the proteins up-regulated in multicellular spheroids of COGA-5 cells was 
identified as LMNA protein (Table 4 and 5). The database used for peptide mass 
fingerprinting indicated a molecular weight of 53 kDa for the LMNA protein. 
Surprisingly, the spot that was identified here as LMNA protein possesses a much 
lower molecular weight according to its location on the 2D gels of multicellular 
spheroids of COGA-5 cells (Fig. 5). It is remarkable that MALDI-TOF mass 
spectrometry only revealed peptides that could be ascribed to the first 216 amino 
acids or the last 98 amino acids of the LMNA protein (Fig. 9D). No peptides were 
obtained that fit to a sequence of about 150 amino acids located in the middle 
between these amino acid sequences (as shown in Fig. 45). Therefore, the identified 
protein is most likely a yet unknown variant of the LMNA protein that is generated by 
alternative splicing. A protein with the 150 amino acid truncation would be about 18 
kDa smaller than the entire LMNA protein. The amino acid sequence of LMNA 
protein is identical to that of lamin C besides a deletion of 107 amino acids (amino 
acids 448 – 554 of lamin C) as shown in Fig. 45. Lamin C is encoded by the same 
gene as lamin A by different splicing. Two more splice variants of this gene have 
been described suggesting the likely identification of further splice variants (Moir and 
Spann, 2001). Therefore, it is likely that both the LMNA protein and the supposed 18 
kDa smaller variant found in COGA-5 multicellular spheroids are also splice variants 
of this gene. In addition to these splice variants two other lamins are known in 
humans, namely lamin B1 and B2 that are encoded by two separate genes (Moir and 
Spann, 2001). 
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Fig. 45. Schematic illustration of the human lamin A/C gene and its gene products. White 
coloration indicates sequences identical for both lamin A and C, black coloration indicates the 
sequence specific for lamin C and vertical stripes the sequence specific for lamin A. (A) Arrangement 
of the exons in the lamin A/C gene (Lin and Worman, 1993). The splice site enabling the generation of 
lamin A and lamin C is indicated. (B) Schematic diagram of lamin A and C proteins. The grey 
highlighted area in lamin C indicates the amino acids missing in the LMNA protein. The approximate 
array missing in an assumedly 18 kDA smaller LMNA protein isotype found in COGA-5 multicellular 
spheroids is indicated by an arrow.  
The lamins are the major proteins forming the nuclear lamina that is connecting the 
inner nuclear envelope membrane with chromatin (Shumaker et al., 2003). They play 
an important role for the assembly and shape of the nucleus. Furthermore, it has 
been suggested that lamins are also involved in DNA replication and transcription 
(Moir and Spann, 2001; Shumaker et al., 2003). The role of the up-regulated novel 
variant of the LMNA protein in COGA-5 multicellular spheroids remains to be 
clarified. However, altered cell and nucleus shape as a consequence of changes in 
cytoskeletal elements and nuclear structure is a hallmark of cancer cells that 
contribute to altered properties compared to normal cells (Konety and Getzenberg, 
1999). It is likely that cells in multicellular spheroids mimic these alterations of in vivo 
tumor cells better than monolayer cells. This hypothesis is further supported by the 
fact that not only the nucleoskeletal LMNA protein but also the cytoskeleton-
associated calponin are differentially regulated in COGA-5 multicellular spheroids 
compared to the corresponding monolayers. 
Another protein that was up-regulated in multicellular spheroids of COGA-5 cells was 
identified as 15-hydroxyprostaglandin dehydrogenase (15-PGDH) (Table 4 and 5). 
15-PGDH is responsible for the degradation of prostaglandins (Tai et al., 2002) and 
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therefore antagonizes the effect of cyclooxygenase 2 (COX-2), a prostaglandin-
synthesizing enzyme (Badawi, 2000). According to the literature, prostaglandins 
promote growth factor signaling and antagonize apoptosis (Badawi, 2000). 
Therefore, 15-PGDH is considered to expose tumor suppressor activity, whereas 
COX-2 may exert tumor promoting activities. Moreover, it was demonstrated that 15-
PGDH is down-regulated in colorectal cancers compared to normal colonic epithelial 
cells (Yan et al., 2004; Backlund et al., 2005). The up-regulation of 15-PGDH 
detected here in COGA-5 multicellular spheroids was in contrast to these previous 
findings and its up-regulation was therefore unexpected. However, Tong and Tai 
recently demonstrated that IL-6 induces the expression of 15-PGDH in prostate 
cancer cells (Tong and Tai, 2004). In this case 15-PGDH was supposed to be up-
regulated to antagonize the effect COX-2 as a defensive regulatory mechanism or to 
inactivate lipoxins, which are potent inhibitors of cell proliferation (Claria et al., 1996). 
Finally, two protein spots up-regulated in COGA-12 multicellular spheroids, were 
identified as the same protein, i.e. acidic ribosomal protein P0 (Table 4 and 5). This 
protein appears at two neighboring positions on the 2D gel most likely as a result of 
different posttranslational modifications (PTMs). This conclusion is supported by the 
fact that both proteins are located at approximately the same height on the 2D gel 
(implying the same molecular weight) and only differ in their isoelectric points (Fig. 
7). P0 forms the lateral stalk of the 60S ribosomal subunit together with two hetero- 
or homo-dimers of acidic ribosomal proteins P1 and P2; P0 functions as ribosomal 
core protein for the anchorage of P1 and P2 (Uchiumi et al., 1987; Tchorzewski et al., 
2000). This stalk is located at the active site of the ribosome particle, where 
interactions between mRNAs, tRNAs and translation factors take place during protein 
synthesis. 
The P-proteins can be phosphorylated by casein kinase II at the serine closest to the 
carboxy-terminus (Hasler et al., 1991). Furthermore, PK60, RAPI, RAPII and RAPIII 
kinases are able to phosphorylate the stalk proteins (reviewed in Ballesta et al., 
1999). However, the state of phosphorylation of the P-proteins does not affect the 
overall translating activity of the ribosome, but it has been suggested that 
phosphorylation influences the preferential translation of certain mRNAs with a 
specific secondary structure (Rodriguez-Gabriel et al., 1998). More recently, Wu and 
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Storey reported that the expression of P0, which is highly conserved in vertebrates, 
was regulated by oxygen levels in wood frog (Rana sylvatica) brain tissue suggesting 
a role of P0 in anoxia resistance (Wu and Storey, 2005). The function of P0 up-
regulation under anoxia, however, remains unclear. Hence, P0 might be up-regulated 
in COGA-12 multicellular spheroids as a consequence of the lower oxygen supply in 
the inner layers of the spheroids. It was demonstrated previously that mRNA levels of 
P0 were increased in hepatocellular and colon carcinoma in accordance with cancer 
progression and biological aggressiveness (Barnard et al., 1992; Kondoh et al., 
1999). Hence, P0 expression pattern in multicellular spheroids demonstrated that this 
three-dimensional culture system was superior compared to traditional monolayer 
cultures to reflect the expression pattern of in vivo tumors. 
In summary, the investigation of the protein expression pattern of multicellular 
spheroids of the low passage colon cancer cells by 2D electrophoresis revealed a 
panel of alterations in comparison to monolayers affecting a wide variety of cellular 
functions regarding most likely growth signaling, protein biosynthesis and regulation 
of the cyto- or nucleoskeleton, respectively. Some of these alterations were also 
demonstrated in tumors in vivo. Thus, in comparison to monolayer cell cultures, 
multicellular spheroids represent a suitable model that recapitulates not only the 
three-dimensional structure but very likely also the protein expression of in vivo 
tumors. Therefore, the analysis of the expression pattern of multicellular spheroids 
may further contribute to better understanding of cancer. 
It is important to note that acidic ribosomal protein P0 as well as lamins and the 
neutral isoform of calponin have been identified to be apoptosis-associated proteins 
(Brockstedt et al., 1998; Holubec et al., 2005). Therefore, it must be taken into 
consideration that the observed alterations could also be attributed to apoptosis 
occurring in the center of multicellular spheroids. 
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4.2. Regulation of cytoskeleton- and mitochondria-associated 
proteins related to chemoresistance against 5-FU 
Surgery combined with 5-FU chemotherapy is the standard treatment of colorectal 
cancer. A major problem of such treatment is the resistance of colorectal cancer cells 
against 5-FU that frequently develops during chemotherapy. Chemoresistant 
sublines of the low passage colon cancer cell lines represent potential model 
systems for the identification of alterations involved in acquired 5-FU 
chemoresistance. Hence, the cell lines that were already investigated regarding their 
altered expression profile as a consequence of multicellular spheroid formation, i.e. 
COGA-5, COGA-5L and COGA-12 were used for the generation of chemoresistant 
sublines. However, it was not possible to generate resistant sublines of the cell lines 
COGA-5 and COGA-5L. COGA-5 cells required 10 µM 5-FU for a reduction of 
proliferation by nearly 50 % but did not survive treatment with 5-FU longer than one 
month. COGA-5L cells required 5 µM 5-FU for a 50 % decrease of proliferation but 
did not develop increased 5-FU resistance despite long-term treatment with 5-FU for 
three months. During the whole term of 5-FU treatment the cells exhibited the same 
reduced proliferation as 5-FU-treated parental COGA-5L cells. COGA-5L cells 
originate from the same patient as COGA-5 cells, but COGA-5 cells were isolated 
from the primary tumor, whereas COGA-5L cells were derived from the respective 
lymph node metastasis (Vecsey-Semjen et al., 2002). Hence, alterations must have 
occurred in the lymph node metastasis COGA-5L compared to COGA-5 cells, which 
are responsible for the distinct response to 5-FU between both cell lines. 
In contrast, long-term (three months) pretreated COGA-12 cells exhibited enhanced 
proliferation in the presence of 5-FU compared to non-pretreated parental COGA-12 
cells (Fig. 16). A concentration of 5 µM 5-FU reduced proliferation of the long-term 5-
FU pretreated cells, termed as COGA-12/G6, to approximately 75 % of the 
proliferation of untreated cells whereas non-pretreated cells exhibited a more 
pronounced reduction of proliferation, i.e. 50 %. Thus, COGA-12/G6 cells were 
considered chemoresistant against 5-FU. Control COGA-12 cells that were 
propagated long-term in absence of 5-FU, termed as COGA-12/NO, exhibited no 
resistance against 5-FU in the proliferation assay (Fig. 20). The COGA-12/G6 cells 
were also resistant against 5-FU induced apoptosis (Fig. 17). Surprisingly, the long-
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term cultivated COGA-12/NO cells exhibited a similar reduced apoptosis level like 
COGA-12/G6 cells compared to parental low passage COGA-12 cells (Fig. 21). This 
phenomenon can be ascribed to alterations that result from the long-term 
propagation. This finding reveals the relevance of low passage numbers of cell lines 
for maintaining biological properties of the original tumor cells. It is important to note 
that the development of 5-FU chemoresistance through long-term cultivation or 5-FU 
pretreatment was associated with the regulation of different proteins (see below). 
The investigation of the expression profile of the chemoresistant COGA-12/G6 cells 
by 2D electrophoresis revealed four proteins that were differentially regulated 
compared to parental sensitive COGA-12 cells (Fig. 22). These proteins were not 
altered in long-term cultivated COGA-12/NO cells. In contrast, one other protein was 
found to be differently expressed between the long-term cultivated COGA-12/NO and 
parental low passage COGA-12 cells (Fig. 22). Since no common alterations in the 
expression profiles of both sublines G6 and NO were obtained by 2D electrophoresis, 
it is likely that different mechanisms contribute to the same apoptosis resistance 
phenotype in both sublines. However, it cannot be fully excluded that the resistance 
against 5-FU induced apoptosis of COGA-12/G6 cells is also due to long-term 
propagation and not due to 5-FU treatment, although the protein expression pattern 
was not identical to COGA-12/NO cells. 
Three of the altered proteins in the chemoresistant subline COGA-12/G6 were down-
regulated and only one was up-regulated (Table 6). This is consistent with previous 
observations, where a similar proportion of up- versus down-regulations was 
detected in 5-FU chemoresistant colon cancer sublines compared to the original 
colon cancer cells (Schmidt et al., 2004). It cannot be excluded that further 
alterations contribute to the chemoresistant phenotype of the subline COGA-12/G6, 
which, however, stay unrevealed because of the limitations of 2D electrophoresis as 
mentioned before. Two of the three protein spots observed to be down-regulated in 
the chemoresistant subline COGA-12/G6 were both identified as heat shock protein 
27 (HSP27) (Table 6 and 7). Most likely, HSP27 appeared at two nearby positions 
on the 2D gel as a consequence of different posttranslational modifications (PTMs). 
The most common PTM of HSP27 is phosphorylation. HSP27 belongs to a group of 
highly conserved proteins defined as molecular chaperones that fulfill a 
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cytoprotective role in cells undergoing various environmental stresses like 
hyperthermia, oxidative stress, or even exposure to chemotherapeutic drugs. The 
cytoprotective action of HSP27 is based on its ability to mediate resistance against 
apoptosis (Samali and Cotter, 1996; Concannon et al., 2003). HSP27 inhibits 
apoptosis by interfering with cell death signaling triggered by death receptor 
stimulation or through the mitochondrial pathway (Mehlen et al., 1996; Garrido et al., 
1999). HSP27 is frequently expressed at high levels in tumor cells and was already 
reported to be involved in mediating resistance against several chemotherapeutic 
drugs like cisplatin, doxorubicin and etoposide (Garrido et al., 1997; Garrido et al., 
1999). A major role of HSP27 in resistance against 5-FU has not been reported 
before. Large oligomers of HSP27 were proposed as the active form in inhibiting cell 
death; but only unphosphorylated HSP27 is capable to form large oligomers (Mehlen 
et al., 1997; Preville et al., 1998; Garrido et al., 1999). Recently, it was reported that 
the assembly of HSP27 oligomers can also be regulated independently of 
phosphorylation by S-thiolation (Eaton et al., 2002). HSP27 oligomers efficiently 
decrease the intracellular level of apoptosis-inducing reactive oxygen species (ROS) 
in a glutathione-dependent manner (Arrigo, 1998). HSP27 increases the activity of 
glucose-6-phospate dehydrogenase, glutathione reductase and glutathione 
transferase which altogether uphold glutathione in its reduced form thereby 
decreasing levels of intracellular ROS (reviewed in Arrigo, 2001; and Arrigo et al., 
2005). The increased activity of these enzymes may be conferred by the chaperone 
properties of HSP27 (Rogalla et al., 1999). In addition, HSP27 may protect cells from 
oxidative damage because it presents oxidized proteins to the ubiquitin-independent 
20S proteasome degradation machinery and thereby mediates their elimination 
(Arrigo, 2001; Arrigo et al., 2005). How ROS induce apoptosis is not well understood. 
ROS may modulate the mitochondrial membrane potential, resulting in the release of 
cytochrome c, finally leading to apoptosis (Chandra et al., 2000). Another possibility 
is that ROS up-regulate the expression of Fas and Fas ligand (Chandra et al., 2000). 
This is particular interesting since 5-FU induces apoptosis via upregulation of Fas 
and Fas ligand (Petak et al., 2000; Petak and Houghton, 2001). It was proposed that 
this increase was mainly due to p53-mediated transcriptional upregulation of Fas 
(Muller et al., 1998; McDermott et al., 2005). ROS are generated after treatment with 
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chemotherapeutic drugs (Davis et al., 2001), and recently, it was demonstrated that 
also the treatment with 5-FU increased the level of ROS in mitochondria of colorectal 
cancers thereby promoting apoptosis (Hwang et al., 2001; Liu and Chen, 2002). The 
5-FU-induced increase in ROS depends on intact p53 and therefore it is interesting to 
note that COGA-12 cells are expressing wildtype p53 (Vecsey-Semjen et al., 2002). 
After treatment with 5-FU p53 increases the level of mitochondrial ferredoxin 
reductase, which in turn is supposed to hinder the detoxification of ROS resulting in 
the lethal accumulation of ROS (Liu and Chen, 2002). Furthermore, it was 
demonstrated that overexpression of ferredoxin reductase also suppressed the 
growth of colon cancer cells (Hwang et al., 2001). Overall, the data above imply a 
protective role of HSP27 which is in sharp contrast to its down-regulation in 5-FU 
chemoresistant cells in the present study. However, the chemoresistant COGA-
12/G6 cells might have developed an alternative, yet unknown mechanism for the 
elimination of 5-FU-induced ROS levels and in this case HSP27 may not longer be 
required to survive ROS-associated stress. 
Yet, the disappearance of the both HSP27 spots in the chemoresistant subline 
COGA-12/G6 compared to the sensitive cell line may also represent the vanishing of 
phosphorylated isoforms of HSP27. In this case the following model may be 
postulated: The phosphorylation of HSP27 could be inhibited by a yet unknown 
mechanism in the resistant subline. Alternatively, the efficiency of HSP27 
dephosphorylation could be increased. Both mechanisms would lead to the supply of 
an increased level of unphosphorylated HSP27 to form large oligomers preventing 
ROS-mediated apoptosis after 5-FU treatment. HSP27 contains three potential 
phosphorylation sites on Ser residues at position 15, 78 and 82 (Landry et al., 1992; 
Cairns et al., 1994; Gusev et al., 2002). It is predominantly phosphorylated by 
MAPKAP (mitogen-activated protein kinase-activated protein) kinase-2 and -3, which 
in turn are activated by MAP (mitogen-activated protein) kinase SAPK2 (stress-
activated protein kinase-2) as a response to oxidative stress (Landry and Huot, 1999; 
Dalle-Donne et al., 2001). Furthermore, protein kinase D and certain isoforms of 
protein kinase C were found to be involved in phosphorylation of HSP27 (Maizels et 
al., 1998; Doppler et al., 2005). Dephosphorylation of HSP27 is accomplished 
amongst others by protein phosphatase 2A (Cairns et al., 1994). Whether the 
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regulations or activities of these enzymes are altered in the chemoresistant cell line 
COGA-12/G6 remains to be clarified.  
Cuesta and co-workers demonstrated that HSP27 additionally functions as an 
inhibitor of cellular protein synthesis by interaction with the translation initiation factor 
eIF4G during heat shock (Cuesta et al., 2000). Along these lines, the down-
regulation of HSP27 could also be the reason for the enhanced proliferation of the 
chemoresistant subline COGA-12/G6 despite 5-FU treatment. 
HSP27 is further described as a polymerization modulator of actin, a major 
constituent of the cytoskeleton microfilaments. Small oligomers of phosphorylated 
HSP27 stabilize the actin filament network thereby preventing actin degradation in 
response to stress (Mounier and Arrigo, 2002). In contrast, nonphosphorylated 
monomeric HSP27 acts as an actin cap-binding protein thereby inhibiting actin 
polymerization (Benndorf et al., 1994; Mounier and Arrigo, 2002). Taken together, 
also a rearrangement of the cytoskeleton enabled by differential expression of the 
actin-modulator HSP27, may contribute to the chemoresistant phenotype of COGA-
12/G6 cells. In addition, Perng and co-workers demonstrated that HSP27 was also 
associated with cytokeratin 18 (CK18) (Perng et al., 1999), a major constituent of the 
cytoskeleton intermediate filaments. This suggests a role of HSP27 also in the 
control of filament-filament interactions. 
Interestingly, CK18 was identified to be the up-regulated protein in the 
chemoresistant cell line COGA-12/G6 (Table 6 and 7). Intermediate filaments (IFs) 
are one of the three structural units of the cytoskeleton besides actin-containing 
microfilaments and tubulin-containing microtubules. Several proteins are known that 
form IFs: e.g. vimentin (found in mesenchymally derived cells), desmin (found in most 
myogenic cells), glial fibrillary acidic protein (found in astrocytes), neurofilament 
proteins (found in neurons), CKs (found in epithelial cells) and hair-related keratins 
and, further, the three nuclear lamins (Hatzfeld and Franke, 1985; Oshima, 2002). 
CKs can be divided in subfamilies of type I and type II cytokeratins. The type I 
subfamily comprises eleven acidic CKs (CK9 - 20) and type II nine larger, more basic 
CKs (CK1 - 9) (Chu and Weiss, 2002). Two different CKs, one of each subfamily, 
form a polar coiled-coil heterodimer (Fig. 46B). The type I and type II cytokeratins are 
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arranged in parallel within this coiled-coil dimer (Fig. 46A). Two of these polar dimers 
form staggered antiparallel tetramers that in turn join together into apolar 
protofilaments. Two of these protofilaments associate into protofibrils which finally 
associate into IFs (Fig. 46C) (Rao et al., 1996; Fuchs and Cleveland, 1998; Owens 
and Lane, 2003). 
A
B
C
Ser34
phosphorylated
in mitosis
Ser53
phosphorylated
in mitosis/stress
CK8
CK18
 
Fig. 46. Structure of intermediate filaments. (A) Cytokeratins of type I (CK18) and type II (CK8), 
arranged in parallel. Phosphorylation sites in CK18 are indicated (adapted from Owens and Lane, 
2003) (B) Polar coiled coil heterodimer composed of a type I and type II cytokeratin (adapted from Rao 
et al., 1996) (C) Polar coiled coil dimers form staggered antiparallel tetramers that associate into 
apolar protofilaments and protofibrils. Protofibrils associate into IFs (adapted from Fuchs and 
Cleveland, 1998; Strelkov et al., 2003). 
The type II cytokeratin partner of CK18 is CK8. Both are typically expressed in simple 
epithelial cells and in many adenocarcinomas (Moll et al., 1983; Chu and Weiss, 
2002). The presence of CK18 has already been described previously in the cell line 
COGA-12 (Vecsey-Semjen et al., 2002). Thus, the observed up-regulation in 
chemoresistant COGA-12/G6 cells (Fig. 22, Table 6 and 7) may rather represent an 
enhanced posttranslational modification of CK18 such as phosphorylation than 
transcriptional regulation since CK18 expression is highly abundant in parental 
COGA-12 cells. CK18 possesses, for example, two phosphorylation sites (Fig. 46A) 
that are phosphorylated in mitotic or stressed cells (Owens and Lane, 2003). The 
differential regulation of CK18 in the subline COGA-12/G6 most likely contributed to 
Discussion 105 
the chemoresistant phenotype of this cell line. CK18, besides CK8, has been 
described previously to mediate a resistant phenotype to five different 
chemotherapeutic agents, i.e. mitoxantrone, doxorubicin, melphalan, bleomycin, and 
mitomycin C (Anderson et al., 1996). This resistance may be attributed, in part, to a 
cytokeratin-conferred protection against apoptosis. A similar protection against 
apoptosis mediated by CK8 and CK18 was also reported for normal epithelial cells. 
Gilbert and co-workers demonstrated that in murine hepatocytes CK8 and CK18 
provide resistance against Fas-mediated apoptosis by reducing the targeting of Fas 
to the cell surface (Gilbert et al., 2001). Fas protein is retained in the Golgi 
compartment and upon activation transferred to the surface membrane in a 
microtubule-dependent manner (Sodeman et al., 2000). How CK8 and CK18 
influence this microtubule-dependent process that regulates the Fas density at the 
surface membrane has not yet been elucidated. Furthermore, actin may also be 
involved in this process as actin is responsible for the clustering of Fas in the surface 
membrane (Parlato et al., 2000). 
Overall, the results obtained in this thesis strongly suggest that the cytoskeleton 
plays an important role for the development of acquired resistance against 5-FU in 
the low passage colon cancer cell line COGA-12, since CK18 and the actin-
modulator HSP27 are differentially regulated. Schmidt and co-workers demonstrated, 
however, that colon cancer cell lines resistant against 5-FU exhibited a down-
regulation of other CKs, namely CKB1, CK6, CK5, CK7 and CK19 (Schmidt et al., 
2004). 
Another protein that was down-regulated in the chemoresistant subline COGA-
12/G6, was identified as aldehyde dehydrogenase 1B1 (ALDH1B1) by peptide mass 
fingerprinting (Table 6 and 7). Nineteen enzymes belong to the human aldehyde 
dehydrogenase superfamily as known so far (Vasiliou and Nebert, 2005). They 
catalyze the pyridine nucleotide-dependent oxidation of aldehydes to acids and are 
therefore involved in detoxification reactions (Sladek, 2003). ALDH1A1 and 
ALDH3A1, for example, catalyze the detoxification of the chemotherapeutic drug 
cyclophosphamide by degradation of cyclophosphamide metabolites (Sladek, 1999). 
ALDH3A1 is highly expressed in several tumors where it mediates chemoresistance 
against cyclophosphamide (Vasiliou et al., 2004). In contrast, mitochondrial 
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ALDH1B1 is involved in the detoxification of acetaldehydes that accumulate, for 
example, in the course of ethanol metabolism (Stewart et al., 1995). Besides 
ALDH1B1 two other ALDHs are involved in acetaldehyde degradation, namely 
ALDH1A1 and ALDH2 (Vasiliou and Pappa, 2000; Vasiliou et al., 2000). A role for 
ALDH1B1 in tumor growth, apoptosis or survival signaling has not yet been clarified 
(Vasiliou et al., 2004). The activity of ALDHs was demonstrated to be equally in colon 
cancers and respective normal tissue (Jelski et al., 2004). Another investigation 
implicated that the content of acetaldehyde degrading ALDHs was decreased in 
colon cancer tissue compared to corresponding normal tissue, though the ALDH 
content remained still high (Hengstler et al., 1998). Moreover, it was reported that 
carmofur, a derivative of 5-FU, inhibits the activity of acetaldehyde degrading ALDHs 
(Kan et al., 1998). In addition to the potential role of HSP27 in 5-FU chemoresistance 
as discussed before, the observed regulation of mitochondrial ALDH1B1 further 
supports the conclusion that mitochondrial mechanisms are involved in the 
chemoresistance against 5-FU. 
According to previous work 5-FU resistance was ascribed to alterations in the 
(fluoro)pyrimidine metabolism (Banerjee et al., 2002). Unexpectedly, none of the 
differentially regulated proteins identified in this thesis was involved in 
(fluoro)pyrimidine metabolism. However, a recently performed comparison of the 
expression profiles of a colon cancer cell line and the corresponding 5-FU resistant 
subline via GeneChip-arrays also revealed that the regulation of enzymes of the 
(fluoro)pyrimidine metabolism only played a minor role in the development of 5-FU 
resistance in this particular subline (Schmidt et al., 2004). Yet, it has to be considered 
that the activity of a certain protein can be altered in chemoresistant cells whereas its 
expression level remains unaffected. 
The protein up-regulated in the long-term cultivated subline COGA-12/NO, was 
identified as maspin (Table 6 and 7). Maspin was described as an inhibitor of serine 
proteases exhibiting tumor-suppressing activity in breast cancer (Maass et al., 2000). 
It has been suggested that maspin functions at the level of invasion and metastasis 
by blocking tumor cell migration and proliferation (Maass et al., 2000). Furthermore, 
maspin was reported to promote apoptosis through the regulation of Bcl-2 family 
proteins (Zhang et al., 2005). However, in thyroid carcinoma, for example, maspin 
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expression directly correlated with biological aggressiveness (Ito et al., 2004). 
Moreover, maspin overexpression correlated with poor prognosis in several other 
cancers of pancreas, ovary, stomach, lung, bladder and skin (Bettstetter et al., 2005). 
Bettstetter and co-workers further demonstrated that in colorectal cancers maspin 
was also overexpressed compared to benign colonic mucosa (Bettstetter et al., 
2005). They further proposed that the subcellular localization of maspin in the 
nucleus or the cytosol affected its biological activity, although this is a matter of 
controversial discussions. More recently, it was demonstrated that maspin was 
capable to reduce ROS levels by direct interaction with glutathione S-transferase (Yin 
et al., 2005). This fact could explain the observation that also the long-term cultivated 
subline COGA-12/NO demonstrates resistance against 5-FU induced apoptosis. The 
overexpression of maspin could lead to decreased levels of 5-FU-induced ROS by 
increasing glutathione S-transferase activity that would otherwise promote apoptosis. 
In the chemoresistant subline COGA-12/G6 this task may be accomplished by 
HSP27. These findings indicate that two different alterations can provide a similar 
resistance against 5-FU-induced apoptosis in the chemoresistant and the long-term 
cultivated sublines. Furthermore, the observation that the cell line COGA-12 exhibits 
different response to the treatment with 5-FU after long-term cultivation again 
underlines the importance of using low passage colon cancer cell lines that closely 
reflect the properties of the corresponding in vivo tumors. 
In conclusion, the investigation of the chemoresistant subline of the low passage 
colon cancer cell line COGA-12 by 2D electrophoresis revealed that alterations of the 
cytoskeleton may contribute to acquired chemoresistance against 5-FU. In addition, 
alterations in the expression of mitochondria-associated proteins seem to co-
contribute to this process. Besides acquired chemoresistance also intrinsic 
chemoresistance plays a major role for failure of colorectal cancer chemotherapy. 
Intrinsic resistance differs from acquired resistance because it is present from the 
beginning of the treatment and does not develop in course of the treatment. 
Therefore, the investigation of intrinsic chemoresistance is also important. For this 
purpose, the multicellular spheroids of the low passage cell lines appear as a suitable 
model system that closely reflect the features of in vivo tumors. It was reported 
previously that multicellular spheroids demonstrated a higher resistance against 
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chemotherapeutic drugs than their respective monolayers (Kobayashi et al., 1993). 
Hence, changes in the expression profiles of multicellular spheroids of the low 
passage colon cancer cells compared to monolayers may contribute to clarify the 
phenomenon of intrinsic chemoresistance. Interestingly, some of the alterations 
between multicellular spheroids and monolayers of the low passage colon cancer cell 
lines, as identified in this work, were also related to the cytoskeleton or 
nucleoskeleton. 
4.3. Lipopolyplexes mediate efficient gene transfer to low passage 
colon cancer cells 
In addition to conventional chemotherapy strategies for colorectal cancer alternative 
therapy concepts have to be developed. Accumulating evidence demonstrates that 
bilateral treatment of colorectal cancer can be a promising approach since the impact 
of chemotherapy is enhanced by simultaneous immunotherapy with IL-2 (Gez et al., 
2002; de Gast et al., 2003). However, the systemic application of IL-2 protein often 
exhibits severe side effects, like capillary leakage syndrome, and hepato- and 
nephrotoxicity (Bubenik, 2004). A promising alternative to avoid these side effects 
provides the application of IL-2 by gene therapy. Bishop and co-workers recently 
demonstrated that the antitumoral effect of the chemotherapeutic drug 5-FU could be 
enhanced by simultaneous IL-2 expression via gene therapy (Bishop et al., 2000). 
Currently, the relatively low efficiency of existing gene transfer systems represents a 
major problem for their broad application. Comparing the available gene delivery 
methods, nonviral systems provide several advantages over viral vectors, like e.g. 
minimal side effects and reduced immunogenicity. 
A promising improvement for current nonviral gene delivery is the combination of 
cationic lipids and polycations to form lipopolyplexes that may significantly improve 
gene transfer (Gao and Huang, 1996; Lampela et al., 2002; Lampela et al., 2004). In 
this thesis various formulations of different polycations (PLL18, PEI22lin, PEI25br, 
PEI2k), cationic lipids (DOSPER, DOCSPER, DOTAP) and their combinations were 
therefore compared for their capability of effective gene transfer. First of all, 
biophysical properties of these formulations were analyzed, because the size of the 
transfection particles is a critical parameter influencing also their efficiency in gene 
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transfer. For in vivo applications small particles are necessary. At low ionic strength, 
all tested lipopolyplex formulations were small, with particle sizes in the range from 
50 to 130 nm (Fig. 28). At physiological ionic strength, however, lipopolyplex 
formulations containing PLL18, PEI22lin or PEI2k aggregated rapidly. In contrast, the 
lipopolyplexes of PEI25br combined with DOCSPER or DOSPER retained their small 
size at the 4 h time point (140 to 220 nm). Although PEI25br and PEI22lin have 
similar molecular weight, they differ in their chemical structure (branched versus 
linear) and display different behavior in their ability to condense DNA and to transfect 
cells (Wightman et al., 2001). PEI22lin/DNA complexes aggregate already at low salt 
concentrations (0.5 x HBS), while PEI25br/DNA complexes generate small particles 
and condense DNA to a greater extend than PEI22lin under these conditions (Dunlap 
et al., 1997). The gene transfer efficiencies of the salt stable lipopolyplexes 
consisting of PEI25br and the cationic lipids DOCSPER or DOSPER were tested on 
the low passage colon cancer cell lines as these cells provide more relevant model 
systems than other available cell lines. Three candidates were chosen as 
representatives for the broad heterogeneity of these cell lines each representing a 
different phenotype, i.e. COGA-3 cells as representatives for rounded-up, COGA-5 
cells for epithelial-like and COGA-12 cells for piled-up morphology. In addition, two 
control cell lines, HeLa and SW480, were used. The stable lipopolyplexes displayed 
up to 400-fold enhanced gene transfer compared to the corresponding lipoplexes or 
PEI25 polyplexes (Fig. 29). These experiments demonstrated that lipopolyplexes are 
superior to lipoplexes and polyplexes in gene transfer not only in the control cells 
HeLa and SW480 but also in the low passage colon cancer cell lines. 
Large transfection particles often achieve higher in vitro gene transfer efficiency 
compared to small particles due to enhanced sedimentation onto cells and/or 
enhanced endosomal release (Boussif et al., 1996; Ogris et al., 1998). Interestingly, 
the stable DOSPER/PEI25br/DNA formulations of medium size displayed very similar 
gene transfer efficiency as the large aggregated (> 1 µm) DOSPER/PEI22lin/DNA 
lipopolyplex formulations (Fig. 30). In this case the improved gene transfer efficiency 
of the stable PEI25 lipopolyplexes cannot be attributed to a sedimentation process. 
Furthermore, experiments using EGFP as a reporter gene demonstrated that the 
number of EGFP positive cells was significantly higher when lipopolyplexes were 
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used for transfection in the presence of serum compared to the corresponding 
lipoplexes or polyplexes (Fig. 36). It is interesting to note that in the absence of 
serum the percentage of EGFP positive cells was almost equal independent whether 
lipopolyplexes or their corresponding lipoplexes were used for gene transfer. This 
phenomenon can be explained by the different biophysical properties of the both 
formulations leading to different levels and velocities of aggregation in serum-free 
medium. It is well known, that gene transfer efficiency in vitro strongly depends on 
the size of the particles applied (Ogris et al., 1998; Pelisek et al., 2005). Hence, rapid 
aggregation of a formulation leads to enhanced gene transfer efficiency. 
However, despite the comparable number of transfected cells, the expression levels 
of luciferase were significantly lower with lipoplexes compared to lipopolyplexes also 
in the absence of serum (Fig. 29). This contradiction can be explained as follows: 
When using lipoplexes endosomal release and dismantling of DNA from cationic 
lipids occurs usually in a coordinated process thus the DNA is unprotected against 
degradation by cytoplasmic nucleases (Xu and Szoka, Jr., 1996). In contrast, in 
lipopolyplexes the polycation is believed to be still associated with the DNA following 
endosomal release, thus allowing better protection against degradation and greater 
DNA stability (Bieber et al., 2002) (see also discussion below). Therefore, less 
molecules of DNA will reach the nucleus in the case of lipoplexes compared to 
lipopolyplexes leading to lower expression levels, although the same amount of cells 
is transfected by both formulations (in the absence of serum). 
The data obtained by transfections using the reporter genes luciferase and EGFP 
revealed an obvious independence between the number of transfected cells and the 
level of gene expression. The amount of transfected cells depends on the efficiency 
of cellular uptake of the gene transfer complexes. The level of gene expression, 
however, depends on the ability of the formulations to disrupt endosomal membrane, 
the stability of DNA within the cytoplasm and the efficiency of DNA to achieve the 
nucleus of the respective cells. This was confirmed by the fact that, for example, by 
using lipopolyplexes COGA-5 cells exhibited the highest level of luciferase 
expression among the tested low passage colon cancer cell lines (Fig. 29), although 
the lowest number of EGFP positive cells was detected in this cell line (Fig. 36). 
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The inefficiency of DNA formulations to escape the endosomolytic pathway strongly 
limits the efficiency of gene transfer. Free cationic lipids or PEI are able to enhance 
gene transfer by enhancing endosomal membrane disruption (Gao and Huang, 1996; 
Boeckle et al., 2004). PEI is known to possess high buffering capacity and 
consequently high endosomolytic activity (Boussif et al., 1995). In the case of 
lipopolyplex formulations, cationic lipid and PEI25br may act simultaneously in 
releasing DNA from endosomes, thus enhancing gene transfer. For the preparation 
of lipopolyplexes DNA was mixed with PEI25br first following addition of cationic lipid, 
because it was previously demonstrated that this order of mixing resulted in the 
highest transfection efficiencies (Lee et al., 2003; Pelisek et al., 2005). Therefore, 
cationic lipids may form an additional protective layer around the pre-condensed 
polycation/DNA formulations or cause partial rearrangement of these formulations 
where both polycation and cationic lipid work synergistic in DNA protection. Following 
dismantling of lipopolyplexes in the endosomes, polycations may still be associated 
with DNA after endosomal release, thus allowing enhanced protection of DNA 
against cytoplasmic nucleases. 
The high potential of lipopolyplexes as an improved nonviral gene transfer system 
was further demonstrated by the observation that this formulation provided also the 
ability to efficiently transfect multicellular spheroids that mimic the three-dimensional 
structure of in vivo tumors. When using lipopolyplexes and the reporter gene for 
EGFP in multicellular spheroids efficient gene transfer could be observed (Fig. 31). 
Confocal microscopy and cryosectioning demonstrated that only cells located near 
the surface of the multicellular spheroids exhibited EGFP fluorescence and were 
therefore transfected (Fig. 32). This finding strongly suggested that the gene transfer 
complexes are able to diffuse only to limited distance into the compact spheroid 
structure. However, in contrast to multicellular spheroids in vivo tumors usually 
exhibit strong vascularisation (Auguste et al., 2005), which enables the transport of 
the lipopolyplexes also into the inside of the tumor. 
In summary, only lipopolyplex formulations containing PEI25br and the cationic lipids 
DOSPER or DOCSPER generated at physiological salt conditions were stable to 
aggregation. These particles with medium sizes of 140-220 nm mediated efficient 
gene transfer in low passage colon cancer cell lines. Such formulations are therefore 
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promising tools for in vitro and potentially also in vivo gene transfer to colorectal 
cancer cells. They not only enabled efficient gene transfer in cells cultivated as 
traditional monolayers but also in multicellular spheroids which are more relevant with 
respect to in vivo applications. 
4.4. The artificial CTP4 promoter enables high colorectal cancer 
specific gene expression 
Besides the improvement of gene transfer efficiency, colon cancer specific gene 
expression is another promising strategy for the development of an efficient tumor-
targeted gene therapy system. Mutations leading to β-catenin accumulation 
throughout the cell are found in more than 70 % of human colon tumors (Kinzler and 
Vogelstein, 1996). Therefore, a ß-catenin/TCF-dependent promoter would be highly 
specific for expression in most colon cancer cells. Such a promoter, CTP1, was 
recently developed by Lipinski et al. (2001) and further optimized for its specificity, 
resulting in the artificial CTP4 promoter (Lipinski et al., 2004).  
In this thesis the efficiency of this CTP4 promoter was tested in various human low 
passage colon cancer cell lines and as control in SW480 (standard colorectal cell 
line) and HeLa (non- colorectal) cells using at first Lipofectamine 2000 for gene 
transfer. The tumor specific promoter enabled high expression levels of luciferase in 
SW480 cells and all seven low passage colon cancer cell lines tested despite the 
broad heterogeneity of the different cell lines (Fig. 33). In SW480 cells and in three 
low passage colon cancer cell lines (COGA-2, COGA-3 and COGA-12) the 
expression levels by the tumor specific CTP4 promoter were even higher than 
expression levels achieved by the strong, but unspecific CMV promoter. In one cell 
line (COGA-1) the CTP4 promoter led to CMV promoter comparable expression 
levels and in three cell lines (COGA-5, COGA-5L and COGA-10) to slightly lower 
expression levels than the CMV promoter. These results clearly demonstrated that 
the CTP4 promoter was efficient in a broad range of heterogeneous colorectal cancer 
cells, however, with different degrees. Different mutations in the various cell lines 
may account for the observed differences in the efficiency of the CTP4 promoter in 
comparison to the CMV promoter. For example, it was demonstrated that in COGA-3 
cells a β-catenin mutation prevented its proteasome-mediated degradation, which 
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resulted in accumulation of β-catenin in the nucleus (Vecsey-Semjen et al., 2002). 
COGA-12 cells also expose elevated levels of ß-catenin (Vecsey-Semjen et al., 
2002). Therefore, the high efficiency of the CTP4 promoter in both cell lines can be 
ascribed to elevated β-catenin levels. The lower efficiency of the CTP4 promoter in 
COGA-5 cells, for example, correlates with the fact that in these cells β-catenin is 
mainly located at cytoplasmic membranes (Vecsey-Semjen et al., 2002). Other 
mutations associated with the Wnt signaling pathway (Peifer, 1999) may further 
influence the specificity and expression level of the CTP4 promoter. For example, the 
APC protein that is involved in the degradation of β-catenin is truncated in the cell 
lines COGA-5 and COGA-12, while it is not mutated in the cell line COGA-3 (Vecsey-
Semjen et al., 2002). In control experiments in non-colorectal HeLa cells the CTP4 
promoter was at least 1000-fold less effective than the CMV promoter, in agreement 
with published results by Lipinski and co-workers (Lipinski et al., 2004). This 
underlines the high specificity of the CTP4 promoter for colon cancer cells with 
deregulated β-catenin. 
More detailed analysis of the CTP4 promoter was performed using COGA-3, COGA-
5 and COGA-12 cells and optimized lipopolyplexes of the cationic lipid DOSPER and 
the polycation PEI25br as well as their corresponding lipoplexes and polyplexes for 
gene transfer (Fig. 34). Importantly, the results demonstrated that also the 
transcriptionally targeted lipopolyplexes mediated an up to 1300-fold higher 
luciferase expression compared to the corresponding lipoplexes and polyplexes. In 
COGA-3, COGA-12, and control SW480 cells the CTP4 promoter had higher 
luciferase expression levels than the CMV promoter, similar to the results achieved 
with Lipofectamine 2000 above. In the cell line COGA-5, the CTP4 promoter had 
again lower luciferase expression levels than the CMV promoter, but the expression 
level was still in a high range. 
Furthermore, the analysis of EGFP expression controlled by the CTP4 or the CMV 
promoter showed equal percentages of EGFP positive cells regardless which 
promoter was used (Fig. 36). This demonstrates that the enhanced luciferase 
expression levels obtained by the CTP4 promoter compared to the CMV promoter 
are due to higher transcriptional activity achieved by the CTP4 promoter and not 
attributable to differences in transfection efficiencies. 
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Finally, transfection of multicellular spheroids with transcriptionally targeted 
lipopolyplexes led also to a high quantity of EGFP positive cells (Fig. 37). The 
amount of EGFP positive cells was comparable with the amount obtained by 
lipopolyplexes containing the EGFP gene under control of the CMV promoter. This 
suggests that the transcriptionally targeted lipopolyplexes are suitable for future in 
vivo applications. 
In conclusion, the use of transcriptionally targeted lipopolyplexes that combine 
efficient lipopolyplex formulations with tumor specific CTP4 promoter containing 
plasmids can be a powerful approach for the treatment of colon cancer as it 
combines enhanced gene transfer efficiency, high expression levels and high tumor 
specificity. 
4.5. Transcriptionally targeted lipopolyplexes enable sufficient 
expression of the immune stimulatory gene IL-2 
The transcriptionally targeted lipopolyplexes might be applied for a therapeutic 
treatment of colorectal cancer. For example, the tumor specific expression of the 
immune stimulatory gene IL-2 at high levels directly in tumor cells will be a very 
promising approach. Furthermore, combination therapy of colorectal cancers with the 
IL-2 gene (applied by the transcriptionally targeted lipopolyplexes) together with 
conventional chemotherapy is conceivable. Therefore, the expression levels of IL-2 
after transfection with transcriptionally targeted lipopolyplexes in comparison to 
lipopolyplexes harboring the IL-2 gene under control of the CMV promoter were 
investigated in the colon cancer cell line SW480 and the low passage colon cancer 
cell line COGA-12 (Fig. 38). High amounts of IL-2 were expressed in the two cell 
lines after application of both the CMV and the CTP4 promoter (up to 95 ng IL-2 per 
1 x 105 cells in 24 h). However, while large amounts of DNA (1 µg IL-2 DNA per 1 – 
1.5 x 105 cells) were necessary to obtain high IL-2 levels by utilization of the CMV 
promoter, already small amounts of DNA (0.25 µg IL-2 DNA per 1 – 1.5 x 105 cells) 
were sufficient to obtain high levels of IL-2 by utilization of the CTP4 promoter. The 
CTP4 promoter directed 3-fold and even up to 350-fold higher IL-2 expression levels 
than the CMV promoter when low DNA amounts were used for transfection of the cell 
lines COGA-12 and SW480, respectively. When the amount of transfected DNA was 
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increased (to 1 µg DNA per 1 – 1.5 x 105 cells), equal IL-2 expression levels were 
obtained by both promoters in COGA-12 cells. Comparable results were achieved 
regarding luciferase expression levels (Fig. 35). Again, the differences in the 
luciferase expression levels were less pronounced between both promoter systems 
when high DNA doses were applied. A probable reason for these observations is that 
with increasing amounts of DNA the expression machinery of the cell is saturated 
which limits the maximum expression level of the exogenous gene. The benefit of the 
CTP4 promoter over the CMV promoter was clearly visible when using lower DNA 
doses, where the DNA concentration and not the expression machinery was the 
limiting factor. This also explains why the CTP4-driven IL-2 expression level of 
SW480 cells could not be further increased with high DNA amounts compared to low 
DNA amounts. The saturation level of protein expression was achieved already with 
the low DNA amount. Thus, the present investigations with IL-2 gene transfer 
demonstrated that if the extend of DNA transfer is high, the use of the tumor specific 
CTP4 promoter leads to expression levels comparable with the expression levels of 
the widely used, strong, but unspecific CMV promoter. However, in the case of lower 
gene transfer efficiency, for example after in vivo applications, the use of the tumor 
specific promoter CTP4 may lead to favorable expression levels compared to the 
CMV promoter expression levels. Hence, the use of the CTP4 promoter may partially 
compensate for low transfection efficiencies in vivo.  
Furthermore, transfection of multicellular spheroids of COGA-12 cells with 
lipopolyplexes resulted also in pronounced IL-2 expression (up to 1.4 ng per 
multicellular spheroid) (Fig. 39), although only cells at the surface of the multicellular 
spheroids were transfected according to the EGFP expression pattern of transfected 
multicellular spheroids (Fig. 32). Again, the expression levels were higher with the 
CTP4 promoter than with the unspecific CMV promoter.  
In summary, the transcriptional targeted lipopolyplexes developed in this thesis 
enabled high expression of the reporter genes luciferase and EGFP, and also high 
expression of the therapeutic gene IL-2 following transfection of the low passage 
colon cancer cells, even in multicellular spheroids. 
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4.6. Therapeutic potential of combined immune stimulatory and 
cytotoxic gene expression in colorectal cancer cells 
High expression levels of immune stimulatory IL-2 after transfection of tumor cells is 
a promising therapeutic approach. However, an even higher impact of gene therapy 
may be achieved, if the expression of a cytotoxic gene would reduce viability or 
proliferation of the transfected cells in addition to the activation of the immune system 
by e.g. IL-2. The efficiency of bicistronic constructs enabling simultaneously 
expression of a cytotoxic and a cytokine gene for gene therapy has already been 
demonstrated (Kwong et al., 1997; Pizzato et al., 1998). In this thesis a novel 
bicistronic construct, 2A-IRES-IL2, enabling the simultaneous expression of the 
cytotoxic rhinoviral protease 2A and the immune stimulatory IL-2 was investigated. 
Protease 2A inhibits cap-dependent translation and therefore the expression of 
cellular proteins in general, which in turn leads to reduced viability. In contrast, 
despite the presence of protease 2A sufficient expression of IL-2 is enabled by an 
IRES-element located upstream of the IL-2 encoding sequence in the 2A-IRES-IL2 
plasmid. This IRES enables the cap-independent expression of IL-2 as shown in Fig. 
47.  
Protease 2A expression by such a 2A-IRES-IL2 construct has been reported 
previously (Kisser, 2003). In this study successful mediated protease 2A expression 
was demonstrated by cleavage of translation initiation factor eIF4G, the major 
substrate of protease 2A. Yet, evidence for an influence of the expression of 
protease 2A on the viability of the treated cells was missing. In the present work, the 
therapeutic potential of the 2A-IRES-IL2 construct was analyzed in the low passage 
colon cancer cell line COGA-12, in SW480 cells, and in HeLa cells. In addition, the 
properties of the 2A-IRES-IL2 construct were investigated in combination with the 
CTP4 promoter.  
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Fig. 47. Effect of protease 2A on cap-dependent or IRES-mediated cap-independent translation 
in cells transfected with 2A-IRES-IL2 plasmid. Examples of the 2A-IRES-IL2 mRNA and a cellular 
mRNA are displayed. (A) Translation processes early after initiation of 2A-IRES-IL2 transcription. (B) 
Translation processes at later time point when protease 2A is already expressed at high levels. 
The results demonstrated that protease 2A is capable of reducing the overall gene 
expression of transfected cells. This was demonstrated by measuring the decrease 
of expression levels of the reporter genes luciferase and EGFP, which were 
cotransfected for this purpose (Fig. 40 and 41). The influence of protease 2A was 
considered relatively to cells transfected with appropriate control plasmids without 
protease 2A. In the cell lines SW480 and COGA-12 already one day after 
transfection the expression levels of luciferase were up to 14-fold lower in presence 
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of protease 2A compared to luciferase levels in control transfections independent 
whether the CMV or the CTP4 promoter was used (Fig. 40). Three days after 
transfection the expression of luciferase was further reduced in both cell lines. In 
contrast, in HeLa cells only the CMV but not the CTP4 promoter enabled sufficient 
expression of protease 2A that decreased the luciferase level already one day after 
transfection. This data confirmed again the specificity of the CTP4 promoter in colon 
cancer cells. Three days after transfection the CMV promoter-driven expression of 
protease 2A decreased luciferase levels of HeLa cells even up to 50-fold compared 
to control transfections, while the CTP4 promoter-driven expression of protease 2A 
only slightly decreased luciferase levels. Two days after transfection the mean 
fluorescence intensities (MFIs) of EGFP expression were about 1.8-fold lower in 
presence of protease 2A compared to the MFIs of EGFP expression in control 
transfections in the cell lines SW480 and COGA-12 (Fig. 41). These results were 
again independent of the promoter that was used for the expression of protease 2A. 
Accordingly, the MFI of EGFP expression in HeLa cells analyzed two days after 
transfection was up to 4-fold decreased by the CMV-driven protease 2A compared to 
the MFI of EGFP expression in control transfections. In contrast, the CTP4-driven 
protease 2A expression in HeLa cells was obviously negligible and therefore did not 
significantly decrease the MFI of EGFP expression.  
Protease 2A decreased the expression of luciferase to a greater extent (14-fold in 
SW480 cells) than the expression of EGFP (1.8-fold in SW480 cells). Apparently, for 
analysis of the effect of protease 2A the luciferase reporter system is more sensitive 
than EGFP, because of the higher turnover rate of luciferase compared to the stably 
expressed EGFP. Furthermore, the higher reduction observed in the luciferase 
cotransfection assays was most likely the result of overall gene expression reduction 
and, in addition, cytotoxic effects mediated by protease 2A. In contrast, in the EGFP 
cotransfection assays only surviving cells were analyzed according to the flow 
cytometry settings. Therefore, the reduction of the MFI of EGFP expression 
represented only the protease 2A-mediated decrease of overall gene expression in 
viable cells but not in cells where protease 2A-mediated blockade of protein 
expression exerted strong toxicity and cell death. Nevertheless, a significant 
reduction of protein expression was still clearly detectable. 
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The expression of protease 2A reduced the viability of transfected SW480 and 
COGA-12 cells down to about 60 % and 80 % of control transfected cells three days 
after transfection, again independent of the used promoter (Fig. 42). In contrast, in 
HeLa cells the expression of protease 2A controlled by the CTP4 promoter was 
insufficient to influence cell viability compared to control transfections, while CMV 
promoter controlled expression of protease 2A reduced viability of the HeLa cells 
also to 60 % of control transfections. Despite the fact that protease 2A reduced the 
viability and proliferation of transfected cells, the enzyme did not alter their apoptosis 
level compared to cells transfected with a control plasmid (Fig. 43). This result is in 
contradiction to previously published data reporting enhanced apoptosis levels in cell 
lines that stably expressed protease 2A in an inducible manner (Goldstaub et al., 
2000; Calandria et al., 2004). However, for these experiments polioviral protease 2A 
was used in contrast to the rhinoviral protease 2A used in the present work. 
Nevertheless, the utilization of rhinoviral protease 2A appears as a viable strategy for 
the treatment of colorectal cancer since the inhibition of proliferation of cancer cells is 
a requisite aim of tumor therapy and the missing apoptosis allows the expression of 
IL-2 necessary for the activation of the immune system.  
Furthermore, it was demonstrated that the IRES sequence, located upstream of the 
IL-2 gene in the 2A-IRES-IL2 construct, enabled significant cap-independent 
expression levels of IL-2 (Fig. 44), despite the fact that the overall cap-dependent 
gene expression is reduced by expression of protease 2A. Up to 2 ng IL-2 per 105 
cells were expressed under control of the CMV promoter within 24 h after using 
lipopolyplexes for gene transfer to the cell lines SW480 and COGA-12. The CTP4 
promoter achieved slightly lower IL-2 levels compared to the CMV promoter in both 
cell lines. This result is in discrepancy with former results of the present work using 
another construct expressing only IL-2, where the CTP4 promoter mediated 
significantly higher IL-2 expression levels than the CMV promoter. However, the 
CTP4 promoter may exhibit different efficiencies in the context of the 2A-IRES-IL2 
construct. Most importantly, even in the context of the 2A-IRES-IL2 construct the 
CTP4 promoter provided sufficient expression levels of IL-2 that were comparable to 
the expression levels by the strong CMV promoter. In addition, the CTP4 promoter 
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expression is specific for colorectal cancer cells in contrast to the unspecific CMV 
promoter. 
Moreover, the IL-2 expression levels were in general lower in the context of the 2A-
IRES-IL2 construct compared to plasmids harboring exclusively the IL-2 gene in 
previous experiments, independent of the used promoter. Several reasons could be 
responsible for this discrepancy. Since the 2A-IRES-IL2 construct consists of two 
encoding sequences it is larger than the plasmid exclusively harboring the IL-2 gene. 
Therefore, it is likely that fewer 2A-IRES-IL2 plasmid numbers are complexed in a 
single lipopolyplex compared to lipopolyplexes containing the smaller IL-2 plasmid. 
Hence, fewer numbers of 2A-IRES-IL2 plasmid than of IL-2 plasmid may be delivered 
to the cells. Moreover, the quantity of mRNAs transcribed from the 2A-IRES-IL2 
sequence is probably reduced as the presence of protease 2A reduces the overall 
gene expression of the transfected cells and thereby also the availability of 
components necessary for the transcription machinery. The availability of proteins 
required for the translation of IL-2 is most likely also reduced. Finally, the IRES-
mediated translation of IL-2 may be less effective than the cap-dependent translation 
of IL-2. Nevertheless, the use of the novel 2A-IRES-IL2 bicistronic construct provided 
considerable IL-2 expression levels despite the cytotoxic properties accomplished 
through the protease 2A. 
In conclusion, the bicistronic construct 2A-IRES-IL2 encoding the cytotoxic rhinoviral 
protease 2A and the therapeutic IL-2 applied by transcriptionally targeted 
lipopolyplexes is a promising tool for the treatment of colorectal cancer. The protease 
2A significantly reduced viability not only of transfected standard cell lines but also of 
low passage colon cancer cells while concomitantly sufficient expression of immune 
stimulatory IL-2 was assured. 
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5. SUMMARY 
The development of relevant cellular model systems for colorectal cancer is of utmost 
importance for an improved in vitro assessment of therapeutic strategies against 
colorectal cancer.  
Recently published low passage colon cancer cell lines that closely reflect the 
characteristics of the respective parental in vivo tumor cells represent very promising 
cell culture models and were therefore used for the investigations in the present 
thesis. To provide an in vitro model system that also recapitulates the three-
dimensional structure of in vivo tumors, these low passage cell lines were cultivated 
as multicellular spheroids. Compared to monolayer cultures the multicellular 
spheroids exhibited a wide variety of changes in their expression patterns. The 
differential expression includes proteins that are involved in growth signaling (15-
hydroxyprostaglandin dehydrogenase), protein biosynthesis (acidic ribosomal protein 
P0), and regulation of the cyto- or nucleoskeleton (acidic calponin and LMNA 
protein). These proteins were identified by 2D electrophoresis and subsequent 
MALDI-TOF mass spectrometry. Both methods were established in the lab in the 
context of this work.  
Chemotherapy with 5-FU represents the traditional treatment of colorectal cancer. 
However, in many patients the efficiency of this therapeutic strategy is often limited 
by the development of chemoresistance against 5-FU. Therefore, it was an aim of 
this thesis to detect novel proteins involved in 5-FU chemoresistance that were 
previously not ascribed to resistance against this chemotherapeutic drug. A 
chemoresistant subline of a colon cancer cell line was generated by long-term 
treatment with 5-FU and served as a model for the investigation of 5-FU 
chemoresistance. This subline exhibited resistance against both 5-FU-induced 
inhibition of proliferation and apoptosis. Differences in the expression of cytokeratin 
18, heat shock protein 27 and aldehyde dehydrogenase 1B1 between the 
chemoresistant subline and parental cells were detected by 2D electrophoresis. 
These findings imply that the cytoskeleton plays a role in the development of 
chemoresistance against 5-FU. Furthermore, processes located to the mitochondria 
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seem to be involved in this resistance, since heat shock protein 27 and aldehyde 
dehydrogenase 1B1 are associated with this subcellular organelle. The biological 
relevance of the findings made in the present PhD thesis has to be determined in 
further studies. 
Gene therapy represents a promising alternative strategy for the treatment of 
colorectal cancer. A novel nonviral gene transfer system was developed by 
combination of DNA with the polycation PEI25br and the cationic lipids DOCSPER or 
DOSPER to form lipopolyplexes. These lipopolyplexes enabled enhanced gene 
transfer in vitro and are promising for in vivo applications, since the established 
lipopolyplexes preserved their small size at physiological conditions; a property 
essential for a successful in vivo application. Furthermore, the lipopolyplexes 
exhibited the capability to efficiently transfect three-dimensional multicellular 
spheroids. The potential of lipopolyplexes for therapeutic applications was further 
increased by the utilization of the artificial promoter CTP4 which enables highly 
specific gene expression in cancer cells with mutations in the Wnt signaling pathway 
by transcriptional targeting. In addition to its high specificity, this promoter enabled 
high gene expression levels that were comparable to expression levels obtained by 
the strong, but unspecific CMV promoter. The efficiency of the CTP4 promoter was 
demonstrated in seven low passage colon cancer cell lines and also in multicellular 
spheroids. The transcriptional targeted lipopolyplexes not only enabled high tumor 
specific expression of reporter genes like luciferase or EGFP but also the expression 
of a therapeutic gene, interleukin-2 (IL-2). Furthermore, tumor specific expression of 
cytotoxic protease 2A in combination with IL-2 was possible by using a novel 
bicistronic construct. The expression of the rhinoviral protease 2A led to efficient 
reduction of overall cap-dependent gene expression levels and therefore also the 
proliferation of the transfected cells, while continued IL-2 expression was guaranteed 
by an IRES element enabling cap-independent gene expression in the presence of 
protease 2A. 
In summary, the present results provide a promising basis for the development of 
novel potent strategies in the treatment of colorectal cancer. 
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6. APPENDIX 
6.1. Abbreviations 
aa amino acids 
ALDH aldehyde dehydrogenase 
APC adenomatous polyposis coli 
ATP adenosine triphosphate 
bp base pairs 
BSA bovine serum albumin 
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate 
CK18 cytokeratin 18 
CMV cytomegalovirus 
COX-2 cyclooxygenase 2 
CY5 cyanine-5 
2D two-dimensional 
DAPI 4',6-Diamidino-2-phenylindole 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
DOCSPER  1,3-dioleoyloxy-2-(N-carbamoyl-spermyl)-propane) 
DOSPER  1,3-dioleoyloxy-2-(6-carboxy-spermyl)-propylamide 
DOTAP  N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-ammonium 
methylsulfate 
DTE dithioerythritol 
DTT dithiothreitol 
ECM extracellular matrix 
E.coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
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EGF epidermal growth factor 
EGFP enhanced green fluorescent protein 
ELISA enzyme-linked immunosorbent assay 
FAP  familial adenomatous polyposis 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
5-FU 5-fluorouracil 
g relative centrifugal force 
HBS HEPES-buffered saline 
HCl hydrochloric acid 
HEPES N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
HNPCC  hereditary nonpolyposis colorectal cancer  
hIL-2 human interleukin-2 
HSP27 heat shock protein 27 
IEF isoelectric focusing 
IF intermediate filament 
IL-2 interleukin-2 
IRES internal ribosomal entry site 
kDa kilo Dalton 
Luc luciferase 
MALDI  matrix assisted laser desorption ionization 
MCR  multicellular resistance 
MDR  multidrug resistance 
MFI mean fluorescence intensity 
MMR mismatch repair 
MSI microsatellite instability  
MS mass spectrometry 
MTT 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan 
N/P ratio molar ratio of PEI nitrogen to DNA phosphate 
NA numerical aperture  
NaCl sodium chloride 
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p2A-IRES-IL2 plasmid encoding for rhinoviral protease 2A and interleukin-
2 under control of the CMV promoter/enhancer  
PBS phosphate-buffered saline 
pCMV-2A-IRES-IL2 plasmid encoding for rhinoviral protease 2A and interleukin-
2 under control of the CMV promoter/enhancer based on 
pEGFP-N1 
pCMV-Luc plasmid encoding for luciferase under control of the CMV 
promoter/enhancer 
pCTP4-2A-IRES-IL2 plasmid encoding for rhinoviral protease 2A and interleukin-
2 under control of the CTP4 promoter based on pEGFP-N1 
pCTP4-hIL-2 plasmid encoding for interleukin-2 under control of the 
CTP4 promoter 
pCTP4-Luc plasmid encoding for luciferase under control of the CTP4 
promoter 
pEGFP-LG-CTP4 plasmid encoding for EGFP under control of the CTP4 
promoter 
pEGFP-Luc  plasmid encoding a fusion of EGFP and luciferase under 
control of the CMV promoter/enhancer 
pEGFP-N1 plasmid encoding for EGFP under control of the CMV 
promoter/enhancer 
pEGFP-N1-0 plasmid encoding for EGFP without the presence of a 
promoter 
PEI polyethylenimine 
PEI22lin linear PEI of 22 kDa 
PEI25br branched PEI of 25 kDa 
PEI2k branched PEI of 2 kDa 
PFA para-formaldehyde 
15-PGDH 15-hydroxyprostaglandin dehydrogenase 
Pgp  P-glycoprotein 
pGShIL-2tet plasmid encoding for interleukin-2 under control of the CMV 
promoter/enhancer 
PI propidium iodide 
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PLL18 poly-L-lysine with 18 lysine monomers 
PTM posttranslational modification 
RLU relative light units 
RNA ribonucleic acid 
ROS reactive oxygen species 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute medium  
RT room temperature 
SDS Sodium dodecyl sulfate 
SE standard error 
TFA trifluoroacetic acid 
TGF-β transforming growth factor β 
TOF time of flight 
Tris tris(hydroxymethyl)aminomethane 
TS thymidylate synthase 
w weight 
APPENDIX 127 
6.2. Publications 
6.2.1. Original Papers 
Pelisek, J., Gaedtke, L., DeRouchey, J., Walker, G.F., Nikol, S., and Wagner, E. 
(2006). Optimized lipopolyplex formulations for gene transfer to human colon 
carcinoma cells under in vitro conditions. J. Gene Med. 8, 186-197. 
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resubmitted. 
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submitted. 
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